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ABSTRACT 
 
Genotoxicity of Complex Chemical Mixtures. 
(December 2006) 
Tracie Denise Phillips, B.S., Texas A&M University 
Chair of Advisory Committee: Dr. K.C. Donnelly 
 
Complex chemical mixtures are ubiquitous in the environment.  Humans are 
frequently exposed to these mixtures; therefore, it is important to understand potential 
interactions of chemical mixtures.  Mixture interactions may influence the absorption, 
distribution, metabolism or excretion of the components of a complex mixture.  The 
research conducted for this dissertation has coupled chemical fractionation with in vitro 
and in vivo bioassays to assess the potential carcinogenic risk of complex mixtures.  A 
non-aqueous phase liquid from a wood treatment plant was separated into acid (AF), 
base (BF) and neutral fractions (NF).  The NF was further enriched using column 
chromatography to produce a polychlorinated dinbenzo-p-dioxin (PCDD) and a 
polycyclic aromatic hydrocarbon (PAH) fraction.  The genotoxicity of these mixtures 
were assessed via analytical quantification, in vitro (Salmonella microsome and E. coli 
prophage induction) and in vivo (32P-postlabeling) bioassays.  The NF was further tested 
to measure bulky DNA adducts and induction of tumor formation.  The AF contained the 
highest level of pentachlorophenol and the highest concentration of total PAHs.  
Although the carcinogenic PAHs were highest in the PCDD fraction, the highest 
concentrations of benzo(a)pyrene (BAP), indeno(1,2,3-cd)pyrene and 
dibenz(a,h)anthracene were detected in the PAH fraction.   A positive genotoxic 
response in Salmonella was induced by the crude extract, the PAH and BF, whereas the 
AF and BF induced a positive response in the E. coli assay.  In vivo, the PAH fraction 
induced the highest DNA adduct frequencies in the lung.  The NF, reconstituted mixture 
(RM) (which includes equivalent concentrations of seven carcinogenic PAHs in the NF), 
BAP and the NF amended with BAP (NF+BAP) were all tested in an infant mouse 
iv 
model.  At the highest dose, after a 24 hr exposure, NF+BAP had the highest total DNA 
adducts measured in liver which was three to seven times higher than with other 
treatments.  Adduct levels were comparable to the control after 280 days.  The highest 
incidence of tumors was observed in the liver.  At the high dose, NF+BAP elicited the 
highest incidence of tumors.  The results of this research confirm previous studies and 
indicate that the carcinogenic potential of PAH mixtures may be greater than predicted 
by chemical analysis.   
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CHAPTER I 
INTRODUCTION 
1.1 Background 
Complex mixtures are ubiquitous in the environment.  Mixtures of organic and 
inorganic chemicals have been detected in food, air, water and soil.  Exposure to 
chemical mixtures is common, and could lead to potentially harmful outcomes including 
cancer, respiratory and cardiovascular disease.  Polycyclic aromatic hydrocarbons 
(PAHs) and polychlorinated aromatic compounds (PCAs) are among the most common 
environmental contaminants.  These compounds cause DNA adducts and cancer in 
animal models.  The research described in this dissertation represents a series of 
experiments designed to obtain information to better define potential risks associated 
with exposure to chemical mixtures.  Studies were conducted using microbial cells in 
culture and animal models to assess the genotoxic potential of complex PAH mixtures.  
These included tests using the crude extract of a complex mixture, as well as fractionated 
components of the mixture and model compounds.  Information will be provided in this 
introductory chapter to describe the history of toxicology, as well as provide background 
information on the metabolism and toxicity of mixtures of PAHs and PCAs. 
 
1.1.1  History of Toxicology 
Toxicology is the study of poisons.  In a broader sense, toxicology encompasses 
studying the adverse effects that a chemical may have on living organisms.  The study of 
toxicology can be dated back to pre-recorded history when poisons from plants and 
animals were used for a variety of purposes.  The first attempt at classifying poisons was 
made by Greek physician Dioscorides.  The initial categories described by Dioscorides 
were used for more than sixteen centuries.  Later, Maimonides and Hippocrates 
conducted studies to improve information about bioavailability.  Most toxicology efforts 
during this time period were intended for disposal of ones enemies.  In Italy, Toffana, an  
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infamous figure in the early Renaissance period, sold arsenic-containing cosmetics as a 
form of assassination (Klaassen 2001; Langman and Kapur 2006; Monosson 2005; 
Schonwalder and Olden 2003).   
The individual who had the most profound influence on the development of 
toxicology was Paracelsus.  This early scientist is credited with the phrase: “The right 
dose differentiates a poison from a remedy.” (Klaassen 2001; Langman and Kapur 2006; 
Schonwalder and Olden 2003).  Paracelcus had many revolutionary views for the time in 
which he lived (Klaassen 2001; Mann 1993).  These views can still be seen today in the 
structure of toxicology, as well as in pharmacology and therapeutics.  Paracelcus 
believed that the “toxicon” (toxic agent) is of primary importance.  He had four main 
views, which are still largely followed today, 1) experimentation is necessary in 
determining responses to chemicals, 2) therapeutic properties are not the same as toxic 
properties of chemicals, 3) dose does not always separate these properties, and 4) 
specificity of chemicals, along with the therapeutic and toxic effects, can be determined 
(Klaassen 2001).  Paracelcus introduced mercury as a treatment for syphilis, one of the 
first forms of the dose-response relationship having been put to work (Klaassen 2001; 
Mann 1993).   
During the 15th century, several investigators recognized the hazards of 
occupational exposures.  Ellenbog and Paracelcus published works on toxicity of 
mercury and lead in goldsmithing and mining, respectively.  In 1775, Sir Percival Pott 
recognized a connection between scrotal cancer in chimney sweeps and soot.  This was 
the first report of toxicity associated with mixtures of polycyclic aromatic hydrocarbons.  
Paracelcus and Ramazzini, an occupational toxicologist, both expressed concern for the 
toxicity of soot, as well as smoke (Klaassen 2001; Monosson 2005).   
As the 19th century approached, the science of toxicology advanced at a rapid rate.  
The advent of the industrial revolution was associated with the synthesis of more than 
10,000 organic chemicals by the year 1880.  The introduction of these chemicals into the 
workplace and the environment produced a need for tests that could be used to measure 
their toxicity.   Orfila established the use of autopsy material and chemical analysis to 
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prove poisoning, laying a path for forensic toxicology.  Magendie established adsorption 
and distribution studies; while, Bernard established mechanisms of action studies, 
specifically on carbon monoxide.  Schmiedeberg focused on liver and its detoxification 
mechanisms.  Lewin’s work included chronic toxicity of narcotics, along with toxicity of 
chemicals such as methanol, glycerol, acrolein and chloroform (Breathnach 1987; 
Klaassen 2001; Koch-Weser and Schechter 1978; Langman and Kapur 2006; Monosson 
2005; Morabia 2006; Shampo and Kyle 1987). 
The tools available to measure the mechanistic effects of toxic chemicals have 
changed appreciably over time.  Some of these changes may be attributed to significant 
events in the history of the world.  For example, chemical warfare agents were first used 
in World War I (Roffey et al. 2002).  The novel by Upton Sinclair, “The Jungle”, 
described adverse work conditions that affected not only worker health, but also the 
quality of food in the United States (Schonwalder and Olden 2003; Sinclair 2003).  
Significant advances in toxicology occurred following World War II.  This included the 
study of organophosphate insecticides, antimalarials, and radionuclides, as well as the 
beginning of inhalation toxicology (Borm 2002; Bullman and Kang 1994).  In the early 
1960’s, Rachel Carson’s “Silent Spring” described potential adverse effects to wildlife 
caused by exposure to organochlorine pesticides (Carson 1962; Schonwalder and Olden 
2003).  Around the same time Love Canal was discovered.  Love canal was a canal that 
had been used as a toxic waste landfill by Hooker Chemical Corporation.  The discovery 
of Love Canal raised awareness of the potential toxic effects from chemicals that are 
released into the environment (Brown and Clapp 2002).   
In the last 50 years, the changes to toxicology have been even more dramatic.  
Prior to the late 1900’s, infectious disease was a major cause of death.  Since the 
discovery of antibiotics and immunizations, cancer and heart disease have become the 
major causes of death in most industrialized countries (CDC 2003a; Mann 1993).  In the 
United States, approximately 1.3 million new cases of cancer were diagnosed in 2003 
with about 1,500 deaths per day (CDC 2003b).  For any individual, the risk of cancer is 
affected by genetic, lifestyle and environmental factors.  The significance of each of 
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these factors is greatly dependent on the individual, where they live and work, and 
whether they smoke or have other lifestyle factors that may increase risk.   
In order to improve methods for prevention and treatment of cancer, it is important 
to better understand the molecular mechanisms that precede the formation of a malignant 
cancer cell.  Laboratory studies have demonstrated that the initial step in the 
transformation of a normal cell to a malignant cell is a point mutation.  Chemicals that 
are capable of binding with DNA forming a bulky adduct may increase mutations in 
protooncogenes or tumor suppressor genes.  In order to obtain information regarding the 
potential of chemical mixtures to induce cancer, toxicologists have developed a variety 
of methods to detect chemicals that are capable of modifying genetic material.  Point 
mutation bioassays were developed in the late 1960’s and early 1970’s (Ames et al. 
1975; Malling 1971).  In 1981, Randerath et al. developed a protocol for labeling bulky 
DNA adducts using radioactive ATP.  This 32P-postlabeling method is widely 
recognized as one of the most sensitive methods for detecting genotoxic compounds in 
environmental media (Reddy 2000; Williams et al. 1996).  Today, technologies such as 
the Polymerase Chain Reaction (PCR) and microarray allow toxicologists to measure 
single nucleotide polymorphisms and measure the impact of chemicals and chemical 
mixtures on gene expression (Majtan et al. 2004; Nakayama et al. 2006).  These new 
technologies have provided toxicologists tools to look inside the mammalian genome to 
investigate mechanisms of complex mixture interactions, as well as the impact of genetic 
polymorphisms on sensitivities to chemical exposures.    
 
1.1.2  History of Superfund 
The United States Congress has passed legislation to establish institutes for the 
promotion of research into causes of cancer, as well as to reduce the release of 
carcinogenic chemicals into the environment from industrial operations.  In 1930, the 
National Institute of Health (NIH) was established under the presidency of Herbert 
Hoover.  Approximately thirty years later, the United States government established the 
National Center for Toxicologic Research (NCTR) and the National Institute of 
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Environmental Health Sciences (NIEHS).  The need to regulate the release of toxic 
chemicals to air, water and soil resulted in the establishment of the United States 
Environmental Protection Agency (USEPA) in 1970.  Concern over hazardous wastes, 
chemical dumps, and accurate reporting of hazardous chemical inventories grew with the 
discovery of Love Canal in the 1970s.  The recognition of the existence of a large 
number of uncontrolled hazardous waste sites by the USEPA led to the Toxic Substances 
Control Act (1976) and in 1980 to the Superfund bill (1980).  The goal of this legislation 
was described as cradle to grave.  In principle, this meant that all hazardous chemicals 
would be carefully tracked from synthesis to final disposal (USEPA 2005b, USEPA 
2005c).   
The Resource Conservation and Recovery Act (RCRA) was passed due to concern 
over the impact from releasing hazardous chemicals into environmental media (USC 
1976).  The RCRA set standards for all facilities that treat, store or generate hazardous 
waste.  To deal with those sites which appeared to represent a more immediate threat to 
health and the environment, Congress passed the Comprehensive Environmental 
Response, Compensation and Liability Act (CERCLA) (USC 1980).  This act included 
provisions for the Superfund program.  The Superfund program included a tax on 
hazardous chemicals that would provide funds to assess and reclaim those sites which 
required remediation.  The program also established a methodology for estimating the 
non-cancer and cancer risk associated with contaminated environmental media.  The 
Risk Assessment Guidelines for Superfund (USEPA 1986) defined a four step process 
for ranking uncontrolled hazardous waste sites.  These steps include hazard 
identification, toxicity assessment, exposure assessment and risk characterization.  The 
process allowed regulators to produce an estimate of the non-cancer or lifetime cancer 
risk associated with exposure to contaminated media at a specific site.  This information 
could then be utilized to rank sites and identify those which required more immediate 
action.   
CERCLA also provided Federal authority to respond directly to threatened or 
actual releases of hazardous substances which may endanger public health or the 
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environment.  The three major legislative initiatives that CERCLA provided for include; 
1) establish prohibitions and requirements concerning closed and abandoned hazardous 
waste sites, 2) provide for liability of persons responsible for releases of hazardous 
waste, and 3) establish a trust fund to provide for cleanup when no responsible party 
could be identified.  CERCLA also enabled the National Contingency Plan (NCP) to be 
revised.  The NCP is the legislation that provides the guidelines and procedures needed 
to respond to threatened and actual releases of hazardous substances, pollutants, or 
contaminants.  On October 17, 1986, CERCLA was amended by the Superfund 
Amendments and Reauthorization Act (SARA).  Several important changes and 
additions were made to the program.  SARA reflected the EPA’s experience in 
administering CERCLA during its first six years.  SARA’s revisions included: 1) 
stressing the importance of permanent remedies and innovative treatment technologies, 
2) requiring Superfund actions to consider the standards and requirements found in other 
State and Federal environmental laws and regulations, 3) providing new enforcement 
authorities and settlement tools, 4) increasing State involvement in every phase of 
CERCLA, 5) increasing the focus on human health problems, 6) encouraging greater 
citizen participation in making decisions regarding sites, and 7) increasing the size of the 
trust fund for site assessment and remediation to $8.5 billion.  SARA also stipulated that 
the EPA update the Hazardous Ranking System (HRS) for accuracy (USEPA 2005a; 
USEPA 2005b; USEPA 2005c; USEPA 2005d; USEPA 2006e).  The HRS is used to 
prioritize those sites where contaminants represent a threat to human or ecological 
health.    There are currently 1,609 sites on the EPA’s National Priorities List, although it 
is estimated that by the year 2033 more than 294,000 sites will be identified (USEPA 
2006e). 
A major concern at many of these sites is the potential for human exposure to 
complex chemical mixtures.  Two of the most common classes of contaminants detected 
in environmental media are mixtures of PAHs and chlorinated aromatic hydrocarbons 
(Mueller et al. 1991; Ramesh et al. 2004; Samanta et al. 2002).  PAHs have been 
detected at 47 % of the 1609 Superfund sites in the United States (USEPA 2006e).   
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PAH mixtures may be present at wood preserving sites, refineries and petroleum 
production facilities, coal gasification sites, and other sites where petroleum products 
were stored or disposed of.  In addition, PAH mixtures are common combustion by-
products.  Thus, sources of human exposure to PAH mixtures includes not only the 
release of hazardous chemicals, but also ingestion of cooked foods and inhalation of 
cigarette smoke or other combustion by-products.   
 
1.1.3  Environmental Mixtures 
Complex chemical mixtures are ubiquitous in the environment.  Sources of 
complex mixtures include cooked foods, combustion by-products, and releases 
associated with hazardous waste facilities.  The release of hazardous chemicals from 
industrial facilities is a concern because these chemicals may add to the burden of 
chemicals to which a population is normally exposed.  Sir Percivall Pott (1775) observed 
that young men employed as chimney sweeps had an excess frequency of scrotal cancer.  
It is likely that the accumulation of complex mixtures of polycyclic hydrocarbons from 
the soot in the chimneys was a significant factor affecting the incidence of cancer in 
these young men.  PAH mixtures are common contaminants of petroleum and 
petrochemical facilities, wood preserving facilities, and any industry utilizing 
combustion sources.  Hydrocarbon mixtures are also common at Department of Defense 
and Department of Energy facilities.  The release of hydrocarbon mixtures to the 
environment may result in contamination of air, surface water, soil, sediment and/or 
groundwater.  PAH mixtures are generally persistent in the environment.  PAHs are 
relatively insoluble in water, and thus concentrate in soil and sediment near the 
hazardous waste facilities that released them into the environment.  PAH mixtures may 
also represent a threat to human and/or ecological health when they are concentrated in 
the food chain.   
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1.2   Human Health 
1.2.1  Exposure to Environmental Mixtures 
Humans are constantly exposed to complex environmental mixtures in air, food 
and water.  Populations living near hazardous waste facilities may be exposed to higher 
concentrations of chemicals.  Brender et al. (2006) reported higher rates of cancer in 
populations living within one mile of a Superfund site.  The EPA has established a 
procedure that can be used to estimate the risk associated with exposure to contaminated 
media at a Superfund site.  The National Academy of Science recommends four steps in 
the risk assessment process (Figure 1.1).  The initial step in this process is to identify the 
hazard at a specific site.  Hazard Identification is designed to develop a qualitative 
assessment of risk.  The existing data for a specific site is collected and reviewed.  
Concentrations of each contaminant at a site are compared to Risk Based Concentrations 
(USEPA 2006a) to determine which chemicals represent the greatest health threat.  
Hazard identification is typically used to develop a list of Contaminants of Concern, or 
the 10-15 chemicals which appear to represent the greatest threat to environmental 
health. (USEPA 2006a)  
 
 
Risk Assessment Paradigm 
 
Figure 1.1.  Diagram of the four elements of the NAS risk assessment as used by USEPA’s IRIS 
database.  A similar paradigm can be found in the USEPA’s Risk Assessment Guidelines for 
Superfund (RAGS) Part A where hazard identification would be called data collection:data 
evaluation and dose-response assessment would be called toxicity assessment (USEPA 1986; 
USEPA 1989). 
Hazard 
Identification 
Dose-Response 
Assessment 
Exposure 
Assessment 
Risk 
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The second step in the risk assessment is the toxicity or dose-response assessment.  
In most cases, the EPA’s Integrated Risk Information System (IRIS) is used to identify a 
Reference Dose (RfD) for non-cancer effects, and/or a Cancer Slope Factor (CSF) for 
cancer effects.  Although toxicity values have been established for a large number of 
chemicals, there is a great deal of uncertainty in many of these values.  Sources of 
uncertainty include species extrapolation, and extrapolation from large doses used in 
toxicity studies to the relatively small doses that generally occur in environmental 
exposures.  More importantly, there is no widely accepted protocol for interpreting the 
interactions of chemical mixtures.  Most risk assessments assume additive effects.  Data 
are not available at the present time to accurately assess the potential interactions of 
complex mixture carcinogens and non-carcinogens. (USEPA 1986) 
The USEPA has developed five categories to describe the carcinogenic potential of 
a specific chemical.  These include: 1) Class A—evidence of carcinogenicity in humans, 
2) Class B—probable human carcinogen (limited evidence in humans and adequate 
evidence in animals), 3) Class C—possible human carcinogen (adequate evidence in 
animals), 4) Class D—not classifiable for human carcinogenicity, and 5) Class E—
evidence for non-carcinogenicity in humans.  The cancer slope factor is used by the 
USEPA to rank the carcinogenic potency of various chemicals.  For example, methylene 
chloride is considered a weak carcinogen (Class B2) and has an oral cancer slope factor 
of 7.5 x 10-3 (mg/kg)/day, while vinyl chloride is considered a potent human carcinogen 
(Class A) and has an oral cancer slope factor of 7.2 x 10-1 (USEPA 1995, USEPA 
2000a).  The model carcinogenic PAH benzo(a)pyrene (BAP), is considered a Class B 
carcinogen and has an oral cancer slope factor of 1.2 x 10-1 (mg/kg)/day (USEPA 
1994b).  Mixture interactions may affect risk by affecting the uptake, distribution, 
metabolism or elimination of other chemicals.  Thus, low molecular weight PAHs that 
are capable of inducting Phase I liver enzymes may enhance the toxicity of high 
molecular weight PAHs.  Alternatively, studies by Falahatpisheh et al. (2004) observed 
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that chrysene could inhibit the toxicity of BAP through competition for metabolizing 
enzymes. 
The third step in the risk assessment process is the exposure assessment.  All 
completed exposure pathways at a site for both on-site workers and off-site residents 
must be determined.  This includes exposure to soil, air, groundwater, surface water, 
sediment, or food products that may have become contaminated due to chemicals 
released from the site.  For each completed exposure pathway, the concentration of each 
contaminant of concern in a specific media is estimated.  This estimate may use a mean 
value, an upper 90th percentile value or a maximum value depending on the quantity and 
quality of existing data.  These values are used to estimate a Cumulative Daily Intake for 
each exposure pathway and each contaminant of concern.  Major sources of uncertainty 
in the exposure assessment include assumptions regarding intake variables for 
contaminated media, estimate of chemical concentrations in the media, and rates of 
absorption from various exposure pathways. (USEPA 2006b) 
The final stage in the risk assessment is the characterization of both the non-cancer 
and cancer risk.  The non-cancer risk is a sum of the Hazard Quotient, or a value 
obtained by dividing the Cumulative Daily Intake by the Reference Dose.  Contaminate 
concentrations are considered acceptable as long as the estimated daily intake is not 
greater than an estimate of a No Observable Adverse Effect Level (or the Reference 
Dose).  Hazard Quotients for each chemical and each exposure pathway are summed.  
The Lifetime Cancer Risk is calculated as a product of the Cancer Slope Factor and the 
cumulative Daily Intake.  Residential sites are considered acceptable as long as the sum 
of Lifetime Cancer Risk for all chemicals and all exposure pathways does not exceed 
one in one million.  These risk calculations provide a means of ranking sites and 
assessing acceptable levels for clean-up.  However, as stated previously, significant 
sources of uncertainty exist in each step of the risk assessment process.  One of the 
major sources of uncertainty is knowledge of the potential interactions of complex 
chemical mixtures (USEPA 1986; USEPA 2000b).   The research conducted as part of 
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this dissertation has investigated the ability of model compounds and complex mixtures 
for form DNA adducts and tumors in mouse models.  
 
1.2.2  Chemical Carcinogenesis 
 Cancer is a multi-stage process that may involve multiple chemical exposures over 
many years.  Most animal or occupational studies that have been used to identify 
chemicals that are capable of causing cancer have involved high dose exposures over a 
relatively short time period.  Thus, limited information exists to accurately characterize 
the risk associated with long-term, low dose exposure to chemical mixtures.  
Occupational studies have clearly shown that exposure to PAH mixtures in coke oven 
emissions is capable of causing lung, upper respiratory and alimentary tract cancers 
(Bertrand et al. 1987; Heinrich et al. 1986; Lloyd 1971; Mazumdar et al. 1975; Redmond 
et al. 1976; Rockette and Redmond 1976).  In order to understand the risk of an 
environmental mixture, it is important to have information regarding the mechanism 
through which the mixture induces carcinogenesis.  Farber and Sarma (1987) developed 
a model for tumor formation in the liver.  These steps were largely determined through 
the use of the resistant hepatocyte model created in 1976 by Solt and Farber (Figure 1.2).  
This model was used to establish that three major steps follow exposure to a chemical 
carcinogen prior to the development of a malignant tumor.  The chemical must first be 
adsorbed and distributed into systemic circulation.  Once in circulation, the chemical 
may be transformed through metabolizing enzymes into its ultimate carcinogenic form.  
The first major step is initiation.  Initiation occurs when a carcinogen binds with DNA 
resulting in a mutation.  This mutation leads to the formation of abnormal, initiated cells.  
The growth of these initiated cells is promoted through further mutations, to tumor 
suppressor genes or oncogenes that alter normal cellular growth.  Promoted cells for 
small foci have a variety of altered biochemical characteristics.  Continued exposure 
may cause these foci to progress into neoplastic cells. The nodules formed by these cells 
may be visible, but may also be small enough to grow unnoticed with minimal effect on 
the host.  If these neoplastic cells become malignant, they have the capability to outgrow 
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the normal architecture of the tissue in which they reside, and may break off from a 
primary tumor and migrate to another location in the host forming a secondary tumor 
(Solt and Farber 1976). 
 
 
Figure 1.2.  Diagram of the tumor pathway model for chemical-induced liver cancer.  Adapted 
from Farber and Sarma (1987). 
 
 
1.2.3  Models for Human Carcinogenesis 
The International Agency for Research on Cancer (IARC), part of the World 
Health Organization (WHO), has identified approximately 400 chemicals as human 
carcinogens (potential and definite) (IARC 2004).  A human carcinogen is any chemical 
that has the ability to transform a normal cell into a malignant cancer cell.  Carcinogens 
may be classified as genotoxic or epigenetic.  Epigenetic carcinogens induce cancer by 
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mechanisms that do not involve binding to DNA (e.g. tissue injury, hormonal imbalance, 
immunologic effects, or promotional activity on cells that have been altered by 
genotoxic carcinogens).  Genotoxic carcinogens covalently bind to DNA.  Most 
genotoxic carcinogens are procarcinogens.  That is, they require conversion into an 
electophilic metabolite prior to binding with DNA.  A complex environmental mixture is 
likely to contain both genotoxic and epigenetic carcinogens.  In addition, given the 
multiple interactions that occur in a biological system, chemicals may exhibit both 
genotoxic and epigenetic effects (Weisburger and Williams 1988). 
Occupational exposures to PAHs can occur among different manufacturing 
processes including: petroleum processing (all operations from drilling to refining), 
metalworking, coke production, anode manufacturing, aluminum production, and 
through the use of specific complex mixtures during the manufacturing processes such 
as coal tar, pitch, asphalt, creosote, soot and anthracene oil.  The main occupational route 
of exposure depends on the specific manufacturing process.  For workers in petroleum 
refinement and coal mining, the main route of exposure is generally inhalation, with a 
significant risk from dermal absorption as well (ATSDR 1995; Borm 2002; USEPA 
2006c).  For coke oven workers and metalworkers, the main route of exposure is dermal 
absorption.  Lung and scrotal cancer has been observed in metal workers who use 
refined mineral oils in their machining operations (Jarvholm et al. 1981).  PAHs are 
highly lipophilic compounds which may be difficult to detect in human tissues.  One 
way of assessing exposure to PAHs is to use biomarkers.  1-Hydroxypyrene can be 
analytically monitored in urine.  Although this biomarker of exposure can confirm that a 
person has been exposed to PAHs, it does not provide a quantitative measure of the 
potential for an adverse health effect.  It is important to take into account individual 
PAH exposures outside of the occupational situation when calculating exposure.  Other 
biomarkers of exposure for PAHs include 1-nitropyrene and BAP, determining PAH-
DNA adducts in urine, blood and other tissues as well as cellular macromolecules 
(hemoglobin, globin, large serum proteins) (ATSDR 1995).   
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Although humans are constantly exposed to PAHs and PCAs, the variability of 
these exposures and the variability of the human population make it difficult to study 
cancer incidence (Barrett 1995; DHHS 2004).  In addition, the latency from exposure to 
tumor development in humans may be more than 20 years.  Animal models, because of 
their uniform genetics and uniform dosing, are a valuable tool for measuring the 
genotoxic interactions of chemical mixtures (Barrett 1993; DHHS 2004).  When animal 
data can be combined with epidemiological data, a more accurate prediction can be 
made about the compound(s) in question (Wogen et al. 2004; Miller and Miller 1971; 
DHHS 2004).   
Epidemiological studies are the most relevant studies to human carcinogenicity, 
especially occupational exposure studies (Krewski and Thomas 1992; DHHS 2004).  
However, these studies are often wrought with difficulties, and variances must be 
accounted for when looking at this data.  Within epidemiological studies, there are 
interspecies differences (age, sex, rate of metabolic processes, etc.) that must be 
considered.  In addition, exposure in human populations is often highly variable.  Once a 
tumor has formed, the cells have lost their ability for normal cell function (Wogan et al. 
2004).  Biomarkers, such as metabolites (often PAHs for creosote exposure) and DNA 
adduct formation, may be monitored in exposed populations to determine exposure and 
response relationships as accurately as is possible (DHHS 2004; Grimmer et al. 1997; 
Malkin et al. 1996; Melber et al. 2004).  Epidemiological studies have shown that 
exposure to creosote can cause skin cancer, along with other symptoms (depending on 
source and duration of exposure) (ATSDR 2002; Melber et al. 2004).   
Human exposure to PAHs and PCBs is common.  However, due to the genetic 
variability of the human population and the wide ranges in dose and durations of 
exposure to these compounds, it is difficult to characterize the carcinogenic potential of 
these compounds in humans (Barrett 1995; DHHS 2004).  The latency of most solid 
tumors, often as long as 20 years, can make it difficult to link a previous chemical 
exposure to a specific cancer.  Animal models, because of their uniform genetics and the 
ability to administer consistent dosages, are a valuable tool for studying the genotoxic 
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interactions of chemical mixture (Barrett 1995; DHHS 2004).  The most accurate 
information from which to access the ability of a chemical or chemical mixture to induce 
cancer is a combination of in vitro, in vivo and epidemiologic studies (DHHS 2004; 
Miller and Miller 1971; Wogen et al. 2004). 
Occupational studies, due to the potential for high and frequent exposure, are often 
some of the most relevant data from which to judge the ability of a chemical or chemical 
mixture to induce cancer (DHHS 2004; Krewski and Thomas 1992).  However, it is rare 
for accurate information regarding cumulative exposures to be available for an 
occupational study.  In addition, humans may display significant differences in 
susceptibility to chemical carcinogenesis due to the effect of age and size on metabolic 
processes, as well as genetic differences that may influence not only metabolism, but 
also tumor suppressor genes, oncogenes, and other factors.  A neoplastic lesion has a 
variety of morphological and biochemical properties which differentiate the cell from a 
normal cell (Wogan et al. 2004).  Biomarkers of abnormal cells can be identified as 
changes in enzyme levels and the cell cycle.  Levels of oncogenes and proto-oncogenes 
present in a cell, as well as p53 can help determine if a cell has become abnormal or not.  
Oncogenes, which may control cell growth, once mutated can allow for abnormal 
division and replication of the cell.  Proto-oncogenes are genes that encode proteins 
which stimulate cell growth.  Some proteins from proto-oncogenes are growth factors, 
intracellular signal transducers (G proteins), protein kinases, cyclins, and nuclear 
transcription factors.  Over expression of these proteins may also have an effect on the 
growth of abnormal cells.  One of the most studied is the p53 tumor suppressor gene.  
This transcription factor helps to induce apoptosis in response to cell damage or stress 
(Klaassen 2001; Ress et al. 2002).  Abnormal cell growth is one piece of a complicated 
process which may end in tumor formation.   
This research was designed to add to current knowledge regarding the genotoxic 
potential of complex chemical mixtures.  Microbial genotoxicity studies will be used to 
identify fractions from mixtures that are capable of causing mutations in DNA.  Data 
will also be obtained from animal studies to improve information regarding the 
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relationship between the initiation of the carcinogenic process through the formation of 
DNA adducts, and the ultimate formation of neoplastic lesions including benign and 
malignant tumors. 
 
1.3   Contaminants of Concern 
1.3.1  Complex Chemical Mixtures 
Feron et al. (1995) defined a complex mixture as a substance that contains from ten 
to more than one thousand chemical components.  For the majority of environmental 
mixtures, the composition is not qualitatively or quantitatively known (Groten et al. 
2001).  The properties, both chemical and toxicological, of the components of a mixture 
may be altered by component interactions.  Chemical mixtures are common in air, food 
and water.  Specific examples of complex mixtures that may contain PAHs include 
cigarette smoke, diesel exhaust, cooked foods, and coal tar creosote (Fay and Feron 
1996).  Due to the widespread use of petroleum products in the United States, complex 
mixtures of PAHs are frequently detected in a broad range of environmental media 
(Johnson and DeRosa 1995).  The toxicity and genotoxicity of complex mixtures is often 
difficult to assess because they may contain low concentrations of the most potent 
compounds (e.g. benzo(a)pyrene or tetrachlorodibenzo-p-dioxin), and relatively high 
concentrations of chemicals with a less significant toxic effect.  However, it is important 
to develop methods that can be used to characterize the toxicity of various components 
of a mixture, as well as the potential interactions of these compounds (Fay and Feron 
1996). 
Complex mixtures are difficult to characterize due matrix interferences and the 
close structural similarity of many of the components.  Each compound within a 
complex mixture may have different physical and chemical properties.  For example, 
creosote as a whole is not considered to be water soluble; however, specific compounds 
within the mixture are highly water soluble while others are much less soluble.  Specific 
physical and chemical properties of individual compounds can be found in ATSDRs 
ToxProfiles (ATSDR 1995; ATSDR 2001; ATSDR 2002).  Exposure assessments 
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generally do not take into account interactions among the multiple chemicals in complex 
mixtures (Groten et al. 2001).  An important component of complex mixture research is 
to study the mixtures as a whole, and to break them down into fractions for study (Fay 
and Feron 1996; Johnson and DeRosa 1995).  The mixture as a whole presents a 
problem as each chemical’s toxicity role may be quite different than depending on the 
dose.  As difficult as testing the whole mixture is, testing individual compounds is 
practically unobtainable.  The entire composition of the whole mixture is not known, and 
the possible interactions of individual compounds are almost endless.  Thus, 
fractionation of the whole mixture is an appropriate method for determining genotoxic or 
mutagenic chemical compounds or groups of compounds (Fay and Feron 1996).  The 
concept of fractionating chemical mixtures to better understand toxicity is characterized 
by Fay and Feron (1996) as being “better to have a shattered image of reality than a 
combined image of unreality”.  Other methods that have been recommended for testing 
complex mixtures include identification of the top ten chemicals, and the formation of 
composite standards (Fay and Feron 1996). 
Human exposures are generally to environmental complex mixtures, and not to 
single compounds or even simple mixtures (Gennings 1995; Teuschler and Hertzberg 
1995).  These are usually low dose exposures, through various exposure pathways.   
Limited data exist to characterize the toxicity of complex mixtures.  However, the 
USEPA has published Guidelines for the Health Risk Assessment of Chemical Mixtures 
(Teuschler and Hertzberg 1995; USEPA 1986).  Guidelines for conducting a risk 
assessment for a chemical mixture are shown in Figure 1.3.  Three approaches have been 
recommended for chemical mixtures, including a Surrogate Approach, a Comparative 
Potency Approach, and a Relative Potency Approach (Teuschler and Hertzberg 1995).  
The Surrogate Approach assumes that there is data from occupational or animal studies 
for a similar, or surrogate, mixture.  This data can then be used to extrapolate a toxicity 
value for the mixture of concern.  The Comparative Potency Approach assumes that the 
mixture may be compared to another mixture for which extensive toxicity data are 
available.  Thus, the potency of the mixture of concern is adjusted based on a 
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comparison with a better characterized mixture.  The Relative Potency Approach is the 
most widely used approach.  This approach assumes primarily additive interactions and  
sums the toxicity of a mixture based on the chemical analysis of components.   Ideally, 
risk assessment should be done based on chemical mixture specific information, or on 
classes of compounds found within a particular mixture (Teuschler and Hertzberg 1995; 
USEPA 1986).   
 
 
Mixture Assessment Paradigm 
 
Figure 1.3.  Diagram of mixture assessment paradigm found in USEPA’s Guidelines for the 
Health Risk Assessment of Chemical Mixtures.  Adapted from Teuschler et al.. 1995 and USEPA 
1986.   
 
Assess Data 
Data on Mixture 
Mixture Risk 
Assessment 
Compare and Identify Preferred Risk Assessment 
Integrate Summary with Uncertainties Discussion 
on Similar Mixture 
Sufficiently Similar? 
Mixture Risk 
Assessment 
Interactions Risk 
Assessment 
Only Qualitative 
Assessment 
on Components 
Additivity Risk 
Assessment 
Inadequate 
Adequate 
No No 
No 
Yes 
Yes 
Yes 
19 
The complex mixture that was characterized as a portion of this dissertation is 
creosote.  Creosote is a coal tar distillate that rarely occurs naturally in the environment.  
There are six main classes of chemicals in creosote; 1) aromatic hydrocarbons, 2) tar 
acids/phenols, 3) tar bases/nitrogen-containing heterocycles, 4) aromatic amines, 5) 
sulfur-containing heterocycles, and 6) oxygen-containing heterocycles (ATSDR 2002; 
Melber et al. 2004).  Approximately 400 compounds have been identified in creosote, 
with approximately 10,000 total compounds making up the mixture (ATSDR 2002; Culp 
et al. 1998).  The components of creosote can be found in multiple matrices (air, water, 
sediment, soil, and biota), due to the vast differences in properties of the compounds 
within.  Creosote is a particularly difficult complex mixture to characterize as its 
constituents are influenced by the origin of the coal used and the nature of the distilling 
process.   Polycyclic aromatic hydrocarbons constitute approximately 85-90% of 
creosote, while other constituents are generally less than 1% (Melber et al. 2004; 
Mueller et al. 1989).  Creosote has been used for many purposes, including, wood 
preservation, water-proofing agent for structures (land and water), railway crossing 
timbers, railroad ties, decking (bridge and pier), poles, log homes, fencing, equipment 
for children’s play grounds, anti-fouling applications for marine pilings, insecticide, 
animal dip, fungicide, and components in roofing pitch, and fuel oil.  Major 
environmental sinks for creosote compounds are sediment, soil and groundwater, 
making creosote an important complex mixture to characterize and understand (Melber 
et al. 2004).   
 
1.3.2  Polycyclic Aromatic Hydrocarbon Compounds 
PAHs are ubiquitous environmental contaminants.   These chemicals may be found 
in cooked foods, absorbed to air particulate, as well as in soil, and sediment.  PAHs may 
be released from both natural and anthropogenic sources.  High concentrations of PAHs 
are present in crude oil, coal and oil shale.  These petroleum and petrochemical products 
are used to produce extensively used fuels and synthetics (fibers and plastics) (Harvey 
1997).  The widespread use of petroleum products has resulted in increased levels of 
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these compounds in the environment.  PAHs may also be released into the environment 
from volcanic eruptions, forest fires, burning of coal, burning of wood, expulsion fumes 
from manufacturing industries, and smoking.  Due to the ubiquitous sources of PAHs in 
the environment, exposure to these compounds is common (ATSDR 1995; Ramesh et al. 
2004; Samanta et al. 2002).   
The majority of atmospheric contamination with PAHs can be attributed to 
industrial activities (50% of BAP emissions in the United States) and vehicle emissions 
(35% of PAH air contamination in the United States).  Natural sources account for much 
of the remaining atmospheric contamination with PAHs (Harvey 1997).  The 
composition and concentration of PAHs resulting from combustion of fuels depends on 
the conditions in which they were generated.  High temperatures in the absence of 
oxygen produce simple unsubstituted PAHs, while at lower temperatures, larger and 
more alkyl substituted PAHs will be produced.  Conditions in the atmosphere also 
determine the extent of PAH deposition.  For example, a rise in PAH emissions is 
generally seen in colder months, presumably because more fossil fuels are consumed in 
these months.  Atmospheric conditions, such as temperature inversions, may also 
increase PAH concentrations near ground level.  Density, temperature and emission 
sources are also factors in PAH distribution.  PAHs transition from the gas phase into the 
solid phase (fly ash) when temperatures are below 150°C.  Accordingly, most PAH 
atmospheric contamination is seen as particulate matter, and can be respirable if less 
than 5 µm (Harvey 1997).   
Soil contamination with PAHs is fairly significant, with the most significant 
contamination generally occurring near industrialized areas, or areas with high traffic 
volumes (Harvey 1997; Ciganek et al. 2004; Marr et al. 2004; Johnsen et al. 2006).  The 
National Institutes of Health published a paper on traffic PAH exposure in Mexico City 
in 2004 (Marr et al. 2004).  This study clearly shows high levels of PAHs concentrated 
in areas where vehicles operate.  Ciganek et al. (2004) collected samples at high and low 
traffic areas in the Czech Republic.  They found BAP concentrations of 0.64 ng⋅m-3 in 
the high traffic area and 0.38 ng⋅m-3 in the low traffic area, with total PAH 
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concentrations of 46.2 ng⋅m-3 and 20.7 ng⋅m-3, respectively.  Another study done by 
Johnsen et al. in 2006 not only clearly showed high levels of PAHs at a motorway site, 
they also showed steady contamination of the soil near the asphalt.  They suggest that 
this steady influx of PAH exposure will most likely accumulate and add to human 
exposure.  PAH contamination of surface water is also common.  There are many 
diverse sources for water contamination, with the major source being deposition of 
particulates from the atmosphere.  Other sources of PAHs in surface water include direct 
pollution from household use, discharge of used crankcase oil, and effluents from 
industrial uses.  PAH contamination of surface water may result in distribution of these 
compounds into the food chain.  Because PAHs are lipophilic, PAHs in the food chain 
are likely to bioaccumulate (Harvey 1997).   
Direct contamination of food with PAHs has also been observed.  PAHs have been 
detected in leafy plants, at low levels in seafood, and in cooked meats.  Studies done by 
Kulhanek et al. (2005) and Jakszyn et al. (2004) report levels of PAHs found in leafy 
vegeTables.  The Kulhanek study reportes bioconcentration factors in leafy vegeTables 
from the Czech Republic.  The factor for BAP was 4.92 x 10-6 without attached soil and 
0.01 with soil.  The Jakszyn study put together a database on foods and concentrations of 
chemicals found in them.  They report the following values for leafy greens:  collar 
greens (raw) 0.48 µg/kg BAP; mixed greens 0.14 µg/kg BAP; lettuce 0.007 µg/kg BAP 
and 2.61 µg/kg total PAHs (tPAHs); and spinach 0.10 µg/kg BAP.  Meats that have been 
fried or charcoal broiled are especially high in PAH content (Harvey 1997).  The 
Jakszyn database reports these values for meat and fish:  bacon (pork) 0.35 µg/kg BAP 
and 6.80 µg/kg tPAHs; beef (cooked) 0.40 µg/kg BAP and 9.70 µg/kg tPAHs; chicken 
(barbecued) 4.60 µg/kg BAP and 60.20 µg/kg tPAHs; ham (cooked) nd BAP and 2.60 
µg/kg tPAHs; codfish (cooked) 0.026 µg/kg BAP and 0.58 µg/kg tPAHs; herring 
400/dry weight (dw) µg/kg BAP and 1300 µg/kg tPAHs; salmon (raw) 3.90 µg/kg BAP 
and 86.6 µg/kg tPAHs; shrimp (raw) nd BAP and 9.30 µg/kg tPAHs; and tuna (raw) 
0.015 µg/kg BAP.  Visciano et al. (2006) also reported PAH levels in salmon, fresh and 
smoked.  They found that the mean concentration of BAP in raw salmon was 3.67 ± 3.99 
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ng/g dw and 3.20 ± 2.05 ng/g dw in smoked salmon.  Overall, eleven PAHs were 
quantified, with a total of 231.77 ± 46.56 ng/g dw in raw salmon and 226.27 ± 38.12 
ng/g dw in smoked salmon.  PAHs have also been detected in meteorites, and interstellar 
clouds (Harvey 1997).     
PAHs were first linked to human cancer by Sir Percival Pott in 1775, who 
observed an elevated incidence of scrotal cancer in chimney sweeps exposed to soot.  
Later, Cook et al. (1933) isolated a single PAH, 1:2-benzpyrene which is now called 
benzo(a)pyrene, from a coal tar pitch and observed its capabilities for tumor production 
in rodents.  This study involved isolation of BAP from the complex mixture using a 
distillation extraction process.  Briefly, alcohol extract of pitch distillate (coal tar) was 
distilled and dissolved in benzene.  The liquid phase of benzene was shaken with 5% 
sulfuric acid.  The benzene was distilled off, and the residue dissolved in acetic acid.  
Picric acid was added, and then crystallized 4 to 5 times from benzene.  The liquid phase 
was shaken with sodium carbonate and distilled at 3 mm.  The distillate was then re-
crystallized three times with benzene and alcohol.  1:2-benzpyrene then crystallized and 
was collected.  This fraction was found to be strongly carcinogenic in mice, causing skin 
cancer (methods not described).  After these early studies, BAP became one of the most 
studied PAHs, and still is extensively studied (Miller 1978).  Exposure to PAH mixtures 
can occur through ingestion, inhalation and dermal absorption.  A review by Ramesh et 
al. (2004) indicates that PAHs have been found to induce cancer, hematotoxicity, 
cardiotoxicity, renal toxicity, neurotoxicity, immunotoxicity, reproductive toxicity, and 
developmental toxicity in animals and humans.   
PAHs have been categorized into two groups, peri-condensed PAHs and cata-
condensed PAHs.  Peri-condensed PAHs form a cycle as their lines connect the ring 
centers.  Within peri-condensed there are two subgroups, alternate and non-alternate.  
Alternate peri-condensed PAHs are formed of six-membered rings.  Non-alternate peri-
condensed PAHs are formed of five- and six-membered rings.  Cata-condensed PAHs do 
not form cycles, these can be classified as branched or non-branched.  PAH structure 
plays a very important role in the biological activity of the compound.   
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Depending on structure, PAHs may have varying regions; the K region, the L 
region, the bay region, the distal bay region, and the peri position.  These regions are 
important structural characteristics in determining biological activity.  The most 
biologically active of the regions in the model carcinogen BAP is the bay region.  The 
bay region is an open inner corner of a phenanthrene moiety.  When a PAH is 
metabolized by mammalian enzymes, it can be excreted from the body, or it can be 
activated and bound to nucleic acids in DNA.  The reaction of the 7,8,9,10 
benzo(a)pyrene-diolepoxide with the N-2 of guanine results in the formation of a DNA 
adduct.   
In general, PAHs are lipophilic compounds which readily penetrate cellular 
membranes.  In the absence of metabolic transformations, the majority of an absorbed 
dose of PAHs would remain in the body.  The process of Phase I oxidative metabolism 
of PAHs modifies the structure of the parent compound resulting in a metabolite that is 
usually more water-soluble, and thus more readily excreted from the body.  There are 
multiple pathways for metabolic conversion of PAHs (Figure 1.4).  The Phase I and 
Phase II enzymes for metabolism of PAHs are common in mammalian systems.  
Generally, the highest level of metabolizing enzymes is in the liver, followed by the 
kidney and lungs.   The rate and extent of PAH metabolism also depends on structure of 
the specific compound.  For instance, alternate PAHs are processed differently than non-
alternate PAHs.  Because PAHs consist of multiple fused benzene rings, there structures 
are similar.  This similarity explains why they, as a group, undergo similar 
biotransformations.  BAP, the most extensively studied compound among PAHs, is used 
as a model compound for the metabolism of PAHs (Figure 1.5).  BAP undergoes 
metabolism by the cytochrome P-450 enzymes.  Uno et al. (2001; 2004) have shown that 
CYP1A1 is essential for not only PAH-mediated toxicity, but it is also essential for 
detoxification of oral BAP.  In 2001 Uno et al. showed that when CYP1A1 is not present 
(Cyp1a1(-/-) knockout mice), mice were protected against liver toxicity and death.  They  
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concluded that this was due to the decrease in production of the normally large amounts 
of toxic metabolites.  However, in 2004 Uno et al. showed that CYP1A1 was necessary 
for the detoxification of orally dosed BAP.  Higher levels of DNA adducts were detected 
in the Cyp1a1(-/-) mice as compared to the levels seen in Cyp1a1(+/+) mice.   
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Figure 1.4.  Metabolic pathways of PAH metabolism (Harvey 1991).  MFO is mixed function 
oxidase, EH is epoxide hyrolase, GST is glutathione-S-transferase, R = glucuronate or sulfate. 
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Benzo(a)pyrene Metabolism Pathways 
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Figure 1.5.  Scheme depicting the several different pathways for metabolic activation of 
benzo(a)pyrene.  These pathways are assumed to apply generally to all PAHs, due to the 
structural similarities of these compounds.  Scheme was modified from a Figure in ATSDR 1995. 
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These Phase I oxidation reactions generally produces arene oxides.  Arene oxides 
may then be transformed into several different structures including phenols by 
spontaneous reaction, trans-dihydrodiols by hydration which is catalyzed by microsomal 
epoxide hydrolase, or the arene oxide may bind to glutathione covalently by spontaneous 
reaction in glutathione-S-transferase catayzation.  At this point, 6-
hydroxybenzo(a)pyrene has been formed, and is then oxidized to 1,6-, 3,6-, or 6,12-
quinones via spontaneous or metabolic reaction.  Two further phenols may be oxidized; 
3-hydroxybenzo(a)pyrene to 3,6-quinone and 9-hydroxybenzo(a)pyrene to the K-region 
4,5-oxide.  The 4,5-oxide can then be hydrated to 4,5-dihydrodiol (4,5,9-triol).  
Glucuronides and sulfate esters may then be conjugated from the phenols, quinones, and 
dihydrodiols, while glutathione conjugates can be formed from the quinones as well.  
Conjugation is not the only reaction that the dihydrodiols may undergo.  More oxidative 
metabolism may also modify the structure of the dihydrodiols via cytochrome P-450 
enzymes.  This reaction generally results in the formation of the 7,8-dihydrodiol-9,10-
epoxide.  There are two types of reactions that can conjugate diol epoxides, spontaneous 
reaction or glutathione-S-transferase reaction.  Alternatively, the diol epoxides may form 
tetrols via spontaneous hydrolization.  The 7,8-dihydrodiol-9,10-epoxide is generally 
thought of as being the major compound responsible for carcinogenic activity of BAP 
(ATSDR 1995).   
The USEPA considers seven PAHs to be potentially carcinogenic to humans.  BAP 
(Figure 1.6) is listed as a class B2 probable human carcinogen.  Pure BAP appears as 
pale yellow needles or plates in the solid form (Harvey 1997; USEPA 1994b).  The 
carcinogenic potential of BAP has been demonstrated in numerous animal assays via  
several different routes of administration and numerous genotoxic assays(Culp et al. 
1998; Gaylor et al. 2000; Ramesh and Knuckles 2006; Rodriguez et al. 1997; USEPA 
1994b).   
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Animals showing positive carcinogenic responses include rats, mice, hamsters, and 
guinea pigs.  Routes of exposure reported as carcinogenic in animals include dietary, 
gavage, inhalation, intratracheal instillation, dermal studies, intraperitoneal injection, 
subcutaneous injection, intravenous, transplacentally, implantation in the stomach wall, 
lung, renal parenchyma and brain, injection into the renal pelvis, and vaginal painting.  
In oral exposure, the type of tumors seen include forestomach, squamous cell papillomas 
and carcinomas.  BAP, often considered a model carcinogen, has multiple areas for 
metabolic activation, including a bay-region.  The pathway for binding to DNA is shown 
in Figure 1.7.  The benzo(a)pyrene diol epoxide attached to the N2 of deoxyguanosine is 
shown in Figure 1.8.  In a review done by the USEPA (1991), the report shows that 
intraperitoneal injections have higher numbers of injection site tumors in mice and rats.  
Neal and Rigdon (1967) administered BAP at 0, 1, 10, 20, 30, 40, 45, 50, 100 and 250 
ppm in the diet of male and female CFW-Swill mice.  Forestomach tumors were 
detected in the 20+ ppm dose ranges.  Tumor of incidence was also observed to increase 
with dose.  Brune et al. (1981) fed 0.15 mg/kg BAP to Sprague-Dawley rats.  Dose times 
ranged from every nine days to 5 times a week until death, making the average dose 6 or 
39 mg/kg respectively.  Tumors were observed in the forestomach, esophagus and 
larynx.  A statistical trend for tumor incidence was also observed based on dose.   
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USEPA Class B2 Carcinogenic PAHs 
Chrysene Benz(a)anthracene Dibenz(a,h)anthracene
Benzo(a)pyrene Indeno(1,2,3-cd)pyrene Benzo(b)fluoranthene
(Benzo(e)acephenanthrylene)
Benzo(k)fluoranthene  
Figure 1.6.  PAHs classified as class B2 carcinogens by the USEPA (Harvey 1991; USEPA 
2006b). 
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Mechanism of BAP-DNA Binding 
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Figure 1.7.  Mechanism by which the anti configuration of benzo(a)pyrene diol epoxide binds to 
DNA covalently (Harvey 1991). 
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Figure 1.8.  Benzo(a)pyrene diol epoxide, anti configuration, adduct attached at the N
2
 position 
of deoxyguanosine (Harvey 1991). 
 
 
Benz(a)anthracene (BAA) (Figure 1.6) is also classified as a class B2 probable 
human carcinogen by the USEPA IRIS database.  According to the USEPA’s IRIS 
database, BAA has been shown to produce tumors in vivo in mice via gavage, 
intraperitoneal injection, subcutaneous injection, intramuscular injection, and topical 
application.  It has also been shown to produce mutations in vitro via bacterial cells and 
mammalian cells.  There is no human carcinogen data for BAA, although an excess rate 
of cancer has been observed in humans exposed to complex mixtures that include BAA 
including cigarette smoke, coal tar, and soot.  The mechanisms of action and metabolic 
activation for PAHs in general fit BAA for carcinogenic potential, as this compound 
does posess a bay region (ATSDR 1995; USEPA 1994a).  Wislocki et al. (1986) injected 
90-100 male and female CD-1 mice intraperitoneally with BAA in DMSO at 1, 8, and 15 
days of age for a total dose of 638 µg/mouse.  A statistical incidence of tumor adenomas 
or carcinomas was observed in the male mice, while pulmonary adenomas were 
observed in the female mice as statistically significant level.  Steiner and Falk (1951) 
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injected C57Bl mice subcutaneously with BAA in tricaprylin.  Sacromas were observed 
at the site of injection nine months later, with a survival rate of ~70%.   
The third Class B2 carcinogenic PAH is benzo(b)fluoranthene (BBF) (Figure 1.6), 
also called benz(e)acephenanthrylene.  The USEPA’s IRIS database indicates that BBF 
has been found to produce tumor in mice via lung implantation, intraperitoneal injection, 
subcutaneous injection, and skin painting.  In 1987, LaVoie et al. injected male and 
female CD-1 mice intraperitoneally with BBF in DMSO at 1, 8, and 15 days old.  The 
total dose given was approximately 126 µg/mouse.  After 52 weeks of age, the mice 
were sacrificed and tumor incidence observed.  Liver adenomas and hepatomas were 
significant in males, while lung adenomas were reported in both males and females.  
Wynder and Hoffmann (1959) conducted skin painting assays with BFF and female 
Swiss mice.  Mice were treated with doses of 0.01, 0.1 or 0.5% BFF solutions in acetone 
were three times a week.  By eight months 100% of the high dose mice had papillomas, 
while 90% had carcinomas.  The middle dose produced 65% papillomas and 85% 
carcinomas by 12 months, while the low dose produced one papilloma in 10 animals that 
survived to 14 months.  As with the other PAHs, there is no human carcinogenicity data 
for this compound, although it is linked to human cancer via complex mixtures such as 
cigarette smoke, coal tar, and soot.  The structure of BBF includes a bay-region, thus 
allowing it to fall into the current theories on mechanisms of action and metabolic 
activation of PAHs (ATSDR 1995; USEPA 1994c).   
Benzo(k)fluoranthene (BKF) (Figure 1.8) is also listed by the USEPA as a class B2 
probable human carcinogen.  BKF has been demonstrated in vitro to be mutagenic via 
bacterial assays.  BKF has also been shown to produce tumors in vivo in mice via lung 
implantation and skin painting (with a promoting agent for the latter).  In 1987, LaVoie 
et al. injected male and female CD-1 newborn mice intraperitoneally with BKF in 
DMSO.  A total dose of 126 µg/mouse was given at 1, 8, and 15 days of age.  After 52 
weeks of age, the mice were sacrificed.  Hepatic adenomas and hepatomas were 
increased in the male mice, and lung adenomas were observed in both sexes.  Skin 
painting assays were also preformed by Van Duuren et al. in 1966.  A dose of 11 mg of 
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BDF was treated one time on Swiss mice.  After 63 weeks, no tumors were observed.  
However, tumors were observed when promoting treatments of croton resin were added.  
Papillomas were observed in 18/20 animals, while carcinomas developed in 5/20 
animals.  BKF is another PAH which is present in complex mixtures such as cigarette 
smoke and soot that have been found to increase the risk of cancer in humans (USEPA 
1994d).     
Chrysene, a four ring PAH, is also defined by the USEPA as a class B2 probable 
human carcinogen (Figure 1.6).  The review for chrysene indicates that this chemical has 
been shown to produce carcinomas, malignant lymphomas and chromosomal 
abnormalities in vivo in mice via intraperitoneal injection and dermal exposure and in 
hamster and mouse germ cells via gavage (respectively).  Male and female CD-1 mice 
were injected intraperitoneally with chrysene dissolved in DMSO at 1, 8, and 15 days of 
age (Wislocki et al. 1986).  Total doses were 0, 160 or 640 µg/mouse.  A significant 
incidence of liver adenomas and carcinomas were observed in male mice, 29% and 11% 
in the low dose, and 41% and 75 in the high dose, respectively.  Malignant lymphoma 
was significant in the male low dose (9%), but not in the high dose (0%).  Lung 
adenomas were significantly elevated in males at the high dose, while female mice did 
not see a significant increase in any tumors.  Buening et al. (1979) dosed male and 
female Swiss Webster BLU/Ha(ICR) mice with 320 µg/mouse of chrysene in DMSO at 
1, 8, and 15 days of age via i.p. injection.  After 38-42 weeks of age, mice were 
evaluated for tumor incidence.  Lung tumors were elevated, 21% in males and 9% in 
females.  Hepatic tumors in males were significantly higher (25%), while females had a 
0% incidence.  This compound has also shown positive genotoxicity in bacterial 
mutation assays and in transformed mammalian cells.     Chrysene contains a bay-region, 
and is assumed to be metabolically activated through this structure (USEPA 1994e).   
The USEPA IRIS database has also classified dibenz(a,h)anthracene (DA) (Figure 
1.6) as a class B2 probable human carcinogen.  DA has been shown in vivo to produce 
carcinomas and injection site tumors in mice and other species via oral or dermal 
exposures and subcutaneous or intramuscular injections (respectively).  In vitro, DA has 
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demonstrated the ability to induce DNA damage, along with gene mutations in bacterial 
assays as well as mammalian cells.  DA contains a bay-region structure, through which it 
is proposed to be metabolically activated for its carcinogenic potential (USEPA 1994f).  
Biancifiori and Caschera (1962) showed mammary carcinomas in female Balb/c (1/20) 
and pseudo-regnant (13/24) female mice.  Mice were gavaged twice a week for 15 weeks 
with 0.5% DA for a total dose of 15 mg/mouse.  Lubet et al. (1983) found fibrosarcoma 
development with subcutaneous injections of DA.  Four strains of mice, C3H/HeJ, 
C57B1/6J, AKR/J and DBA/2J, were injected a single time with 150 mg DA in 0.05 mL 
trictanoin.  After 9 months, animals were sacrificed.  Tumor incidence was between 0 
and 80%, strain dependent.  The C3H and C57B1 mice had higher tumor incidence than 
the AKR or DBA mice.  Fibrosarcoma development was inversely correlated with tumor 
incidence.   
Indeno(1,2,3-cd)pyrene (IP) (Figure 1.6) is also a class B2 probable human 
carcinogen, according to the USEPA’s IRIS database.  IP has demonstrated the ability to 
produce tumors in vivo in mice via lung implants, subcutaneous injection and dermal 
exposure.  Hoffmann and Wynder (1966) painted the skin of female Swiss albino 
Ha/ICR/Mil mice with IP in dioxane (0.05 and 0.1%) or acetone (0.01, 0.05 and 0.1%).  
Dioxane treatments did not induce tumor formation, however, acetone treatment did.  
The acetone treatments produced skin tumors in a dose-responsvie manner for the two 
highest doses.  Six papillomas and three carcinomas were observed at 9 months in the 
0.1% treatment, while seven papillomas and five carcinomas were observed in the 0.5% 
treatment with the first appearing at three months.  Rice et al. (1986) applied IP 
dissolved in acetone to the shaved backs of Crl:CD-1(ICR)BR female mice.  Treatments 
were applied every other day for 10 days, total IP dose was 1 mg.  After 10 days, 
tetradecanoylphorbol was applied as a promoter (0.0025% in 100 mL acetone) three 
times a week for 20 weeks.  Tumor incidence was observed to be 100%.  In vitro, IP has 
also produced positive results in bacterial mutation assays.  There is no human 
carcinogenicity data for IP.  Generally, IP is found environmentally as part of complex 
mixtures.  These complex mixtures may include coal tar, coke oven emissions, and 
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cigarette smoke.  Because of the association of IP with these complex mixtures, it may 
also be associated with human cancer (USEPA 1994g).   
The formation of bulky DNA adducts is generally believed to represent the 
initiation step in the three step process (initiation, promotion and progression) to 
transform a normal cell into a malignant cancer cell (Ramesh et al. 2004).  Using a 
battery of in vitro and in vivo studies, this research will develop information regarding 
the ability of PAH mixtures to induce mutations and ultimately to cause tumor 
formation.   
 
1.3.3  Polychlorinated Aromatic Compounds 
The combustion of plastics produces mixtures of both PAHs and PCAs including 
the polychlorinated dibenzo-p-dioxins (PCDDs) and dibenzofurans (PCDFs).  Another 
common complex environmental mixture containing both PCAs and PAHs is the waste 
stream from the treatment of wood with a mixture of diesel oil and pentachlorophenol.  
Many wood preserving facilties used creosote for treating utility poles and railroad ties, 
and pentachlorophenol for treating smaller wood products.  Contamination of soil and 
groundwater with mixtures of PAHs and PCAs at wood preserving sites is common.  
Thus, much like the PAHs, PCAs are ubiquitous environmental contaminants.    PCAs 
are recalcitrant in the environment due to the resistance of chlorinated molecules to 
oxidative degradation.  The electrophilic nature of the chlorine substitution renders 
PCAs highly lipophilic.   Thus, PCAs, especially PCDDs and pentachlorophenol (PCP), 
will partition into lipids or organic matter and are likely to bioaccumulate in the 
environment as well as in the food chain.   
Environmental media contaminated with PCAs may contain several hundred 
different chemicals.  These complex mixtures contain various isomers and congeners of 
the halogenated compounds.  The chemical, physical and toxicological properties of the 
PCA congeners are dependent on the amount of halogens present in the aromatic ring 
(Safe et al. 1990).  PCDDs include 75 different congeners, including 2,3,7,8-
35 
tetrachlorodibenzo-p-dioxin (TCDD).  TCDD is considered to be the most toxic 
congener of the PCDDs, and thus is the most widely studied (ATSDR 1998).   
The most noted toxic response in humans from acute exposure to PCDDs is 
chloracne.  Safe et al. (1990) indicate that PCDDs have also been shown to cause body 
weight loss, thymic atrophy, impairment of immune responses, hepatotoxicity and 
porphyria, dermal lesions, tissue-specific hypo and hyperplastic responses, 
carcinogenesis, teratogenicity and reproductive toxicity, and are highly species, sex and 
age specific.  PCDDs are a class of chemicals that contain eight different congeners.  
Potency of these congeners depends upon their affinity for the AhR receptor.  In general, 
the more chlorinated the congener, the less potent.  TCDD is the most toxic congener, 
and the model compound for PCDDs (Anderson and Conolly 1998; DHHS 2004; 
Loertscher et al. 2002).  However, it is important to note the species in which the PCDDs 
are being tested, as toxic effects vary greatly between species (Safe et al. 1990).  There is 
large sensitivity among species, and even among strains, for example Long-Evan rats are 
sensitive to dioxins while Han/Wistar rats are resistant.  However, mice, rats and 
hamsters have all shown affinity for dioxin toxicity (DHHS 2004; Viluksela et al. 2000).     
 
1.3.3.1  Polychlorinated Dibenzodioxins and Furans 
Because of the diverse structures of the many congeners (Figures 1.9 and 1.10) of 
the PCDDs and PCDFs these compounds may produce a broad range of toxic, genotoxic 
and epigenetic responses. As by-products of industrial processes and incomplete 
combustion, these compounds have been detected in environmental media in all parts of 
the world.  In Hamburg, 3.5/0.23 pg/m3 levels of TCDF/TCDD were detected in the 
atmosphere in a motorway tunnel (Rappe et al. 1988).  Levels of TCDD/TCDFs have 
been detected in Lake Superior fish are 5.7-22 ppt/0.3-2.8 ppt (Zacharewski et al. 1989).  
The same study also reported levels Lake Ontario fish as 36-45 ppt/13-30 ppt.  Adipose 
Tissue levels were reported by Nygren et al. (1988) as 3.9 ppt for TCDF, 54 ppt for 
PCDF, 3 ppt for TCDD and 15 ppt for PCDD.  The major route of exposure for PCDDs 
and PCDFs is believed to be through food intake (Figure 1.11) (IOM 2003).  In the 
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United States, there are 126 sites on the National Priority List where PCDDs are listed as 
a contaminant of concern.  PCDDs may be classified into eight groups, based on the 
number of chlorine atoms, ranging from mono-chlorinated dioxins to octa-chlorinated 
dioxins.  The chlorine atoms may be bound to any of eight carbon atom positions 
available on the aromatic rings.  The toxicity of PCDDS is highly dependent on the 
number of chlorine atoms, and their position.  The most toxic PCDD congener is TCDD.  
Thus, TCDD is the most studied of these compounds (ATSDR 1994).  Since the 
production of most chlorinated chemicals has been reduced in recent years, there has 
been a corresponding reduction in the release of PCDDs into the environment.  
However, because these compounds are persistent and capable of bioaccumulation, there 
is still concern for their potential adverse human and ecological health effects.   
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Figure 1.9.  Polychlorinated dibenzo-p-dioxins and 2,3,7,8-tetrachlorodibenzo-p-dioxin (Poland 
1984). 
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Figure 1.10.  Polychlorinated dibenzofurans and 2,3,7,8-tetrachlorodibenzofuran (Poland 1984). 
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PCDD Food Exposure Pathways 
 
Figure 1.11.  Pathways for the major source of exposure to PCDDs, food exposure.  Light 
arrows depict smaller contribution sources than the dark arrows.  Adapted from Figure 4-1 in the 
book Dioxins and Dioxin-like Compounds in the Food Supply, Institute of Medicine of the 
National Academies, 2003.   
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release and recirculate PCDDs via short, long and intermediate releases.  Atmospheric 
transportation is the major cause for release to the environment.  Due to the low water 
solubility and high lipophilicity of these compounds, they tend to be transported through 
air, and then soil.  When in the water column, PCDDs bind to particles in the water, and 
are eventually removed through sedimentation (IOM 2003).  The largest impact on 
PCDD contamination can be attributed to anthropomorphic practices such as 
incineration and combustion processes.  PCDDs are almost always accompanied by 
PCDFs, due to the processes in which they are formed, and their similar structure.  These 
same reasons account for their association with chlorinated phenols as well.  This 
tendency makes it difficult to discern PCDD and PCDF effects from exposure in human 
populations.  TCDD is the most toxic and most studied compound, it is considered to be 
the model compound for PCDD toxicity.  Toxic Equivalent Factors (TEFs) were 
developed as a way of expressing toxicity of dioxin-like compounds as a fraction of the 
toxicity of TCDD.  Potency of the PCDD and PCDF congeners is thought to depend 
highly on their AhR affinity.  Therefore, dioxin like compounds are compared to TCDD, 
which has the highest affinity for AhR.  The TEF value for TCDD is 1.0, with all others 
based on their fractional potency relative to TCDD (ATSDR 1998; Finley et al. 2003; 
Safe et al. 1990).  The AhR protein has a binding specificity for aromatic hydrocarbons.  
AhR can be set free from its chaperone proteins by ligand binding.  This allows it to 
enter the nucleus and bind to ARNT.  This ligand-AhR-ARNT comlpex enhances 
transcription of multiple genes (CYP1A1, 1A2, 1B1, and glutathione-S-transferase) 
(Franc et al. 2001a).  TCDD has a high affinity for the AhR (Franc et al. 2001a; Franc et 
al. 2001b).     
PCDDs have a half life of elimination of 8.5 years in adults (ATSDR 1998).  
TCDD promotes tumor formation and altered hepatice foci (Pitot et al. 1980; Walker et 
al. 2000; Wyde et al. 2002).  TCDD also depletes hepatic vitamin A (Fattore et al. 2000); 
(Fletcher et al. 2001).  This reduction of hepatic viatamin A along with decreasd weight 
gain can be a biomarker for TCDD exposure in laboratory animals.  Poland et al. (1982) 
demonstrated TCDDs ability to promote tumor formation.  In HRS/J hairless mouce, 
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exposure to a carcinogen followed by repeated exposures to TCDD produced papillomas 
in hr/hr mice, but not hr/+ mice.  In mice treated with N-methyl-N’-nitroN-
nitrosoguanidine (MNNG), 55-100% tumor incidence was observed (doses from 3.75 ng 
to 15 ng).  Randerath et al. (1988) studied on the DNA adduct levels after TCDD and 
PCDD exposure.  Rats treated with these compounds did not form appreciable levels of 
DNA adducts, thus confirming ealier findings that TCDD was not genotoxic.   
Occupational and environmental exposures to PCDDs and PCDFs occur 
frequently, since these compounds are ubiquitous and highly persistent in the 
environment due in part to their lipophilic nature.  Humans are exposed to these 
compounds in the diet and their lipophilicity results in bioaccumulation in human 
adipose tissues and the environment.  Several epidemiological studies have been done 
regarding PCDDs and PCDFs.  The most well known effect is the dermal effect, 
chloracne.  Eventhough multiple epidemiological studies have been done on PCDDs and 
PCDFs, there is inconclusive evidence for carcinogenicity of PCDDs and PCDFs (Asp et 
al. 1994; Becher et al. 1996; Bertazzi et al. 1997; Green 1991; Hooiveld et al. 1998; 
Kogevinas et al. 1997).  The most obvious exposure sign was chloracne.  However, 
Steenland et al. (1999) did a follow up study on an industrial cohort and showed that 
approximately 334 out of an expected 113 people died from cancer after exposure.  They 
conclude that TCDD exposure does cause cancer.  Unfortunately, statistically this study 
does not provide good evidence for a link to cancer (Cole et al. 2003). 
TCDD is classified as a human carcinogen by the 11th Report on Carcinogens 
(DHHS 2004).  This classification is based on data observed in epidemiological studies.  
Not much is known about the mechanisms of action in humans for PCDDs and PCDFs.  
The mechanism includes binding to the AhR the first and most important step.  Most 
dioxin-like compounds, including PCDFs, are thought to act through similar 
mechanisms of action due to their structural similarities.  It is possible to monitor 
exposure through biomarkers of exposure.  Adipose tissue and liver generally exhibit the 
highest concentrations of PCDDs and PCDFs.  Due to the lipophilicity, these tissues are 
the primary storage sites for PCDDs and PCDFs.  PCDDs and PCDFs are measured in 
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these tissues as biomarkers of exposure.  Other biomarkers of exposure include breast 
milk, and reverse transcriptase polymerase chain reaction (RT-PCR).  The RT-PCR can 
measure CYP1A1 mRNA levels in blood lymphocytes.  When TCDD is present, 
CYP1A1 has been demonstrated to increased by 21 times.  Biomarkers of effect, 
chloracne and biochemical changes are also observed (ATSDR 1998).   
 
1.3.3.2  Pentachlorophenol 
The National Priorities List (NPL) includes 313 sites where PCP has been 
identified as a contaminant of concern.  This chemical is listed by the USEPA as a a 
class B2 probable human carcinogen.  Pentachlorophenol has a chemical formula of 
C6HCl5O (Figure 1.12) and a molecular weight of 266.35.  Pure PCP appears as 
colorless crystals (ATSDR 2001; USEPA 1993).   PCP is produced using a catalyst 
stepwise process that chlorinates phenols (ATSDR 2001).  The USEPA oral cancer slope 
factor for PCP is 1.2 x 10-1 (USEPA 1993).  The cancer slope factor is based on the 
finding that animals administered PCP developed hepatocellular adenomas, carcinomas, 
adrenal medulla pheochromocytomas, malignant pheochromoxytomas, 
hemangiosarcomas and hemangiomas.   Although occupational and environmental 
exposures to this compound are common, the USEPA believes that there is inadequate 
data for the human carcinogenicity of PCP (USEPA 1993).   
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Figure 1.12.  Pentachlorophenol. 
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PCP was widely used as a pesticide/biocide in the United States before its 
restriction in 1987.  This all purpose biocide (herbicide, defoliant, mossicide, and 
disinfectant) was used in multiple applications including, but not limited to leather 
tanning, wood preservation, and in paints (ATSDR 2001; Klaassen 2001; USEPA 1993).  
The use of PCP as a wood preservative began in the 1930s.  Shortly after, in 1947, some 
3,200 metric tons were used in wood preservation. In 2002, approximately 11 million 
pounds of PCP were consumed in the United States due to restrictions on use (USEPA 
1993).  Exposure to PCP is generally to the technical grade, which contains a number of 
impurities including lower chlorinated phenols, polychlorinated dibenzo-p-dioxons and 
dibenzofurans (Ahlborg and Thunberg 1980).  Occupational exposures generally occur 
through inhalation and dermal contact.  Environmental exposures may occur when a 
person comes in contact with contaminated media.  Exposure routes of concern are 
inhalation of contaminated air and volatilized PCP, as well as ingestion of contaminated 
food and dermal contact with contaminated soils or surfaces.   
Several case studies have suggested that there is a relationship between 
occupational exposure to PCP and cancer (Dahlgren et al. 2003; Demers et al. 2006; 
Eriksson et al. 1990; Hardell et al. 1994; Jappinen et al. 1989).  Oral administration of 
PCP to animals has shown several target organs.  These target organs include the liver, 
kidney, central nervous system, endocrine system, immune system and the reproductive 
system (IARC 1998a; Seiler 1991).    A proposed mechanism of action for PCP is the 
uncoupling of oxidative phosphorylation.  This results in an acceleration of aerobic 
metabolism and the production of heat.  Although no single organ or tissue is 
specifically targeted, multiple organs may exhibit signs of PCP toxicity following 
exposure (ATSDR 2001).  
PCP contains a benzene ring with a single hydroxyl substituent and five chlorine 
substituents.  This structure results in a nonpolarity for this compound which decreases 
water solubility and increases lipid solubility.  These attributes facilitate the transfer of 
PCP across cell membranes.  PCP also has an affinity for binding to plasma proteins, 
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which allow for distribution via the blood streem.  PCP is not easily metabolized, and 
therefore generally persists in mammalian systems as the parent compound (Ahlborg et 
al. 1974; Braun et al. 1979; Larsen et al. 1972).  PCP can be monitored through 
biomarkers of exposure (Chou and Bailey 1986; Drummond et al. 1982; Edgerton et al. 
1979; Holler et al. 1989; Jorens and Schepens 1993).  Because PCP remains unchanged 
for a large part, it can be quantified in urine, a major route of excretion (Benvenue et al. 
1968; Needham et al. 1981).  PCP can also be quantified in blood serum and adipose 
tissue.  PCP has also been detected in adipose tissue as an ester of palmitic acid (Kuehl 
and Dougherty 1980; Needham et al. 1981; Ohe 1979).  However, this is not a specific 
biomarker for PCP, as other chemicals may be metabolized into PCP after exposure 
(lindane, etc.).  Two other biomarkers of exposure are TCHQ in urine (still not specific 
to PCP) and 8-hydroxydeoxyguanosine in the liver (increased levels due to oxidative 
DNA damage) (Ahlborg et al. 1974; Jorens and Schepens 1993; Juhl et al. 1985; Sai-
Kato et al. 1995; Umemura et al. 1996).  Approximately 90% of PCP was eliminated in 
the urine and feces of volunteers withing 7 days (Ahlborg and Thunberg 1980).  The 
liver and kidney are the two major target organs in humans and animals.  Elevated serum 
ALT and AST levels in the liver and increased enzyme levels, blood urea nitrogen, and 
loss of proximal tubular alkaline phosphatesase activity for kidney are biomarkers of 
effects for PCP exposure (ATSDR 2001).   
 
1.4 Toxicity Test Methods 
 Chemical analysis provides important information regarding the composition and 
concentration of compounds in a complex mixture.  Bioassays provide a tool to 
investigate mechanisms and interactions of the components of a complex mixture.  In 
vitro and in vivo bioassays play and important role in toxicity evaluation of chemicals 
and mixtures (Ciganek et al. 2004).  Microbial genotoxicity assays provide a useful tool 
for screening complex mixtures and isolated fractions.  A major limitation of microbial 
bioassays is their inability to replicate the pharmacokinetic (e.g., absorption, distribution, 
metabolism and excretion) factors that may influence mixture carcinogenicity.  Thus, it 
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is important to use multiple assays when evaluating the toxicity or genotoxicity of a 
substance.  The optimal protocol as defined by Maron and Ames (1983) would include 
multiple bioassays where “the strengths of one test can compensate for the inadequacies 
of another”. 
 
1.4.1  In Vitro Bioassays 
 In vitro bioassays provide a valuable tool for screening a large number of complex 
environmental mixtures.  Microbial bioassays are inexpensive, provide a response within 
a short time frame, and are relatively easy to conduct.  Short-term in vitro bioassays have 
been used in previous studies to screen potential carcinogens (McCann et al. 1975), to 
detect genotoxic compounds in complex environmental mixtures (Donnelly et al. 1998), 
and to identify genotoxic compounds in isolated fractions (DeMarini et al. 1990).  Data 
collected from these assays can be used to prioritize mixtures or compounds for further 
study using in vivo assays. 
 
1.4.1.1  Salmonella/microsome Assay 
The most widely studied in vitro bioassay is the Salmonella mutagenicity test, also 
known as Ames assay.  There have been multiple revisions to the original protocol, first 
validated by McCann et al. (1975).   The protocol in current use was described in Maron 
and Ames (1983).  The Salmonella/microsome assay has been used to detect mutagens 
in samples of cigarette smoke (Roemer et al. 2004), diesel exhaust (Seagrave et al. 
2005), hazardous waste (Donnelly et al. 1987; Houk and Claxton 1986), surface waters 
(Ohe et al. 2004), sewage sludge (Perez et al. 2003), and soils (Watanabe et al. 2005).  
This bioassay has also been used to identify and characterize mutagens such as 
heterocyclic amines in cooked foods (Knize et al. 2003; Shishu and Kaur 2003; 
Sugimura et al. 2004).     
McCann et al. (1975) report of the more than 300 chemicals that have been tested 
using this assay, 90% of the known carcinogens tested showed a positive mutagenic 
response.  They also report that the correlation between carcinogenicity and 
44 
mutagenicity is 83%.  In 1987, Tennant et al. (1987a) conducted a detailed comparison 
of short-term tests and rodent carcinogenicity.  They observed that although the 
sensitivity was only 45% (percent of carcinogens yielding a positive result in microbial 
bioassay), 83% of the compounds that induced a positive response in the Salmonella 
microbial bioassay were also rodent carcinogens.    Tennant et al. (1987b) also found 
that the majority of chemicals that are trans-sex/trans-species carcinogens are also 
genotoxic in microbial tests.   
In analytical chemistry, a variety of systems may be used to detect different classes 
of chemicals.  This is a result of the different chemical structures and properties and 
reflects knowledge gained from many years of environmental measurements.  Similarly, 
microbial bioassays exhibit differing sensitivities to different classes of chemicals.  
Purchase et al. (1976) found that 95% of the PAHs that induced a mutagenic response in 
Salmonella were also rodent carcinogens.   Although the Salmonella bioassay in a 
sensitive method for detecting carcinogenic PAHs, it is relatively insensitive towards 
carcinogenic PCAs.  In addition, the Salmonella bioassay is relatively insensitive to 
compounds that may be cytotoxic at low doses (Maron and Ames 1983).  These 
limitations need to be considered when designing a protocol using multiple bioassays.  
The research described in this dissertation used two microbial mutagenicity bioassays to 
screen model carcinogenic chemicals and complex mixtures.  Compounds and isolated 
complex mixtures that tested positive in the microbial bioassay were further tested using 
an infant mouse model to measure the ability of these to induce tumors.  The results 
from this battery of bioassays were then compared with the composition of the mixtures 
as determined by quantitative chemical analysis.    Standard Salmonella  tester strains 
include TA89, TA90, TA92, TA94, TA97, TA98, TA100, TA102, TA110, TA1530, 
TA1534, TA1535, TA1538, TA1950, TA1964, TA1975, TA1978, TA2410, TA2631, 
and TA2641.  The standard tester strains that are recommended for general mutagenesis 
testing include TA97, TA98, TA100 and TA102.   These microbial strains have been 
engineered to be sensitive to different classes of genotoxic compounds.   
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A variety of mutations and deletions have been incorporated into the Salmonella 
typhimurium tester strains in order to increase their sensitivity towards certain classes of 
carcinogens.  All of the tester strains were originally derived from S. typhimurium LT2.  
The different tester strains of bacteria contain a primary deletion in the histidine operon.  
These include a hisG46, hisD3052, hisD6610, and hisG428 deletion.  Strains TA98 and 
TA1538 were derived from the hisG46 deletion, whereas the hisD3052 deletion was 
used to derive strains TA100 and TA1535.  This hisG gene codes for first enzyme in the 
process of histidine biosynthesis.  Bacteria with a deletion in this gene are unable to 
grow in media that has not been supplemented with histidine.  Thus, approximately 
100,000 cells are added to an agar plate containing a minimal media.  The media is 
supplemented with sufficient histidine to allow cells to undergo two replications.  
Chemicals that react with DNA inducing a reverse mutation produce a cell that is able to 
grow in minimal media and may be detected as a visible colony.   
The deletion in the hisG operon results in the substitution of one G and one C 
(proline, -GGG- -CCC-) for an A and T (leucine, -GAG- -CTC-), respectively.     The 
hisD3052 mutation eliminated the function of the histidinol dehydrogenase enzyme.  
The mutation sequence for this is 8 repetitive -GC- near a -1 frameshift mutation (-
CGCGCGCG- -GCGCGCGCG-).  Thus, strains TA1538 and TA98 are generally more 
sensitive to compounds that induce frameshift mutations.  During replication, pairing can 
become shifted in repetitive sequences.  Frameshift mutagens can stabilize this by a 
frameshift mutation, restoring the correct reading frame.  The hisD6610 mutation, 
another frameshift mutation, also is located in the hisD gene.  However, this strain has 
an added cytosine.  As a result, there are 6 repetitive cytosines in this sequence (-
CCCCCC-), along with another run of alternating -GC- near the cytosines.  The hisG428 
mutation is also located in the hisG gene.  This is called the ochre mutation (-TAA- -
ATT-).   
In addition to the primary mutation at the histidine operon, other mutations 
have been incorporated into the tester strains to increase sensitivity to certain types of 
chemical carcinogens.  The deep rough, or rfa, mutation results in an increase in 
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permeability of the microbial cell membrane.  As many carcinogens are high molecular 
weight compounds, this is an important mutation.  Cells containing the deep rough 
mutation were isolated using a large phage that could only enter cells that were absent of 
their lipopolysaccarhide membrane.   This membrane is located on the outer surface of 
the microbial cell wall.  In the absence of this membrane, permeability to chemicals is 
greatly increased.   Thus, large compounds, such as BAP are able to gain access to the 
cytoplasm of the microbe.  Many cells also contain an uvrB mutation.  This mutation 
affects the DNA excision repair system by a deletion in the gene code.  Without a 
properly functioning excision repair system, the cell looses the ability to repair chemical 
induced mutations.  The uvrB deletion eliminated both the excision repair and biotin 
synthesis enzymes.  Thus, strains with this deletion will also require trace amounts of 
biotin for growth.   
The addition of a plasmid that increased error prone repair was found to 
greatly increase the sensitivity of the Salmonella bioassay.  The plasmid, pKM101 was 
added to strains TA1535 and TA1538 to produce TA98 and TA100.  In fact TA97, 
TA98, TA100 and TA102 are all standard tester strains, and they all contain this 
plasmid.  The strains containing this plasmid are reverted by a number of mutagens that 
test as weak positive, or negative in the other strains.  This R-factor enhances chemical 
and spontaneous mutagenesis.   
 
1.4.1.2  E.coli Prophage Induction Assay 
This research was conducted to investigate the genotoxicity of complex mixtures 
containing chlorinated compounds and PAHs.  Since it is known that the Salmonella 
bioassay is relatively insensitive to chlorinated compounds, a test battery was designed 
to include a system that could be used to detect genotoxic chlorinated compounds.  The 
E. coli prophage induction assay, also known as the Microscreen prophage induction 
assay has been found to be sensitive to chlorinated compounds (DeMarini et al. 1990).  
The procedure for this bioassay was first described by Rossman et al. (1984) and revised 
slightly by DeMarini et al. (1990).   Most chlorinated compounds are unable to induce 
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point mutations.  As a result, reverse mutation assays, such as the Salmonella bioassay, 
are relatively insensitive to these compounds.   Most chlorinated compounds induce 
genotoxic damage by causing DNA strand breaks or chromosomal aberrations.  
DeMarini et al. (1990) found that the microscreen prophage induction assay detected 
chlorinated compound toxicity.   
The E. coli assay uses two bacterium, WP2s(λ), and TH008.  WP2s(λ) is a lambda 
lysogen from E. coli B/r, while TH008 is an indicator strain from E. coli C.  The 
WP2s(λ) lysogen has an ochre nonsense mutation.  This particular mutation has the 
ability to block a part of the tryptophan synthesis process.  For phage induction, the 
WP2s(λ) strain is grown overnight to mid-log phase and then inoculated into wells that 
contain the test sample and a minimal medium.   The wells are incubated overnight, and 
then scored for turbidity.  Turbid cells indicate that there is cell growth, where clear 
wells indicate there is no cell growth.  No cell growth can be due either to cytotoxicity or 
to growth inhibition.  The quantity of phage that is released to the media is a measure of 
the extent of DNA damage that has occurred.  Introduction of a chemical turns the SOS 
response on inside the cell.  Once the SOS response is activated, the prophage activates 
and turns into the phage.  The phage reproduces, multiplies and the E. coli cell then 
lyses.   An aliquot of the turbid cells is then diluted and plated with the indicator strain 
TH008.   The indicator strain is sensitive to the phage, and is supplemented with 
streptomycin.  The use of streptomycin is to select against the lysogen WP2s(λ).  The 
phage lyses the indicator strain resulting in the formation of a plaque.  If a chemical or 
mixture of chemicals is capable of producing a three-fold increase in plaque formation 
(compared to an acetone solvent control), the sample is considered to have induced a 
positive genotoxic response.  Thus, the two in vitro bioassays described in this section 
are capable of detecting chemicals that induce point mutations or DNA strand breaks.   
 
1.4.2  In Vivo Bioassays 
 Microbial bioassays are useful tools to measure the ability of a chemical or 
chemical mixture to react with DNA and induce genotoxic damage.  However, as stated 
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previously, microbial bioassays are unable to replicate the pharmacokinetic factors that 
influence the potential of environmental mixtures to cause cancer in humans.   Animal 
studies, in conjunction with in vitro and epidemiological studies, are important tools to 
identify environmental mixtures that increase the incidence of cancer in exposed 
populations.     
 
1.4.2.1  DNA 
32
P-postlabeling Assay 
DNA adducts are formed when an exogenous compounds enters into a cell and 
binds with the DNA.  DNA adducts can also be formed from indigenous compounds 
already present in the biological system.  These DNA adducts are called I-compounds.  
I-compounds increase linearly with age of an animal, the older the animal, the more 
difficult it is to determine differences between I-compounds and bulky DNA adducts 
with exogenous compounds (Randerath et al. 1986; Randerath and Randerath 1994; 
Randerath et al. 1999; Reddy 2000).  Analysis of exogenous DNA adducts can be used 
as a biomarker of exposure to toxic compounds, as well as an indication of potential 
carcinogenic effects a compound might pose.  The process of identifying quantitatively 
DNA adducts, especially at low levels, requires very sensitive and specific 
methodologies.  There are methods that contain the level of sensitivity necessary: 32P-
postlabeling (can detect 1 adduct in 107-1010 nucleotides), fluorescence detection 
methods (can detect 1 adduct in 106-107 nucleotides), immunoassays (can detect 1 
adduct in 106-107 nucleotides)and gas chromatography/mass spectrometry (GC/MS) 
(Hemminki et al. 2000; Reddy and Randerath 1986).  Of these methods, the 32P-
postlabeling assay is considered to be the most sensitive for DNA adduct.  Although 
DNA adducts are detected readily with this method, it does have weaknesses.  Probably 
the most obvious weakness is the inability to identify chemical structures with this assay.  
However, as with most weaknesses, there are ways to overcome.  Internal standards can 
be included within the method, to aid in the structure identification.  Co-and re-
chromatography can also be preformed.  This method involves scraping the spots off the 
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cellulose and running them on a highly sensitive technique, such as GC/MS or liquid 
chromatography/mass spectrometry (LC/MS) (Hemminki et al. 2000).   
DNA adducts are formed when exogendous, or endogenous, compounds are 
converted into electrophiles by metabolic activation.  Once an electrophile is formed, the 
nucleophilic centers found in nucleic acids and proteins attract them.  This attraction 
causes a covalent bond to occur which binds the metabolite to DNA (Reddy and 
Randerath 1986).  Once a DNA adduct is formed, a mutation can occur when the 
adducted DNA undergoes replication.  An adducted base has the ability to cause 
multiple problems.  Some of these problems include: misincorporation, slippage by 
DNA polymerase, and misrepair.  All of these problems may lead to a mutation.  Not all 
DNA mutation is caused by bulky DNA adducts, however, as endogenous DNA damage 
is possible, and mutations may spontaneously appear as well.  The benzo(a)pyrene diol 
epoxide (BPDE), which has been shown to bind to the N2 of guanine (N2-G), has also 
been shown to cause a GC       TA mutation by Jelinsky et al. in1995.  Compounds that 
will bind to the DNA generally will bind at multiple places, creating multiple adducted 
sites (Hemminki et al. 2000).   
DNA adducts have been identified in various known human carcinogens.  For 
compounds such as aflatoxins, 4-aminobiphenyl, benzidine, ethylene oxide and 
tamoxifen DNA adducts have been identified in vitro and in vivo (animals, as well as in 
humans) (Hemminki 1993; Randerath et al. 1996).  BAP has been studied extensively 
with 32P-postlabeling assays.  These assay have shown large levels of DNA adducts with 
after BAP treatment (Booth et al. 1999; Boysen and Hecht 2003; Godschalk et al. 1998; 
Gupta et al. 1982; Lu et al. 1986; Reddy and Randerath 1986; Reddy et al. 1984).  There 
have also been studies on the association between levels of DNA adducts and tumor 
formation.  Nesnow et al. (1995) did a study on linking DNA adducts and tumor 
formation of PAHs.  They tested BAP, BBF, DA, 5-methlychrysene(5MC) and 
cyclopenta(cd)pyrene (CPP) in A/J male mice that were administered PAHs in 
tricaprylin with a single i.p. injectyion (0 - 200 mg/kg).  With increasing levels of PAHs, 
the lung cancer incidence increased as well.  However, there was not a strong difference 
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observed with regard to adduct formation, they did find that DBA, 5MC and CPP all had 
a much higher potency for tumor formation than BAP.   
Otteneder and Lutz 1999 did a study on the correlation of DNA adduct levels with 
tumor incidence.  They tested several compounds, including several PAHs, and found 
that fluoranthene (FA) exhibited the highest DNA adduct levels, follwed by CPP with 
BF and BAP at relatively the same potency.  They also found it difficult to correlate 
DNA adduct levels with tumor incidence.  One explanation that they offer for this is due 
to the reduction in DNA adduct levels after each replication.  They suggest that DNA 
adducts are reduced by a factor of two when replication occurs.  This in return would 
suggest that cell division is a confounder for interpretation of DNA adduct levels.  
Reddy and Randerath (1986) studied the DNA adduct levels of BAP, 7-12-
dimethylebenz(a)anthracene (DMBA), debenzo(c,g)crabazole (DBC), and 4-
aminobiphenyl (ABP).  They showed that DBC had the highest DNA adduct levels, 
followed by DMBA, ABP and finally BAP.  Booth et al. (1999) did a study on the 
effects of solvent on BAP DNA adduct formation.  They found that the type of solvent 
used affected BAP adduct formation (n-dodecane showed less DNA adduct formation 
then tetrahydrofuran).  However, they also observed no DNA adduct formation from the 
solvent controls, suggesting that carcinogens need to be present for DNA damage to 
occur.  DNA adduct damage has also been observed in application of mixtures.  
Randerath et al. (1994) induced DNA damage in rat lung DNA from wood preserving 
wate (WPW) extracts in vitro.   They demonstrated that it was possible to induce DNA 
adducts from WPW through in vitro application.  Randerath et al. (1997) demonstated 
levels of DNA adducts in mice exposed to WPW extracts.  Very diverse patterns of 
adducts were observed in this assay, and these included exogenous adducts and 
endogenous (I-compounds) adducts.  They showed that a complex mixture induces type 
I I-Compounds (adducts), which areassociated with carcinogenesis (Moorthy et al. 1994; 
Randerath et al. 1988; Randerath et al. 1995).  Randerath et al. (1999) found that 
sediment extracts also showed varying patterns of DNA adducts.  They analyzed total 
adducts as well as the levels of spot 4 adducts, which is associated with the BAP diol 
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epoxide (Lu et al. 1986).  Interestingly, the spot 4 adducts make up approximately half 
of the total adducts detected.  Boysen and Hecht (2003) analyzed BAP DNA and protein 
adduct levels found in humans.  They found that for the number of samples analyzed, 
39% detected BPDE-DNA adducts while 59% detected BPDE-protein adducts, however 
no single exposure type (smoking, occupational, environmental, non-smoking) was 
associated with overwhelming levels of adducts.  This study demonstrates the 
importance of studying PAHs and their ability to produce DNA adducts and tumors.   
DNA adducts are a good quantitative measure of DNA damage, and potential 
carcinogenic outcome.  However, they cannot be interpreted as a measure of the absolute 
carcinogenic potential of a compound.  It is important to carry out a tumorigenesis model 
in order to identify if DNA adduct frequency correspons to carcinogenic potential of 
certain compounds (Hemminki et al. 2000).   
 
1.4.2.2  Infant Male Mouse Tumor Model 
DNA adducts can lead to a tumorigenic outcome, however, the presence of DNA 
adducts alone does not mean tumors will develop (Hemminki et al. 2000).  It is 
important to determine if tumorigenesis is the endpoint of an exposure to certain 
compounds.  This is the ultimate measurement of carcinogenic potential of a compound 
or chemical mixtures.  The research reported in this dissertation was modeled after a 
study carried out by Rodriguez et al. in 1997.  Male and female infant B6C3F1 mice 
were exposed one time via intraperitoneal injection to BAP or a complex mixture of 
manufactured gas plant residue (MGP).  Maximum tolerable doses for BAP were 
determined previously (Rodriquez et al. 1997).  In the current study, only the male mice 
were used, along with the same doses of BAP used by Rodriquez et al. (1997).  Infant 
mice, 15 days old, were treated with six chemicals in the Rodriguez study.  However, 
due to constraints from the breeder and the animal facility, mice in this study were 
received at 15 days, and treated at 21 days of age.  Mice were weighed and then injected 
intraperitoneally with a single dose, and then sacrificed at 26, 39, and 52 weeks after 
exposure.  Based on the data gathered, this study sacrificed animals at 280 days, 40 
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weeks, after exposure.  Liver, lung, forestomach tissues were harvested from the mice 
for histopathology and tumor classification.     
 
1.5   Objectives and Specific Aims 
This research investigated the genotoxic interactions of various fractions isolated 
from a WPW oil.  This material is a common contaminant of soil and groundwater in the 
United States.  The WPW used in this study was a complex mixture of petroleum 
hydrocarbons, PAHs, chlorinated compounds and PCAs.  Due to the prevalence of these 
compounds in the environment, and the potential for exposure to human and ecological 
receptors, detailed information regarding the genotoxic potential of WPW mixtures 
would be very useful for regulatory agencies.  The overall hypothesis of the study is that 
isolation of high molecular weight PAHs from a complex mixture will allow increased 
expression of genotoxicity in vitro and in vivo.  Research activities have included 
chemical separation and fractionation of a complex WPW mixture, analysis of chemical 
components and genotoxicity using microbial cell cultures and animal models, and for a 
limited number of samples, evaluation of carcinogenic potential in an infant mouse 
model.    
The specific aims of this research include: 
1.   Separate a complex PAH mixture into acid, base and neutral fractions, 
enrich a PAH and PCDD fraction and analyze genotoxicity using in vitro 
and in vivo bioassays. 
2.   Investigate the frequency and persistence of bulky DNA adducts 
produced by the model carcinogen BAP, a reconstituted mixture and 
isolated fractions from WPW in vivo.  
3.   Investigate the relationship between the formation of DNA adducts and 
tumors in infant mice exposed to the model carcinogen (BAP), a 
reconstituted mixture, and the neutral fraction from WPW. 
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In order to accomplish the goals of this research, a series of experiments have been 
completed.  Initially, a complex WPW was collected from a Superfund site in the 
Northwestern United States.  This material was separated, using a liquid-liquid 
extraction method, into acid, base and neutral fractions.  These fractions were initially 
screened for genotoxicity using in vitro microbial bioassays.  Genotoxicity fractions 
were further analyzed in vivo using the 32P-postlabeling assay.  Next, a pure compound, 
reconstituted mixture and neutral fraction were evaluated for their ability to bind with 
DNA and form bulky adducts.  Finally, a model compound, reconstituted mixture and 
the neutral fraction were evaluated using an infant male mouse tumor model.  These 
studies have been conducted to determine if the formation of DNA adducts is a valid 
predictor of tumor incidence.   
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CHAPTER II 
GENOTOXICITY OF A COMPLEX CHEMICAL MIXTURE AND ISOLATED 
FRACTIONS 
 
2.1   Introduction 
The ability of a complex chemical mixture to induce cancer in humans has been 
clearly demonstrated (IARC 1998a, IARC 1998b).  Studies of populations exposed to 
PAH mixtures have demonstrated a link between these exposures and cancer of the lung, 
respiratory system and stomach (Bertrand et al. 1987; Krewski and Thomas 1992; 
Puisieux et al. 1991; and Vyskocil et al. 2004).  Complex PAH mixtures have also been 
clearly shown to cause cancer in animals (Culp et al. 2000; Rodriguez et al. 1997; 
Vesselinovitch et al. 1975a; Vesselinovitch et al. 1975b; Von Tungeln et al. 1999).  
Although PAH mixtures are known to cause cancer in animals and humans, the potential 
interactions of carcinogenic and non-carcinogenic PAHs are poorly understood.  Short-
term in vitro and in vivo bioassays provide a useful tool for investigating potential 
interactions of chemical mixtures. 
The use of creosote, a PAH mixture, to extend the life of wood is associated with 
extensive environmental contamination at treatment plants.  A range of materials 
including creosote, PCP and heavy metals have been used as wood preservatives.  
Creosote is composed of PAHs, phenolic compounds, and heterocyclic compounds (N-, 
S-, and O-) at approximately 85%, 10%, and 5% respectively (Creosote-contaminated 
sites paper).  PCP, a biocide, was widely used as a wood preservative in the United 
States until 1987, when its use was restricted (USEPA 2006d).  Technical grade PCP 
contains trace levels of chlorinated dioxins that are by-products of the production 
process.  In the United States, there are 26 wood preserving sites on the National 
Priorities List (NPL) with 18 on the Final NPL.  In addition, there are 749 sites on the 
NPL where PAH mixtures are listed as contaminants of concern.  Data are needed to 
more accurately characterize the genotoxic potential of the complex mixtures that are 
common in the environment.   
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There is currently no widely accepted protocol for risk assessment of complex 
mixtures.  Complex mixtures typically contain hundreds of different chemical 
components.  This may include components that are toxic or non-toxic, soluble or 
insoluble.  These components may produce a broad range of chemical interactions that 
may result in additive, synergistic or antagonistic interactions.  In some cases, it may be 
necessary to isolate similar components of a complex mixture in order to identify the 
most genotoxic constituents.  The USEPA has published “Guidelines for the Health Risk 
Assessment of Chemical Mixtures” in an effort to produce consistent risk assessments 
concerning chemical mixtures.  These guidelines define a mixture as any combination of 
more than one chemical.  The guidelines suggest three different approaches to mixture 
assessment.  The approaches are based on the amount of information that is available on 
the mixture of concern.  When data is available on the mixture of concern, chronic and 
subchronic toxicities can be used in the risk assessment.  When there is no data available 
for the mixture of concern, but there is a sufficiently similar mixture with data available, 
that data may be used.  However, dissimilarity of the mixtures should be taken into 
consideration.  Finally, when data is not available on the mixture of concern as well as 
any reasonably similar mixtures, toxic or carcinogenic properties of the individual 
components may be used.  Most important, risk assessment should be tailored to the 
mixture of concern, taking into account the many levels of complexity a mixture poses.   
An understanding of how chemicals will interact is extremely important when 
evaluating the risk associated with an exposure.  Adsorption, distribution, metabolism, 
excretion and activity at the receptor site are all processes where chemical interactions 
may occur.  Therefore, when a risk assessment is done on a chemical mixture, all 
assumptions and processes should be considered in order to have the most complete 
picture possible.  The criteria specified include different approaches, tailored to the 
specific chemicals in question (USEPA 1986).  The approaches, however, concentrate 
on what is known about specific chemicals in the mixture.  The problem with complex 
mixtures is that most of the interactions that take place are unknown.  It is important to 
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evaluate chemical mixtures as a whole, and in parts, in order to better understand the 
interactions that may take place. 
The following text reports on experiments to isolate and characterized the most 
genotoxic components of a complex mixture.  A complex WPW was seporated via a 
liquid-liquid extraction in order to obtain an acid, base and neutral fraction from which 
PAH and PCDD enriched fractions were isolated.  A series of in vitro and in vivo 
bioassays were used to identify the most genotoxic fractions.     
 
2.2 Materials and Methods 
2.2.1 Site History 
The material used for this study was collected from a former wood treatment 
facility.  This facility was active for approximately 23 years, from 1946 to 1969.  During 
operations, the site used waste pits to dispose of waste water and tank bottom sludge 
collected from wood-treating fluid tanks.  Area homeowners detected contamination in 
their private wells around 1979, and the USEPA listed the site on the NPL in September 
of 1983.  Two Record of Decisions (RODs) were filed, and direct the three stages of 
work that were agreed to by the responsible party.  In 1988 the USEPA decided on the 
following remedy for cleaning and containing the source of contamination: 1) 
Excavation and consolidation of 45,000 cubic yards of contaminated soil and debris, 
treatment by biodegradation using microorganism, and disposal by capping in lined 
treatment cells, 2) Collection of contaminated ground water from the upper aquifer and 
above ground treatment by bioremediation using microorganisms, 3) Treating remaining 
contamination in situ by adding oxygen and nutrients through injection wells to the 
ground water, 4) Initiating pilot studies for evaluation of technologies for the lower 
aquifer, and 5) Monitoring the site for five years to ensure effectiveness.  As of 2006, all 
excavation has been completed, while the bioremediation treatments of soil and 
groundwater are ongoing.  
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2.2.2 Sample Collection 
The underground aquifer at this site became heavily contaminated with a dense 
non-aqueous phase liquid (DNAPL) from a WPW.  The WPW collected for use in this 
study is a complex mixture of creosote compounds including PAHs, and elevated 
concentrations of PCP.  Water from the contaminated aquifer is pumped from various 
wells into an oil/water separator prior to bioremediation.  Oil and non-aqueous phase 
liquids from the aquifer accumulate in the bottom of the oil-water separator.  The 
complex mixture used in this research was collected as an aliquot of the material 
accumulated at the bottom of an oil/water separator.  The sample was collected in four 
250 mL amber glass I-Chem bottles, from a spigot connected to the oil-water separator.  
In the laboratory the WPW was autoclaved in 100 mL aliquots three times each, for 45 
min, at 121°C, 115 psi using an American sterilizer Company autoclave (Erie, PA).  The 
WPW was then mixed thoroughly, and separated into four sterile 250 mL wide-mouth 
amber I-Chem bottles.   
 
2.2.3 Chemicals and Materials 
Sodium hydroxide (ASC reagent grade, 98.2% pure), and silica gel (ACS grade, 3-
8 mesh size) were purchased from Fischer Scientific (Fairlawn, NJ).  Sulfuric Acid (95-
98% pure), methylene chloride (ACS reagent grade, 99.5% pure), and acetone (ACS 
reagent grade, 99.5% pure) were purchased from EM Science (Gibbstown, NJ).  
Pentachlorophenol (98% pure), benz(a)anthracene (99% pure), chrysene (98% pure), 
benzo(b)fluoranthene 98% pure), benzo(k)fluoranthene (98% pure), benzo(a)pyrene 
(97% pure), dibenz(a,h)anthracene (200µg/mL in CH2Cl2), tetradecane ( olefine free, 
>99% pure), carbon (>99%), alumina (~150 mesh, 58/ standard grade), sodium sulfate 
(ACS grade), and sand (white quartz, -50 + 70 mesh) were purchased from the Sigma-
Aldrich Group (St. Louis, MO).  The following chemicals were purchased from 
Honeywell Burdick & Jackson (Muskegon, MI):  hexane (capillary GC/MS solvent, 
87.3% pure), methanol (high purity solvent, 99.9%+ pure), acetone (high purity solvent, 
99.9%+ pure), toluene (high purity solvent, 99.9%+ pure), methylene chloride (high 
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purity solvent, 99.9%+ pure), and cyclohexane (high purity solvent, 99.9%+ pure).  
Indeno(1,2,3-c,d)pyrene (1000 µg/mL in CH2Cl2) was purchased from Absolute 
Standards (Hamden, CT).  Glass fiber filter (type A/E 8”x10” sheet) was purchased from 
Pall Gelman Sciences (Ann Arbor, MI).   
 
2.2.4 Animals 
All animals were obtained from Harlan (Houston, TX).  Strains used were Hsd:ICR 
(CD-1®) female mice, 15 weeks old, 21 to 24 g.   These mice are outbread albino 
descents from Charles River Laboratories (Wilmington, MA) animals.  Mice were 
shipped via Harlan truck in filtered shipping containers.  Mice were housed in a barrier 
facility, 3 mice per filtered cage.  Mice were fed ad libitum using sterilized food 
provided by the facility.  Water was also ad libitum, using filtered and sterilized water 
provided by the facility. 
 
2.2.5 Statistics 
Statistics were preformed using Systat Software, Inc. SigmaStat 3.11 software and 
SPSS Inc. SigmaPlot 8.02 software.  Simple statistics were preformed using this 
software, once all data was transformed to the log value of the raw data.  Normality test 
used was Kolmogorow-Smirnov.  One Way ANOVA test was preformed using the 
Holm-Sidak method for all pairwise multiple comparison procedures using α = 0.05.  P-
values were equal to <0.001 for all ANOVAs preformed, except for the lung tissue total 
DNA adduct analysis.  The p-value for that analysis was equal to 0.004.  Descriptive 
statistics were also preformed, to obtain data for SigmaPlot graphs. 
 
2.2.6 Extraction and Fractionation of Complex Mixture   
Since the WPW was collected as pure oil, no extraction was necessary.  The WPW 
oil was partitioned into acid, base and neutral fractions following the USEPA 3650B 
method (USEPA 1997a).  A schematic of this separation is provided in Figure 2.1.  All 
fractions were then analyzed for chemical content using GC/MS.  A 120 mL volume 
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(119g) of WPW was fractionated into an acid/base/neutral fraction following the EPA’s 
Standard Method 3650B.  A 30 mL volume of WPW, 60 mL of CH2Cl2, and 60 mL of 
NaOH pH12 was added to a 2000 mL separatory funnel and shaken for 2 min.  Once the 
phases separated, the upper aqueous layer was removed, and the lower organic layer 
(base/neutral fraction) extracted two more times.  The three aqueous layers were 
combined and the pH adjusted to <2 with 1:1 H2SO4:dH2O.  In a clean separatory funnel, 
the aqueous layers and 60 mL of CH2Cl2 were shaken for 2 min, followed by the 
removal of the organic layer.  The aqueous layer was then extracted two more times.  
The three organic layers were combined to form the acid fraction.   
 The base/neutral fraction plus three volumes (~633 mL) of 1N H2SO4 and 300 mL 
CH2Cl2 were then shaken in a new separatory funnel for 2 min.  Once the phases 
separated, the organic phase was removed and the aqueous phase extracted one more 
time with 300 mL CH2Cl2.  The two organic layers were combined to form the neutral 
fraction.  The neutral fraction was further enriched for PCDDs and then for PAHs using 
column chromatography.  The aqueous layers were combined and adjusted to a pH of 12 
with 10N NaOH.  This layer was then extracted with a volume of 600 mL, 300 mL, and 
30 mL CH2Cl2, in succession.  Each extraction was shaken for 2 min and the organic 
layer collected.  The three organic layers were combined to make the base fraction.  
Fractions were concentrated on a Kuderna-Danish (K-D) apparatus after passing through 
anhydrous sodium sulfate (Na2SO4).  
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Figure 2.1.  Schematic of the protocol used to partition WPW oil into acid, base and neutral 
fractions.   
 
  
Liquid-Liquid Extraction  
WPW Oil 
30 ml Crude Oil placed in a 2000 ml Seperatory funnel, NaOH added 
to turn solution basic; Extract aqueous phase 3x’s with CH2Cl2 
Base 
Fraction 
Organic 
Phase 
Neutral 
Fraction 
Organic 
Phase 
Aqueous 
Phase 
Discard 
Organic 
Phase 
3 volumes 1N H2SO4 added to turn solution 
Neutral; Extract aqueous phase 2x’s with CH2Cl2 
Aqueous 
Phase 
Adjust pH to 12 with 10N NaOH; 
Extract aqueous phase 3x’s with 
600, 300, and 30 ml of CH2Cl2 
Acid 
Fraction 
Aqueous 
Phase 
Adjust pH to <2 with 1:1 H2SO4:dH2O; 
Extract 3x’s with CH2Cl2 
Organic 
Phase 
Aqueous 
Phase 
Discard 
*H2SO4 = Sulfuric Acid 
*dH2O = Distilled Water 
*CH2Cl2 = Methylene Chloride 
*NaOH = Sodium Hydroxide 
*N = Normal (Normality) 
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2.2.7 PCDD Enrichment 
A total of 32 g of the neutral fraction, isolated from the WPW, was enriched for 
PCDDs following the protocol developed by the Texas A&M University Geochemical 
and Environmental Research Group (GERG) (Wang and Chambers 1997).  A schematic 
of this enrichment is provided in Figure 2.2.  For PCDD enrichment, 4.4g of neutral 
fraction, 200 mL of hexane, and 40g of 40% H2SO4/silica gel slurry were stirred for 2 hr 
(for quantification, 25 µl of tetradecane was added).  The sample was then filtered 
through sodium sulfate, rinsed with hexane three times, and reduced to a volume of ~50 
µl, using a rotary evaporator at 250 mbars.  A mixed bed silica column was prepared by 
packing a 300 mm x 13 mm (i.d.) column with (bottom to top): a combusted glass wool 
plug, approximately 1 cm of combusted sand, 1 g activated room temperature silica gel, 
4 g 33% 1N NaOH/silica gel, 1 g activated room temperature silica gel, 8 g H2SO4/silica 
gel acid slurry, 2 g activated room temperature silica gel, and approximately 1 cm 
combusted room temperature sodium sulfate.  The column was pre-rinsed with 100 mL 
hexane.  A 250 mL collecting flask was placed under the column, and the sample added, 
rinsing the flask three times with 2 mL of hexane.  A 120 mL volume of hexane was 
added to the column, and allowed to drain.   
The column eluate was collected and reduced to a volume of ~100 µl, using a 
rotary evaporator at 250 mbars.  The eluate from the silica column was enriched further 
using a carbon column.  The carbon column (1.2 cm i.d. x 13 cm) was prepared as 
follows: a glass wool plug was placed approximately 1 ½ in from the bottom, a 1 cm 
layer of activated silica gel was added, followed by 1 g of 5% AX-21 carbon/silica gel, 
and a second glass wool plug.  The column was then inverted and primed by rinsing with 
a 5 mL volume of 1:1 dichloromethane:cyclohexane (DCM:CHX), inverted again, and 
rinsed a second time with a 5 mL volume of 1:1 DCM:CHX.  Excess solvent was 
allowed to drain from the carbon column.  Silica gel eluate was transferred to the carbon 
column by rinsing the flask three times with 2 mL volume of 1:1 DCM:CHX.  An 
additional 6 mL of 1:1 DCM:CHX was added to the carbon column, bringing the total 
volume to 22 mL.  A 20 mL volume of 75:20:5 dichloromethane:methanol:toluene 
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(DCM:MEOH:TOL) mixture was then added to the carbon column, and allowed to drain 
by gravity flow.  The column was then inverted, and the PCDD fraction eluted.  A 125 
mL collecting flask was placed under the column, and two 25 mL volumes of toluene 
were added.  The sample was then reduced on a rotary evaporator at 250 mbars, 
transferred by rinsing the flask three times with toluene to a pre-weighed glass vial, and 
dried under a stream of nitrogen.  This process was preformed a total of seven times 
each.   
 
 
 
Figure 2.2.  Schematic of the protocol used to produce enriched PCDD and PAH fractions. 
 
  
2.2.8 PAH Enrichment 
A 10 g aliquot from the neutral fraction was enriched for PAHs following the 
protocol developed by the Texas A&M University GERG (Wang and Chambers 1997).  
A schematic of this enrichment is provided in Figure 2.2.  For PAH enrichment, a 1.6g 
mass of neutral fraction WPW was directly added to an alumina/silica column (13 mm x 
300 mm i.d.).  The alumina/silica column was prepared as follows: a glass wool plug, 10 
Alumina/Silica 
Column Filter through 
Na2SO4 
Mixed Bed Silica 
Column 
Carbon 
Column 
Neutral Fraction 
PAH 
Fraction 
PCDD 
Fraction 
Carbon Column 
2 ml NF; 200 ml Hexane; 40 g 40% 
H2SO4/Silica gel; swirl for 2 hr 
2 ml NF 
*NF = Neutral Fraction 
*H2SO4 = Sulfuric Acid 
*Na2SO4 = Sodium Sulfate 
Column Chromatography  
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g alumina (mixed with dichloromethane to reduce formation of air pockets), 20 g silica 
gel, and approximately 1 cm of anhydrous Na2SO4.  The dichloromethane was allowed 
to drain from the column, after which a 100 mL volume of hexane was added.  Once the 
hexane front was 1 cm from the Na2SO4 layer, a 1.6 g mass of the neutral fraction was 
added to the column.  The enriched PAH fraction was then eluted from the column.  
First, an 80 mL volume of hexane was added to the column.  Once the hexane reached 
the Na2SO4 layer, a 125 mL collecting flask was placed under the column and a 100 mL 
volume of toluene was added.  The sample was then reduced to a volume of 
approximately 20 µL on a rotary evaporator at 80 mbars, and further enriched using a 
carbon column (as described above for the PCDD fraction).  The sample eluate was 
collected in a flask and transferred by rinsing the flask three times with toluene to a pre-
weighed glass vial, and dried under a stream of nitrogen.  This process was conducted a 
total of six times each.   
 
2.2.9 Preparation of a Reconstituted Mixture 
A reconstituted mixture was prepared for comparison with the neutral fraction in 
the 32P-postlabeling study.  This mixture contains seven USEPA carcinogenic PAHs, as 
well as PCP.  All of these compounds are defined as class B2 carcinogens by the 
USEPA.  These chemicals were chosen because they represent the carcinogenic 
chemicals quantified in the neutral fraction, and include chrysene, BAA, DA, BAP, IP, 
BBF, BKF, and PCP (Figure 2.3).   
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Chemical Composition of Reconstituted Mixture 
Cl
Cl
Cl
OH
Cl
Cl
Chrysene Benz(a)anthracene Dibenz(a,h)anthracene
Benzo(a)pyrene
Indeno(1,2,3-cd)pyrene
Benzo(b)fluoranthene
(Benzo(e)acephenanthrylene)
Benzo(k)fluoranthene
Pentachlorophenol
(1750 ng/mg NF) (1750 ng/mg NF) (35.4 ng/mg NF)
(574 ng/mg NF) (442 ng/mg NF)
(715 ng/mg NF)
(224 ng/mg NF) (2030 ng/mg NF)  
Figure 2.3.  Structures and quantities of the eight class B2 USEPA carcinogens present in the 
reconstituted mixture. 
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Chemical analysis of the neutral fraction was used to calculate the mass of each of 
the eight chemicals that would be equivalent to the quantity detected in the neutral 
fraction for a 3 mg/mouse dose in the in vivo assay.  Neutral fraction chemical analysis 
values were used to calculate mg fraction/mL dose volume.  Calculations were prepared 
as follows: 
Calculation for mg chemical/mL methylene chloride per mouse (highest dose shown): 
ng chemical 
3.0 mg 
fraction 
ng 
chemical 1 µg 1 mg 
mg 
chemical 
mg fraction 
x 
Mouse 
= 
Mouse 
x 
mg fraction 
x 
mg fraction 
= 
mouse 
           
mg chemical 
mg 
chemical 
0.150 mL/ 
mouse 
= 
mL/mouse 
in highest dose 
 
Calculation for mg chemical needed for a 4 mL total volume: 
mg chemical 
mL/ mouse 
x 4 mL vol. of highest dose = mg chemical/4 mL 
 
Calculation for µL of 5mg/mL stock solution needed to obtain mass of chemical 
calculated: 
5 mg chemical mg chemcial 
mL 
= 
X mL 
 
X = mL Stock = µL Stock 
 
All calculations were checked, and entered into excel spreadsheets.  A 5 mg/mL stock 
solution was prepared for all chemicals, except chrysene, indeno(1,2,3-cd)pyrene and 
dibenz(a,h)anthracene.  Due to the low solubility of chrysene, a 1 mg/mL stock solution 
was made.  A 1 mg/mL and 0.2 mg/mL stock solution was made for indeno(1,2,3-
cd)pyrene and dibenz(a,h)anthracene respectively as only neat solutions could be 
obtained and not crystals.  The 5 mg/mL stock solutions were made by weighing 15 mL 
of chemical into a 5 mL glass vial using a Sartorius CP64 analytical balance, Aldinger 
Company, Dallas, TX.  Next, 3 mL of methylene chloride were added to each vial.  Once 
each chemical was dissolved, the calculated amount of stock solution, in µL, was added 
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to the 3 mg/mouse dose equivalent reconstituted mixture vial.  After all chemicals were 
pipetted into the vial, a volume of methylene chloride was added to make the total 
volume in the vial 4 µL.  The final solution in this vial was 20 mg/mL, a 3 mg/mouse 
dose equivalent.  To make an 8 mg/mL solution, a 1.2 mg/mouse dose equivalent, 0.8 
mL of the 20 mg/mL solution was added to a new vial with 1.2 mL of methylene 
chloride.  An aliquot of 1 mL from the 20 mg/mL solution was put into another vial for 
chemical analysis.  Each vial was sealed with a teflon lined cap, and put in the freezer 
for short-term storage.  Vials were wrapped in teflon tape, and placed on ice for 
transport.  Solutions were made one day prior to use.   
 
2.2.10 Chemical Analysis 
2.2.10.1 PAH Analysis 
PAH analysis was conducted using a modified 8270B USEPA standard method 
(USEPA 1997b).  Analysis was conducted on a Hewlett-Packard 5890 Series II gas 
chromatograph with a 5972 mass selective detector in selected ion monitoring mode.  A 
60m x 0.25mm ID x 0.25mm film thickness column (Agilent Technologies, Palo Alto, 
CA) was used.  The injection port is maintained at 300°C and the transfer line at 280°C.  
The temperature program is as follows:  60°C for 6 min, increased at 12°C/min to 180°C 
and then increased at 6°C/min to 310°C and held for 11 min for a total run time of 47 
min. 
 
2.2.10.2 PCDD Analysis 
PCDD analysis was done using an analytical method which is similar to USEPA 
Test method 1613 (USEPA 1997c).  Dioxins/furans were analyzed by a high resolution 
gas chromatography (Hewlett Packard 6890 /high resolution mass spectrometer (VG 
Autospec) equipped with a DB-5ms column (60 m x 0.25 mm, i.d., J&W Science).  The 
GC oven temperature was programmed to from 190ºC to 260ºC at a rate of 4ºC/min after 
holding at 190ºC for 2 min.  The oven temperature was held at 260ºC for 3 min and then 
raised to 320ºC at a rate of 8ºC/min and was held for 10 min at 320ºC.    Isotopically 
67 
labeled PCDDs and PCDFs were added to each sample prior to sample processing to 
facilitate the identification and quantitation of PCDDs and PCDFs. 
 
2.2.11 In Vitro Bioassays 
2.2.11.1 Salmonella/microsome Assay 
The standard Salmonella/microsome assay, first described by Ames et al. (1975) 
and then revised by Maron and Ames (1983), was used to measure the mutagenicity of 
the WPW oil and acid, base, and neutral fractions.  Briefly, a 50 µl volume of sample, 
0.1 mL of TA98 Salmonella overnight culture, and 0.5 mL of 20% S-9 Rat Liver 
Enzyme (for +S-9 plates), or 0.5 mL PO4 buffer (for –S-9 plates) were added to 2.5 
mL minimal top agar.  The agar was then poured onto the plate, swirled, and allowed 
to set.  The plates were then inverted and incubated for 72 hr at 37ºC.  After 
incubation, revertant colonies were enumerated using an Artek 880 automatic plate 
counter, Dynatech Laboratories Inc., Chantilly, VA.  Positive controls included 2-
nitrofluorene (2NF) (25 µg/plate) and BAP (10 µg/plate), while the negative control 
was dimethylsulfoxide (DMSO).  The mixtures were tested at a dose of 50, 20, 10, 5, 
2, and 1 mg/mL.  A positive response is equal to a two fold increase over the solvent 
control (negative control).  All samples were tested on duplicate plates in two 
independent experiments. 
 
2.2.11.2 E. coli Prophage Induction Assay 
The standard E. coli prophage induction assay, described by Rossman et al. (1984) 
and DeMarini et al. (1990), was used to screen the samples for DNA damage or 
inhibition of DNA replication.  Briefly, a 250 µL volume of VBMM supplement was 
added to the first row of wells in the microtiter plate, and 150 µL of VBMM 
supplement were added to the remaining rows of the microtiter plate.  A 50 µL volume 
of sample or control (acetone, VBMM supplement, 2NF for –S9 or 2AA for +S9) was 
added to the appropriate wells in the first row.  A 2-fold dilution was then preformed 
by transferring 150 µL from row A sequentially through row H.  75 µL of E. coli 
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lambda lysogen WP2s(λ)18 and 25 µL of 2.5% S9 (for the +S9 microtiter plate) or 
VBMM (for the –S9 microtiter plates) were added to each of the eight wells.  The 
microtiter plates were then covered with mylar film, wrapped in plastic wrap, and 
incubated for 24 hr.  Two tubes of TH008 indicator strain were prepared as overnights 
via the following method.  Frozen permanents, and oxoid broth were allowed to come 
to room temperature.  A 100 µL volume of the frozen permanents was aseptically 
transferred to two oxoid broth tubes.  The two inoculated oxoid broth tubes, plus one 
non-inoculated oxoid broth tube (control) were shaken/incubated overnight for 10 hr at 
200 rpms and 37°C.  After overnight growth, a volume of 250 µL of TH008 overnights 
were transferred aseptically to four tubes of room temperature oxoid broth tubes per 
microtiter plate for mid-log phase growth (approximately 1.5 hr).  The microtiter plates 
were scored for cytotoxicity (clearing of media) and the five highest turbid wells were 
then sampled.  The quantity of the phage released during this incubation is a measure 
of the extent of DNA damage.  A 50 µL volume of diluted phage was then transferred 
to 5 mL of VBMM supplement and vortexed.  A 200 µL volume of log-phase indicator 
cells was added to 2.5 mL volume of Luria broth top agar.  Next, a 100 µL volume of 
diluted phage was added to two top agar + TH008 tubes (for A and B plate replicates), 
and vortexed.  Top agar contents were then poured onto tryptone media plates, 
inverted, and incubated for 24 hr at 37°C.  After incubation, plates were scored for 
plaque formation using a manual colony counter.  The phage was quantified at the five 
highest, non-cytotoxic dose levels per treatment.  The dose ranges tested were 2.5, 
1.25, 0.625, 0.3125, and 0.15625 mg/mL in acetone.  Positive controls used were 2-
aminoanthracene (2AA) and 2NF, while negative controls used included VBMM and 
acetone.  All samples were tested + and – S9 in two independent experiments.   
 
2.2.12 In Vivo Bioassays 
2.2.12.1 DNA Adducts in Mice, Topical Application 
Dosing procedures were followed as previously described in Reddy and Randerath 
(1986).  CD-1 female mice, 15-weeks old, were weighed and placed into groups to 
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ensure that the average weight for each group was approximately the same.  Mice were 
then shaved and left for 24 hr.  After 24 hr, the mice were shaved once more, allowing 
the chemicals to be applied directly to the skin, reweighed, and groups adjusted so any 
mice with nicked skin were not used.  A 150 µl volume of sample in CH2Cl2 at doses of 
3, 1.2, or 0.48 mg/mouse was topically applied.  A total of eleven groups of mice, four 
mice per group, were treated with samples.  Treatments included one each for crude oil, 
acid fraction, base fraction, PAH fraction and PCDD fraction at a dose of 3 mg/mouse.  
Three groups were treated with different concentrations of neutral fraction, for dose-
response, at doses of 3 mg/mouse, 1.2 mg/mouse and 0.48 mg/mouse.  Two groups were 
treated with different concentrations of reconstituted mixture, for dose-response, at doses 
of 3 mg/mouse and 1.2 mg/mouse.  After 24 hr, mice were sacrificed, and exposed skin, 
lung and liver tissues were harvested.  Tissues were immediatley stored in a -80°C 
freezer.   
 
2.2.12.2 
32
P-postlabeling  
DNA was extracted from mouse tissues, digested and labeled with γ32P[ATP] 
following methods described previously by Reddy and Randerath (1986).  A 0.2 to 0.5 g 
weight of minced mouse tissue was weighed into a 15 mL glass tube.  A 3 mL volume of 
1% SDS/1mM EDTA was added, and the tissue was homogenized for 30 to 60 sec at 
15,000 to 20,000 rpm.  Next, 100 to 150 µL proteinase K (15 mg/mL) was added to the 
homogenate, and the sample was then vortexed and incubated for 40 min at 38°C.  The 
next step involves deproteinization using three solvent extractions.  A 170 µL volume of 
1M Tris-HCL, pH 8.0, and 35 µL 100 mM EDTA were added, and then vortexed.  For 
the first extraction, a 3 mL volume of phenol saturated with 50 mM Tris-HCL, pH 8.0, 1 
mM EDTA was added, and shaken for a minimum of 3 min.  The sample was then spun 
for 10 min at 10000 rpm.  The aqueous phase was transferred to a fresh tube.  For the 
second extraction, a 3 mL volume of 1:1 mixture of saturated phenol and SEVAG (24 
volumes Chloroform + 1 volume isoamyl alcohol) was added, and shaken for at least 3 
min.  The sample was then spun as described above.  The aqueous phase was then 
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transferred to a fresh tube.  For the third extraction, a 3 mL volume of SEVAG was 
added, and shaken as described above.  The sample was then processed as previously 
described, and the aqueous phase was transferred to a fresh tube.   
 For precipitation of DNA (+RNA), 0.3 mL (=0.1 volume) 5 M NaCl + 3.3 mL ice-
cold absolute ethanol are added, and vortexed.  The sample was placed in -20°C freezer 
for 30 min.  The sample was then spun for 10 min at 10000 rpm, and supernatant 
discarded.  Precipitant was washed 2 times with 3 mL 70% ice-cold ethanol, and 
supernatant decanted.  The sample was semi-dried for 4-5 min.  The DNA (+RNA) was 
dissolved in 1 mL 0.01 SSC (150 mM NaCl, 15 mM Na citrate) + 10 µL 100 mM 
EDTA.  Next, 50 µL 1 M Tris-HCL, pH 8.0, + 15 µL Rnase A (10 mg/mL) + 16.5 µL 
Rnase T1 (5,000 units/mL) are added to sample.  The sample was then vortexed, and 
incubated for 40 min at 38°C.  After incubation, 500 µL 0.01 x SSC was added to 
increase volume.  Deprotieniztion was again carried out by solvent extraction.  A 1.5 mL 
volume of SEVAG was added, and shaken for at least 3 mintues.  The sample was 
processed as stated above, and the aqueous phase transferred to a fresh tube.  DNA was 
precipitated by adding 150 µL 5 M NaCl + 1.5 mL ice-cold absolute ethanol.  The 
sample was put in -20°C freezer for 30 min.  The DNA was spun, washed, and semi-
dried as stated above.  DNA was redissolved in 0.3 to 0.6 mL 0.01 x SSC to reach the 
desired concentration of 2 µg/µL.  The concentration of DNA was checked via UV-Vis 
Spectrophotometer, the A260 (DNA)/A280 (RNA) ratio should range from 1.6 to 1.8.   
DNA digestion and labeling were preformed as follows: 10 µg of DNA in 5 µL of 
SSC and/or water were digested using 3 µL of 0.2 U micrococcal nuclease and 2.4 µg 
spleen phosphodiesterase per µL (MN/SPD) and 2.4 µL of IS-buffer mix (10 µg DNA, 
100 mM CaCl2 and 300 mM Na succinate) for 3.5 hr at 37°C.  MN/SPD digestion 
cleaves the 5’-nucleotide-phosphate bonds, leaving the 3’-monophosphates of the 
normal and adducted deoxyribonucleosides.  The DNA was then digested with 4.75 µL 
of nuclease P1 digestion mix (4 µg/µL nuclease P1, 1 M NaOAc and 1 mM ZnCl2) for 
40 min at 37°C.  Nuclease P1 digestion cleaves the 3’-nucleotide-phosphate bonds on 
normal nucleotides only.  It was reported that adducted nucleotides were mostly or 
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partially resistant to nuclease P1 3’-dephosphorylation (Reddy and Randerath 1986).  
The sample was then labeled using 3.86 µL of polynucleotide kinase (PNK) labeling mix 
(kinase buffer, 100 µCi/µL ATP and 30 U/µL PNK) and incubated for 40 min at 37°C.  
PNK labeling attaches the radioactive phosphate ([γ-32P]ATP) at the 5’-hydroxyl group 
end of the adducted nucleotides through [32P]phosphate transfer from ([γ-32P]ATP).  The 
normal nucleotides lost their 3’-phosphate during nuclease P1 digestion, so PNK will not 
phosphorylate them with the ([γ-32P]ATP).  Once samples were labeled, two specific 
activity (SA) tubes (2 pmol/µL dAP and 50 mM CHES, pH 9.5) were then labeled with 
2.5 µL PNK labeling mix, and incubated same as the samples.   
The samples, with the exception of the SA tubes, were then digested with 1.5 µL of 
40 mU/µL potato apyrase for 30 min at 37°C.  Apyrase digestion destroys the excess 
ATP by removing [32P] from the ATP ([32P]-ATP        ADP + [32P]).  Once apyrase 
incubation was completed, normals and SA tubes were diluted.  Normals are a 
qualitative check to make sure that each sample was digested and labeled well.  Tubes 
contain 250 µL of 20 mM CHES, pH 9.5.  1 µL of sample was added to the 
corresponding tube, and then 5 µL per sample were spotted on PEI-cellulose sheets.  SA 
dilution tubes contain 996 µL of 20 mM CHES, pH9.5.  4 µL of labeled SA tubes 
(d*pAp mix) were added to each corresponding SA tube, and then 5 µL were spotted on 
PEI-cellulose sheets.  Normals and SA PEI-cellulose sheets were run in 0.28 M 
NH4(SO4)2 + 50 mM NaH2PO4, pH 6.7 to 13 cm past the origin line, approximately 1 to 
2 hr (Figure 2.4).  While normals and SA sheets were running, labeled samples are 
spotted onto a PEI cellulose sheet (D1 development).  D1 sheets were run in 80 mL of  
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2.3 M NaH2PO4, pH 5.75, for 16 hr (Figure 2.5).  D1 development removes traces of  
normal nucleotides after the nuclease P1 treatment, as well as residual orthophosphate by 
pushing them to the wick at the top of the sheet, leaving the [32P] adducted nucleotides 
 behind.  D1 sheets were developed on autoradiographic film, and locations of the spots 
were then drawn on the back of the PEI-cellulose sheets.  Spots were then cutout from 
the D1 PEI-cellulose sheet and transferred to single PEI-cellulose sheets (2D maps) 
using a strong magnet (Figure 2.6).  2D maps were run vertically in 65 mL of 95%  LFU, 
pH 3.35 + 5%  dH2O (D3 development) to top marked line after being pre-developed in 
25 mL of dH2O to the origin.  2D maps were then checked for transfer, cut at the second 
line from the top, washed twice in 250 mL of dH2O for 7 min, dried, and a wick attached 
to the right side in preparation for the final development (D4 development) (Figure 2.7).  
For the D4 development, the 2D maps were run horizontally in 65 mL of 90%  PTU, pH 
8.20 + 10%  dH2O to the top of the wick after being pre-developed in 25 mL of 50%  0.8 
M NaH2PO4, pH 8.2 + 50%  dH2O to the second line marked from the left side.  2D 
maps were then checked for separation, cut just below the wick, washed twice in 250 mL 
of dH2O for 5 min, dried, and cut for autoradiographic development and imager reading 
(Figure 2.7).  An instant imager was used to calculate counts per minute (CPM) per spot. 
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Normals and Specific Activity Diagram 
 
Figure 2.4.  Diagram of how the normals and SA PEI-cellulose sheets are set up.  An origin line 
is drawn 2.5 cm from the bottom of the sheet.  Tick marks are drawn to represent where spotting 
of samples will occur.  Tick marks begin 2.3 cm from the edge of the sheet and are placed 1.2 
cm apart.  Each tick mark represents a sample and are numbered accordingly (e.g. 1, 2, …n).  
The solvent line at the top of the sheet is 13 cm from the origin, and represents the point at 
which the sheet is removed from the developing solvent. 
 
Normals/SA PEI-cellulose Sheet 
2.3 
cm 
2.3 
cm 
Origin 
Solvent Line 
2.5 
cm 
1 2 
 
1.2 
cm 
13 
cm 
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D1 Cellulose Sheet Diagram 
 
Figure 2.5.  Diagram of how the D1 PEI-cellulose sheets are set up.  An origin line is drawn 5.5 
cm from the bottom of the sheet.  Tick marks are drawn to represent where spotting of samples 
will occur.  Tick marks begin 2.7 cm from the edge of the sheet and are placed 1.5 cm apart.  
Each tick mark represents a sample and are numbered accordingly (e.g. 1, 2, …n).  The cutoff 
line at the top is 8cm from the top of the sheet, and represents the point at which the sheet will 
be cut, removing the wick which contains approximately 95% of the radioactivity. 
D1 PEI-cellulose Sheet 
2.7 
cm 
Origin 
Cutoff Line 
1 2 
 
1.5 
cm 
5.5 
cm 
8 
cm 
2.7 
cm 
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Figure 2.6.  Diagram of how to place cutout spots on 2D map.  Cutout spot should be placed 
cellulose-side down on the corresponding 2D map, with the origin on the 90° angle (shown by 
the hashed rectangle).  Cutout should be secured to 2D map using a strong magnet.   
 
 
 
 
 
L2 
L2 
Position of cutout.   
PLACING CUTOUTS 
ON 2D MAP 
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Figure 2.7.  Diagram showing developing and trimming guidelines for the 2D map.  For D3 
development, predevelopment should be done to the first line from the bottom, and final 
development should be done to the top line.  After development, the 2D map should be cut at the 
second line from the top.  For D4 development, predevelopment should be done to the third line 
from the left, and final development should be done to the top of the wick (attached after D3 
development).  After development, the 2D map is cut just under the wick.  Final cuts are 0.8 cm 
below the origin, and just to the left of the transfer point.  Final cuts are done to fit 3 sheets per 
autoradiogram. 
 
L2 
L2 
Develop D3 to here 
Cut across here after D3 
Pre-develop D3 to here (origin) 
Final cut at end of 
chromatography to fit 3 per 
cassette (0.8 cm below origin) 
Pre-develop D4 to here 
A
ttach
 D
4
 w
ick
 h
ere  
Cut here at end of chromatography to fit 3 
per autroradiography cassette 
Final imaging 
dimension =10 cm 
D
ev
elo
p
 in
 D
4
 to
 to
p
 o
f w
ick  
DEVELOPING & TRIMMING 
2D MAPS 
77 
2.3 Results 
2.3.1 Chemical Analysis 
 A total of sixty PAHs were quantified in each isolated fraction (Table 2.1).  The 
chemical analysis of the fractions from the WPW oil confirmed that high levels of PCP 
were isolated in the acid fraction (6.93 x 105 ng/mg fraction, Table  2.2).  The neutral 
fraction retained high levels of PAHs, while the base fraction retained a small amount of 
PAHs (1.75 x 103 ng/mg fraction BaA, 1.75 x 103 ng/mg fraction chrysene, 7.15 x 102 
ng/mg fraction BbF, 4.42 x 102 ng/mg fraction BkF, 5.74 x 102 ng/mg fraction BAP, 
2.24 x 102 ng/mg fraction IP, and 3.5 x 101 ng/mg fraction DA Table 2.2).  PAH 
concentrations in the reconstituted mixture were shown to accurately reflect the 
concentrations of the neutral fraction carcinogenic PAHs (cPAHs) (Table 2.3).  The 
cPAH values in the reconstituted mixture were as follows: 1.31 x 103 ng/mg fraction 
BaA, 1.61 x 103 ng/mg fraction chrysene, 7.16 x 102 ng/mg fraction BbF, 4.23 x 102 
ng/mg fraction BkF, 5.33 x 102 ng/mg fraction BAP, 2.09 x 102 ng/mg fraction IP, 3.3 x 
101 ng/mg fraction DA, and 2.28 x 103 ng/mg fraction PCP.  Although the PCP 
concentration was highest in the acid fraction (6.93 x 105 ng/mg), the WPW oil and base 
fraction were also found to contain high concentrations of PCP (Figure 2.8).  Total PAH 
concentrations ranged from 2.95 x 104 ng/mg in the base fraction to 7.78 x 105 ng/mg in 
the acid fraction.  Although the carcinogenic PAH concentration was highest in the 
PCDD fraction (1.25x 105 ng/mg), the PAH fraction was also found to have high 
concentrations of cPAHs (7.11 x 104 ng/mg).  In addition, the high molecular weight 
PAHs, including BAP (1.50 x 104 ng/mg), IP (6.89 x 103 ng/mg) and DA (2.03 x 103 
ng/mg) were enriched in the PAH fraction (Table 2.2 and Figure 2.9).
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Figure 2.8.  Chemical analysis concentrations of PCP and individual carcinogenic PAHs 
detected in WPW oil, isolated fractions, and reconstituted mixture.  Data are presented as 
concentration in nanograms (ng) of compound per milligrams (mg) of sample. 
81 
 
Neutral PCDD PAH
C
o
n
c
e
n
tr
a
ti
o
n
 (
n
g
/m
g
)
0
10000
20000
30000
40000
50000
60000
70000
PCP 
BaA 
Chrysene 
BbF 
BkF 
BaP 
IP 
DA 
 
Figure 2.9.  Chemical analysis concentrations of PCP and carcinogenic PAHs detected in 
neutral fraction from WPW oil, and PCDD and PAH enriched isolates.  Data are presented as 
concentration in nanograms (ng) of compound per milligrams (mg) of sample. 
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2.3.2 Salmonella/microsome Assay 
All six fractions were tested with and without metabolic activation in the 
Salmonella/microsome assay.  A positive genotoxic response was observed from the 
crude extract of the WPW, the base fraction, and the PAH isolate (Figure 2.10 and Table 
2.1).  The neutral fraction induced a weak positive response (doubling at only one dose), 
and all other fractions failed to induce a positive genotoxic response in Salmonella.    
The base fraction induced the maximum response of 129 ± 8 net revertants at a dose of 
0.25 mg/plate.  Although the PAH fraction had the highest concentration of BAP, this 
fraction induced a response of 90 ± 7 net revertants at a dose of 0.25 mg/plate (Table 2.4 
and 2.5).  The acid fraction, which had the highest concentration of total PAHs, failed to 
induce a positive response and induced only 32 ± 4 net revertants at the optimal dose.  It 
is likely that the elevated concentration of PCP in the acid fraction was cytotoxic to the 
bacteria and inhibited mutagenicity. 
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Figure 2.10.  Microbial genotoxicity, as measured by S. typhimurium TA98 strain with metabolic 
activation of WPW oil and isolated fractions.  2-Fold response is equal to a two-fold increase 
over the solvent control.  Data are presented as mean total net revertants per plate ± SEM. 
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2.3.3 E. coli Prophage Induction Assay 
 Due to limitation in volume of sample, only the crude, acid, base, and neutral 
fractions were tested in the E. coli prophage induction assay.  The neutral fraction and 
crude oil did not induce a positive response in this assay at any of the doses tested.  
However, the acid fraction did show a strong positive response, while the base fraction 
showed a weak positive response (Figure 2.11 and Table 2.4).  The acid fraction 
response was well above the three fold increase at doses of 16 µg/mL, 31 µg/mL and 63 
µg/mL.  This response was anticipated due to the large amount of PCP in this fraction.  
The base fraction exhibited a three fold increase at the 16 µg/mL concentration.  The 
most likely source of the genotoxicity in the base fraction is the PCP that did not 
partition into the acid fraction during the liquid-liquid separation; it is also possible that 
nitroaromatics in the base fraction induced an increased level of plaque formation in E. 
coli.   
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Figure 2.11.  E. coli prophage induction assay, as measured by the indicator strain TH008 with 
metabolic activation of WPW oil, acid fraction, base fraction and neutral fraction.  Fold Increase = 
# plaque forming unites (PFUs) per sample/# PFUs for solvent control.  Significance was 
determined by a fold increase of 3, represented by the dashed line, for two or more doses, which 
is considered a positive mutagenic response.  Data are graphed as the mean fold increase 
between two independent experiments with ± SEM. 
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2.3.4 
32
P-Postlabeling Assay 
 Autoradiograms displaying a typical DNA adduct pattern in the skin of animals 
treated with various complex mixtures is presented in Figure 2.12.  Spots produced by 
the RM are much sharper compared to other chemicals.  These sharper spots are due to 
the RM being a mixture of eight chemicals, whereas the other treatments are complex 
mixtures containing innumerous chemicals.    Overall, the locations of the spots are 
similar for all treatments in the skin, with the base fraction as an exception.  The base 
fraction appears to have an extra polar region in the upper right corner of the 
autoradiogram (Figure 2.12).  The results from all tissues for total DNA adducts are 
presented in Table 2.6a, while the statistical significance of these data is presented in 
Table 2.6b.  The PAH fraction, which induced a total DNA adduct relative adduct 
labeling value (RAL) of 109 ± 6.27 per 109 nucleotides in skin at a dose of 3 mg/mouse, 
induced the maximum level of adducts for all fractions.  The PAH fraction treatment in 
skin (Figure 2.13) was the only treatment to produce a significantly larger response than 
all other treatments.  Dose-response data for the NF and RM, in comparison to the PAH 
isolate, are presented in Table 2.7a, with the statistical significance presented in Table 
2.7b.  Both the NF and RM exhibited significant increased total adduct formation from 
the low to the high doses (Figure 2.14).  Only the intermediate dose, 1.2 mg/mouse, was 
significantly higher in the NF as compared to the RM.  The RM, a mixture of eight 
chemicals, is equivalent to the NF composition of those eight chemicals.  Therefore, 
unknown components or compound interactions within the NF produced a larger 
response in the NF when compared to the RM. 
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Figure 2.12.  Autoradiograms of DNA adducts detected in the skin of CD-1 female mice. 
Control Crude Fraction Acid Fraction Base Fraction 
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Mixture 
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Table 2.7b.  Table of DNA adduct levels found in skin, lung and liver of CD-1 female mice.  
Data are presented as log transformed RAL per 10
9
 nucleotides with statistical significance 
indicated (α = 0.05, p-value = < 0.001).  
Tissue
Skin 0.50 1.24
a
1.36
a,b
1.56
a,c
1.13
a
1.44
a,e
2.03
a,f,g
Lung 1.41 1.66 1.67 1.99 1.66 1.57 2.44
a,g
Liver 1.75 1.05 0.98 1.04 0.97 0.93 2.58
a,f,g
Tissue
Skin 0.00 0.81
a
0.93
a
1.16
a,c,d
0.74
a
1.09
a,e
1.68
a,f,g
Lung 0.54 0.93 1.14 1.53
a
0.75 0.72 2.14
a,g
Liver 0.81 0.16 0.04 0.12 0.18 0.13 2.23
a,f,g
RM 1.2 
mg/mouse
RM 3 
mg/mouse
PAH 3 
mg/mouse
Control
NF 0.48 
mg/mouse
NF 1.2 
mg/mouse
NF 3 
mg/mouse
e = RM 3 mg/mouse is significantly greater than RM 1.2 mg/mouse
f = PAH 3 mg/mouse is significantly greater than NF 3 mg/mouse
g = PAH 3 mg/mouse is significantly greater than RM 3 mg/mouse
Control
NF 0.48 
mg/mouse
NF 1.2 
mg/mouse
NF 3 
mg/mouse
RM 1.2 
mg/mouse
RM 3 
mg/mouse
PAH 3 
mg/mouse
Log Total and Spot 4 DNA Adduct Frequency in Treated CD-1 Female Mice
Log Mean Total DNA Adducts (Log of RAL / 10
9
 Nucleotides)
Log Mean Spot 4 DNA Adducts (Log of RAL / 109 Nucleotides)
b = NF 1.2 mg/mouse is significantly greater than RM 1.2 mg/mouse
d = NF 3 mg/mouse is significantly greater than NF 1.2 mg/mouse
a = Significantly greater than Control
c = NF 3 mg/mouse is significantly greater than NF 0.48 mg/mouse
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Figure 2.13.  Total DNA adducts detected in DNA isolated from the skin of CD-1 mice treated 
with a 3 mg/mouse dose of complex PAH isolates or a reconstituted mixture.  Data are 
presented as raw data of mean RAL per 10
9
 nucleotides ± SEM.  When data was transformed to 
log and analyzed, the following significant differences were observed:  a = PAH is significantly 
larger than all other fractions (p-value = <0.001) (N=4, N=3 for PAH fraction).  
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Figure 2.14.  Total DNA adducts detected in DNA isolated from the skin of CD-1 mice treated 
with neutral fraction, reconstituted mixture and PAH fraction.  Data are presented as raw data of 
mean RAL per 10
9
 nucleotides ± SEM.  When data was transformed to log and analyzed, the 
following significant differences were observed:  a = NF 1.2 mg/mouse > RM 1.2 mg/mouse; b = 
NF 3 mg/mouse > 0.48 mg/mouse; c = RM 3 mg/mouse > RM 1.2 mg/mouse; d = PAH 3 
mg/mouse > NF and RM 3 mg/mouse; e = > control (p-value = <0.001) (N=4, N=3 for PAH 
fraction). 
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Spot 4 is a bulky DNA adduct which has been previously shown to be associated 
with the BAP-diolepoxide (BPDE) adduct (Gupta et al. 1982; Lu et al. 1986).  Similar 
results were observed for spot 4 (Tables 2.6a, 2.6b, 2.7a, 2.7b and Figure 2.15).  The 
PAH fraction produced the maximum number of spot 4 adducts observed.  At the highest 
dose tested, the PAH fraction induced approximately three times the number of adducts 
induced by the NF, and almost four times that induced by the RM (Table 2.7a).  Again, a 
dose-response relationship was observed for spot 4 adducts with the NF and RM 
fractions (Table 2.7a).  These data indicate that the level of adducts induced by the 
primary metabolite of BAP appear to be similar between the RM and NF.   
Again, autoradiograms in the lung show a typical pattern for DNA adduct 
formation (Figure 2.16).  As seen in the autoradiograms of skin adducts, the base 
fraction has a second polar region near the top right corner of the autoradiogram, and the 
RM spot are much sharper than those of the other treatments.  All data are presented in 
Table 2.6a for total and spot 4 DNA adduct formation, while the statistical significance 
is presented in Table 2.6b.  The PAH isolate, again, produced the maximum DNA 
adduct frequency, with a RAL of 306 ± 81.90 per 109 nucleotides (Table 2.6a).  The 
PAH fraction elicited a significantly higher response than the RM and Acid fractions in 
this tissue, while the base elicited a significantly higher response than the RM as well 
(Figure 2.17).  Dose-response relationship data, RAL and statistical, for NF and RM as 
compared to the PAH isolate are presented in Tables 2.6a and 2.7b.  As observed in the 
analysis for all treatments, the PAH fraction elicited the highest response, and was 
significantly larger than the RM (Figure 2.18).  No significant difference was observed 
between the RM and NF treatments.   
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Figure 2.15.  Spot 4 DNA adducts detected in DNA isolated from the skin of CD-1 mice treated 
with neutral fraction, reconstituted mixture and PAH fraction.  Data are presented as raw data of 
mean RAL per 10
9
 nucleotides ± SEM.  When data was transformed to log and analyzed, the 
following significant differences were observed:  a = NF 3mg/mouse > NF 1.2 and 0.48 
mg/mouse; b = RM 3mg/mouse > RM 1.2 mg/mouse; c = PAH 3 mg/mouse > NF and RM 3 
mg/mouse; d = > control (p-value = <0.001) (N=4, N=3 for PAH fraction). 
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Figure 2.16.  Autoradiograms of DNA adducts detected in the lung of CD-1 female mice. 
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Figure 2.17.  Total DNA adducts detected in DNA isolated from the lung of CD-1 mice treated 
with 3 mg/mouse of complex PAH isolates or a reconstituted mixture.  Data are presented as 
raw data of mean RAL per 10
9
 nucleotides ± SEM.  When data was transformed to log and 
analyzed, the following significant differences were observed:  a = PAH is significantly larger 
than RM and acid fractions; b = base is significantly larger than RM fraction (p-value = 0.002) 
(N=4, N=3 for PAH fraction).
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Figure 2.18.  Total DNA adducts detected in DNA isolated from the lung of CD-1 mice treated 
with neutral fraction, reconstituted mixture and PAH fraction.  Data are presented as raw data of 
mean RAL per 10
9
 nucleotides ± SEM.  When data was transformed to log and analyzed, the 
following significant differences were observed:  a = PAH 3 mg/mouse > NF and RM 3 
mg/mouse; b = > control (p-value = <0.001) (N=4, N=3 for PAH fraction). 
 
 
Data for the spot 4 analysis are presented in Tables 2.6a and 2.6b, with statistical 
data in Tables 2.7a and 2.7b.  Similar results were observed for spot 4 in this tissue that 
were observed for total DNA adduct formation.  The PAH fraction elicited the highest 
DNA adduct formation for spot 4, and was significantly higher than that of the RM 
(Figure 2.19).  The PAH fraction showed an increase of three times that of the NF, and 
about six times that of the RM (Table 2.7a).  Responses are similar to those seen in the 
skin tissue.   
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Figure 2.19.  Total DNA adducts detected in DNA isolated from the lung of CD-1 mice treated 
with neutral fraction, reconstituted mixture and PAH fraction.  Data are presented as raw data of 
mean RAL per 10
9
 nucleotides ± SEM.  When data was transformed to log and analyzed, the 
following significant differences were observed:  a = PAH 3 mg/mouse > RM 3 mg/mouse; b = > 
control (p-value = <0.001) (N=4, N=3 for PAH fraction). 
 
 
Finally, the autoradiograms for the liver tissue show a slightly different pattern 
than those of the skin and lung tissues (Figure 2.20).  The autoradiograms are much 
darker, which is typical of liver tissue.  However, even though the patterns have changed 
in this tissue, they still exhibit typical DNA adduct patterns.  Even the base fraction is 
typical in this tissue, losing the extra polar region seen in the two previous tissues.  
Again, the RM is much sharper than the other treatments.  All data for total and spot 4 
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Tables 2.7a and 2.7b.  Over all treatments, the PAH has once again produced the 
maximum level of DNA adducts, with a RAL of 383 ± 37.50 per 109 nucleotides.  This 
value is approximately 31 times that of any other treatment (Table 2.6a).  Even though 
the PAH fraction has produced the largest significant difference, the Base, NF and 
PCDD fractions all have produced significantly higher responses compared to the Acid 
and Crude fractions (Figure 2.21).  When looking at the dose-response data, the PAH 
once again has produced the maximum response over the NF and RM.  There are no 
other significant responses detected in this tissue for total DNA adducts (Figure 2.22). 
 
 
 
 
Figure 2.20.  Autoradiograms of DNA adducts detected in the liver of CD-1 female mice.  Liver 
tissue tends to yield “dirty” autoradiograms, due to the large amount of background noise.   
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Figure 2.21.  Total DNA adducts detected in DNA isolated from the liver of CD-1 mice treated 
with complex PAH isolates or a reconstituted mixture.  Data are presented as raw data of mean 
RAL per 10
9
 nucleotides ± SEM.  When data was transformed to log and analyzed, the following 
significant differences were observed:  a = PAH is significantly larger than all other fractions; b = 
base is significantly larger than acid and crude fractions; c = neutral is significantly larger than 
acid and crude fractions; d = PCDD is significantly larger than acid and crude fractions (p-value 
= <0.001) (N=4, N=3 for PAH fraction).    
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Figure 2.22.  Total DNA adducts detected in DNA isolated from the liver of CD-1 mice treated 
with neutral fraction, reconstituted mixture and PAH fraction.  Data are presented as raw data of 
mean RAL per 10
9
 nucleotides ± SEM.  When data was transformed to log and analyzed, the 
following significant differences were observed:  a = PAH 3 mg/mouse > NF and RM 3 
mg/mouse; b = > control; c = control > (p-value = <0.001) (N=4, N=3 for PAH fraction). 
 
 
Spot 4 levels are, once again, similar to those observed in the total DNA adduct 
response analysis.  The PAH fraction has produced the highest spot 4 response, 
approximately 119 times higher than the NF and RM.  The NF and RM are not 
significantly different from the control and each other.  In this tissue, the PAH fraction is 
the only treatment to have elicited a response. 
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Figure 2.23.  Spot 4 DNA adducts detected in DNA isolated from the liver of CD-1 mice treated 
with neutral fraction, reconstituted mixture and PAH fraction.  Data are presented as raw data of 
mean RAL per 10
9
 nucleotides ± SEM.  When data was transformed to log and analyzed, the 
following significant differences were observed:  a = PAH 3 mg/mouse > NF and RM 3 
mg/mouse; b = > control; c = control > (p-value = <0.001) (N=4, N=3 for PAH fraction). 
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2.4 Discussion 
Previous studies have shown that the Salmonella/microsome bioassay is a sensitive 
system for detecting carcinogenic PAHs as baterial mutagens (Chu et al. 1981; Donnelly 
et al. 1998; Purchase et al. 1976; Tennant et al. 1987a).  In the current study the base and 
the crude fractions both had a positive response in the Salmonella microsome assay.  The 
negative response observed for the acid fraction may be due either to the cytotoxicity of 
PCP, or the lack of sensitivity of this bioassay towards chlorinated compounds.  The 
crude extract and neutral fraction both have a larger amount of carcinogenic PAHs 
present than the acid, base and reconstituted mixtures.  Therefore, the mutagenicity of 
both the crude extract and the week response observed for the neutral fraction appear to 
be due to the presence of these carcinogenic PAHs.  The neutral fraction, which had a 
lower response than the crude extract, had a larger number of total PAHs present 
(including low molecular weight PAHs) than the crude extract.  Therefore, it appears 
that inhibition my have occurred via these other PAHs present (presumably by low 
molecular weight PAHs) which affected the neutral fraction.  The base fraction induced 
the maximum genotoxic response for all mixtures tested.  However, this compound has 
the lowest concentration of carcinogenic PAHs.  Nitro aromatics are inherently present 
in this mixture, but were not analyzed in this research.  Due to the lack of large amounts 
of carcinogenic PAHs, as well as a lower concentration of total PAHs, we speculate that 
the postitive response induced by the base fraction may be a result of nitro aromatics or 
other nitrogen containing aromatic compounds present in that fraction.   
The E. coli prophage induction assay was used to complement the Salmonella 
assay in the battery because it detects DNA strand brakes, and is sensitive to chlorinated 
compounds (DeMarini et al. 1990).  In the current study, the acid fraction induced a 
strong positive genotoxic response, while the base fraction induced a week positive 
response and the other fractions were negative.  The positive response observed for the 
acid fraction is due to the presence of PCP, these results confirm the utility of this 
bioassay for detecting genotoxic chlorinated compounds.  The base fraction had levels of 
PCP and this may be the reason for the positive response in this assay.   
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Bulky DNA adducts were measured in skin, lung and liver tissues collected from 
animals treated with complex PAH mixtures.  Each of the complex mixtures induced a 
genotoxic response in vivo.  The highest level of DNA adducts were consistently 
observed in lung tissue, whereas the lowest level of adducts were generally observed in 
the liver tissue.  The exception to this was animals treated with the PAH fraction.  The 
PAH fraction consistently induced the maximum level of total DNA adducts in each of 
the three tissues studied.  In the liver, the PAH fraction induced a total adduct level that 
was more than 30 times greater than the level observed for any of the other fractions.  In 
the lung tissue, the PAH fraction induced the maximum genotoxic response, although 
the PCDD fraction, the neutral fraction and the base fraction each induced more than 100 
per 109 relative adducts.  Spot 4 adducts are believed to represent the BAP diolepoxice 
(BPDE) metabolite of BAP (Lu et al. 1986).  The pattern for spot 4 adducts follow the 
same general trend as the total adduct levels.  Diffrerences observed between tissues can 
be attributed to adsorption and distribution of the chemical.  The samples were applied to 
the skin.  The chemicals had to be absorbed through the skin, and then be distributes 
through the body.  Larger molecular weight chemicals will be slowed down in this 
process, which will effect the overall response.   
Overall the in vitro bioassays were sensitive to selective classes of compounds.  
However, measuring DNA adducts in the animal model provides a useful system for 
incorporating interactions that may be influenced by pharmacokinetics.  Using only the 
microbial bioassays, the two most genotoxic fractions appear to be the acid and base 
fractions, while a weak genotoxic response was observed for the crude, neutral and PAH 
fractions.  However, in the animal model the PAH fraction was the most genotoxic, and 
this positive geonotxic response was observed for all of the fractions.  These results 
indicate that while microbial bioassays provide a viable screen for identifying genotoxic 
mixtures, in vivo models are both more sensitive and appear to be more accurate.  The 
sensitivity and accuracy of in vivo models can be attributed to these reasons as well: in 
vivo models allow for whole system testing of a chemical and its effects while these in 
vitro models do not; and in vivo model data is quantitiative, while the in vitro model data 
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is qualitative.  Chemical analysis is important for quantification of the mixtures.  
However, it is apparent from the in vitro and in vivo assays that the biological 
measurements provide the most accurate assessment of genotoxic potential of complex 
mixtures based on the quantitative data collected.   
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CHAPTER III 
FREQUENCY AND PERSISTENCE OF DNA ADDUCTS IN INFANT MALE 
MICE EXPOSED TO COMPLEX CHEMICAL MIXTURES 
 
3.1 Introduction 
Complex mixtures are ubiquitous in the environment.  Chemical mixtures are 
present in air, water, soil and cooked foods.  Due to the breadth of contamination in the 
environment, humans are exposed to chemical mixtures (Binkova and Sram 2004; 
Mueller et al. 1989; Mueller et al. 1991; Vyskocil et al. 2004).  To reduce the occurrence 
of human disease from complex mixture exposure, it is important to obtain more 
accurate information regarding both the environmental and physiological fate of 
chemical mixtures.  Mixture interactions may increase or decrease the relative toxicity of 
components due to alterations in absorption, metabolism, distribution or excretion.   
WPW is a common environmental contaminant.  WPW is a complex mixture of 
PAHs, PCDDs, and other numerous compounds.  Many of these compounds are formed 
during combustion processes.  The chemical properties of PAHs and the other 
components of WPW make them useful as biocides and wood preservatives.  It is this 
use that has contaminated numerous sites throughout the United States.  Certain PAHs 
are classified as carcinogenic compounds by the United States Environmental Protection 
Agency (USEPA 1992).  Once a PAH carcinogen has entered into a biological organism 
they are considered to be a procarcinogen (inactive).  Metabolic activation converts the 
procarcinogen into a carcinogen.  The progression from a DNA adduct to an actual 
tumor is a rare process.  It is more likely that the progression will be interrupted in some 
manor.  However, this process does occur, making the carcinogenic potential of a 
chemical or group of chemicals very important.  DNA adducts are thought to have a very 
important role in carcinogenesis.  Therefore, it is important to identify DNA adducts 
formed by chemicals.  32P-postlabeling is a very sensitive method used to determine 
DNA adducts in exposed tissues.   Other methods used include fluorescence detection, 
gas chromatography/mass spectrometry and immunoassay.   
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The persistence of DNA adducts has been studied, and it has been shown that after 
about 48 hr, up to 80% of the DNA damage is no longer detected (Phillips 1997).  It has 
also been shown in previous studies that the presence of DNA adducts does not mean the 
chemical is tumorigenic (Hemminki et al. 2000).  However, by linking DNA adduct 
studies with tumor studies; it will help determine if 32P-postlabeling is in fact a good 
assay for determining the carcinogenic potential of a chemical. 
WPW produces DNA adduct formation in lung tissues by Randerath et al. in 1994.  
This study showed the potential of WPW to produce bulky DNA adducts in vitro using 
rat lung DNA.  Again, this same group showed WPWs potential to produce bulky DNA 
adducts in vivo in mouse skin (Randerath et al. 1995; Randerath et al. 1997).  In the 
study conducted in 1995, several tissues were tested for DNA adduct formation.  The 
skin showed the highest levels, as it was the site of application, with the lung following 
behind.  The liver exhibited the next highest levels of DNA adducts produced by the 
WPW.  Persistence of the DNA adducts is the next concern, as this can determine how 
much damage, ultimately, the exogenous compounds may produce.  In general, DNA 
adducts have shown to decrease rapidly within the first two weeks of exposure.  Adducts 
that remain after this time are persistent, and are likely going to be the cause of larger 
problems (Randerath and Randerath 1994).  Adducts that persist in the DNA can be 
detected up to 42 weeks after topical application (Reddy and Randerath 1986).  
However, the older the animal is, the more easily I-compounds will be detected.  I-
compounds are indigenous compounds already present in the biological system which 
may form bulky DNA adducts.  These compounds increase linearly with age of an 
animal.  The older the animal, the more difficult it is to determine differences between I-
compounds and bulky DNA adducts with exogenous compounds (Randerath and 
Randerath 1994; Randerath et al. 1999; Reddy 2000).   
The goal of this study is to investigate the frequency and persistence of bulky DNA 
adduct formation over time and dose in infant mice administered the model carcinogen 
BAP as well as complex mixtures containing BAP. 
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3.2 Materials and Methods 
3.2.1 Sample Collection   
The methods used for collection and extraction of the WPW were described in 
Chapter II. 
 
3.2.2 Chemicals and Materials 
The following chemicals were purchased from EM Science (Gibbstown, NJ):  
methylene chloride (ACS reagent grade, 99.5% pure), isopropyl alcohol (HPLC grade) 
and acetone (ACS reagent grade, 99.5% pure).  Pentachlorophenol (98% pure), 
benz(a)anthracene (99% pure), chrysene (98% pure), benzo(b)fluoranthene 98% pure), 
benzo(k)fluoranthene (98% pure), benzo(a)pyrene (97% pure), dibenz(a,h)anthracene 
(200 µg/mL in CH2Cl2), guanidine HCl (99+% pure), and trizma base (>99.9%) were 
purchased from the Sigma-Aldrich Group (St. Louis, MO).  Indeno(1,2,3-c,d)pyrene 
(1000 µg/mL in CH2Cl2) was purchased from Absolute Standards (Hamden, CT).  The 
following were purchased from QIAGEN Sciences, Inc (Germantaown, MD):  QIAGEN 
Genomic-tip 100/G and RNase A (17500 U).  Proteinase K (recombinant, PCR grade, 
lyphilizate) was purchased from Roche Diagnostics (Indianapolis, IN).  Tween-20 
(enzyme grade) was purchased from Fisher Scientific (Pittsburgh, PA).  Acide MOPS 3-
(N-morpholino) propane sulfonique (Molecular Biology Grade) was purchased from 
VWR International (Batavia, IL).  The following chemicals were purchased from EMD 
Biosciences, Inc. (San Diego, CA):  Na2EDTA•2H2O, Triton X-100 and NaCl (ACS 
grade).     
 
3.2.3 Animals 
All animals were obtained from Harlan (Houston, TX).  Strains used were 
B6C3F1/Hsd male mice, 21 days old, 7-11 g.   These mice are inbred hybrid agouti 
offspring of a cross between a C57BL/6Nhsd inbred female mouse and a C3H/HeNHsd 
inbred male mouse.  Mice were shipped via Harlan truck in filtered shipping containers.  
Mice are housed in a barrier facility, 3 mice per filtered cage.  Mice were fed ad libitum 
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using sterilized food provided by the facility.  Water was also ad libitum, using filtered 
and sterilized water provided by the facility. 
 
3.2.4 Statistics 
Statistics were carried out by the Department of Statistics at Texas A&M 
University using R software.  All data underwent log transformation.  Contrasts to be 
tested were entered into the program.  Contrasts were determined based on scientific 
hypothesis determined for this study.  For lung and forestomach tissues, a series of 
ANOVAs were preformed, building from 3x3x3 ANOVA (three chemicals, three doses 
and three times).  Data was not collected at one time for one chemical, so it was ignored 
in order to make sure the full analysis would follow the same pattern as the smaller 
analysis.  A 4x3x2 ANOVA (four chemicals, three doses and two times) was preformed.  
The one chemical with missing data was added, but the missing time ignored.  Finally, 
the full analysis of four chemicals, three doses and three times (4x3x3) was preformed.  
All three analyses followed the same pattern.  Only the 4x3x3 ANOVA analysis is 
reported in this paper.  The same strategy was used for the liver tissue data.  In the liver 
tissue, there are four times as one last time point of 280 days was added.  Again, data 
was not collected for one chemical, but this time it was for two different times.  A 3x3x4 
ANOVA (three chemicals, three doses and four times) was preformed ignoring the one 
chemical.  A three-way interaction was detected in the spot 4 liver response from the 
3x3x4 analysis.  A 4x3x2 (four chemicals, three doses and tow times) ANOVA was 
preformed ignoring two time points (7 days and 280 days).  There was an inconsistency 
observed in this analysis.  A three-way interaction showed significance (chemical-dose-
time) where there were only two-way significant interactions previously.  Therefore, 
contrasts in this final analysis must be done on a three-way interaction.  Finally, the full 
4x3x4 (four chemicals, three doses and four times) ANOVA was preformed.  The data 
reported in this paper include: two-way 4x3x4 ANOVA interactions for the total adduct 
data, and three-way 4x3x4 ANOVA interactions for the spot 4 adduct data.   
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3.2.5 Preparation of a Reconstituted Mixture  
The methods used for preparation of the RM was described in Chapter II.  Table 
3.1 lists the values of PAHs present for each treatment at the high dose.  The NF was 
spiked with BAP to be equivalent to the level of pure BAP dosed.  The RM was also 
spiked with BAP to be equivalent.  NF was also tested without being spiked with extra 
BAP, to observe differences that may occur. 
 
3.2.6 In Vivo Bioassays 
3.2.6.1 DNA Adducts in Mice, Topical Application 
DNA adducts were quantified in B6C3F1 21 day-old male mice exposed topically 
to 150 µl of sample (in CH2Cl2) at does of 3, 1.2, and 0.48 mg/mouse for 24 hr.  Dosing 
procedures were followed as described by Reddy and Randerath (1986).  Briefly, mice 
were weighed and placed into groups such that the average weight of each group is 
approximately equal.  The backs of the mice were then shaved.  After 24 hr, the mice 
were shaved a second time.  This allowed the chemicals to be applied directly to the 
skin.  Mice were then reweighed, groups readjusted, and any nicked mice were not 
treated.  A total of 10 groups, 5 mice per group, were treated topically, including one 
control group.   
Topical treatment was applied via capillary tubes and mice were left for 24 hr.  
Three groups at different concentrations (3 mg/mouse, 1.2 mg/mouse and 0.48 
mg/mouse) for BAP, RM and NF+BAP mixtures were tested.  Mice were sacrificed after 
24 hr, and exposed skin, lung, and liver were collected and stored at -80°C.   
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3.2.6.2 Infant Male Mouse Model   
DNA adducts were quantified in male B6C3F1 mice using a protocol described by 
Rodriguez et al. (1997).  Briefly, 21 day old male B6C3F1 mice were injected 
intraperitoneally (i.p.) one time with sample or control.  The sample was dissolved in 
50:50 DMSO:Corn oil.  A total of 24 groups of mice were treated.  For ice with a 280 
day endpoint (tumor mice), there were 10 treated groups with 20 mice per group 
(Control, BAP, reconstituted mixture, and neutral fraction + BAP) and one treated group 
having 10 mice per group (neural fraction).  BAP, reconstituted mixture and neutral 
fraction + BAP had three groups each, one for each dose concentration.  Neutral fraction 
was dosed at the highest concentration only.  Mice with a 1 day, 7 day and 21 day 
endpoint (DNA adduct mice), there were 13 treated groups with 15 mice per group (5 
mice per sample endpoint).  Groups included control, BAP, reconstituted mixture, 
neutral fraction + BAP, and neutral fraction.  All treatments had three groups dosed with 
the dose-response concentrations.  Dose concentrations administered to the mice 
included 0.429, 0.171, and 0.069 mg/g body weight in a volume of 7.14 µL vehicle/g 
body weight.  Control was administered as a volume of 7.14 µL vehicle/g body weight.  
Calculations follow: 
Before treatment administration, mice were taken from their mothers and weighed.  
After weight was determined, mice were injected according to weight (Figure 3.1).  
After intraperitoneal injection, tumor mice were watched daily for 3 months, and then bi-
weekly until the 280 day endpoint.  DNA adduct mice were watched daily until the 
endpoints of 1 day, 7 days and 21 days were reached.  For DNA adduct mice, lung, liver 
and forestomach were collected and stored in a -80°C freezer.  For tumor mice, lung, 
liver and forestomach were collected and immediately put into 10% formalin.  A small 
piece of liver was collected from the first three mice of each group and stored at -80°C 
for DNA adduct testing.   
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x 
45° Angle 
from Body 
1) B6C3F1 Infant 
Mice Weighed 
3) B6C3F1 Infant Mice 
Watched Carefully Until 
End Point 
 
Figure 3.1.  Diagram of the procedure for the infant male mouse model.  Mice are weighed and 
then injected into the intraperitoneal cavity.   
 
 
3.2.6.3 
32
P-Postlabeling   
DNA was extracted from mouse tissues using Qiagen Genomic-tip 100/G tips.  
Digestion and labeled with γ32P[ATP] following methods described previously by Reddy 
and Randerath (1986).  The Qiagen extraction is briefly described, 0.08 to 0.1 g of 
minced mouse tissue were weighed into a 15 mL polypropylene centrifuge tube.  19 µL 
of RNase A stock solution (100mg/mL) and 9.5 mL buffer G2 were added to the tube.  
Tissues were then homogenized for 45 to 60 sec at 15,000 to 20,000 rpm.  0.5 mL of 
Proteinase k stock solution (20 mg/mL) was then added, and the sample was incubated at 
50°C for 2 hr.  Qiagen Genomic-tip 100/G tips were equilibrated with 4 mL of buffer 
QBT, and emptied via gravity flow.  Samples were vortexed for 10 sec and poured onto 
the corresponding tip.  Flow was regulated by gravity.  Tips were then washed with 7.5 
mL buffer QC twice via gravity flow.  DNA was then eluted from the tips with 5 mL of 
buffer QF into a 50 mL polypropylene centrifuge tube.  3.5 mL of room temperature 
isopropanol was added to the tube.  The samples were then vortexed and centrifuged at 
10,000 rpm, 4°C, for 15 min.  Supernatant was carefully poured off the DNA pellet.  
DNA was then washed with 2 mL of ice cold 70% ethanol, vortexed and spun in the 
centrifuge at 10,000 rpm for 10 min.  Supernatant was carefully poured off, and DNA 
was washed a second time as described above.  DNA was then dried for 10 min and 
2) B6C3F1 Infant Mice Injected 
Intraperitoneally 
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redissolved in 0.08 to 0.15 mL 0.01 x SSC.  The desired concentration is 2µg/µL.  
Concentration was checked via UV-Vis Spectrophotometer, the A260 (DNA)/A280 (RNA) 
ratio should range from 1.6 to 1.8.   
DNA digestion and labeling are described briefly: 10 µg of DNA in 5 µL of SSC 
and/or water were digested using 3 µL of 0.2U micrococcal nuclease and 2.4 µg spleen 
phosphodiesterase per µL (MN/SPD) and 2.4 µL of IS-buffer mix (10 µg DNA, 100 mM 
CaCl2 and 300 mM Na succinate) for 3.5 hr at 37°C.  MN/SPD digestion cleaves the 5’-
nucleotide-phosphate bonds, leaving the 3’-monophosphates of the normal and adducted 
deoxyribonucleosides.  The DNA was then digested with 4.75 µL of nuclease P1 
digestion mix (4 µg/µL nuclease P1, 1 M NaOAc and 1 mM ZnCl2) for 40 min at 37°C.  
Nuclease P1 digestion cleaves the 3’-nucleotide-phosphate bonds on normal nucleotides 
only.  It was reported that adducted nucleotides were mostly or partially resistant to 
nuclease P1 3’-dephosphorylation (Reddy and Randerath 1986).  The sample was then 
labeled using 3.86 µL of polynucleotide kinase (PNK) labeling mix (kinase buffer, 100 
µCi/µL ATP and 30 U/µL PNK) and incubated for 40 min at 37°C.  PNK labeling 
attaches the radioactive phosphate ([γ-32P]ATP) at the 5’-hydroxyl group end of the 
adducted nucleotides through [32P]phosphate transfer from ([γ-32P]ATP).  The normal 
nucleotides lost their 3’-phosphate during nuclease P1 digestion, so PNK will not 
phosphorylate them with the ([γ-32P]ATP).  Once samples are labeled, two specific 
activity (SA) tubes (2 pmol/µL dAP and 50 mM CHES, pH 9.5) were then labeled with 
2.5 µL PNK labeling mix, and incubated same as the samples.  All samples, with the 
exception of the SA tubes, were then digested with 1.5 µL of 40 mU/µL potato apyrase 
for 30 min at 37°C.  Apyrase digestion destroys the excess ATP by removing [32P] from 
the ATP ([32P]-ATP        ADP + [32P]).  After apyrase incubation, normals and SA tubes 
were then diluted.  Normals were a qualitative check to make sure that each sample was 
digested and labeled well.  Tubes contain 250 µL of 20 mM CHES, pH 9.5.  1 µL of 
sample was added to the corresponding tube, and then µL per sample were spotted on 
PEI-cellulose sheets.  SA dilution tubes contained 996 µL of 20 mM CHES, pH 9.5.  4 
µL of labeled SA tubes (d*pAp mix) were added to each corresponding SA tube, and 
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then 5 µL are spotted on PEI-cellulose sheets.  Normals and SA PEI-cellulose sheets 
were run in 0.28 M NH4(SO4)2 + 50 mM NaH2PO4, pH 6.7 to 13 cm past the origin line, 
approximately 1 to 2 hr (Figure 2.4).   
 While normals and SA sheets are running, labeled samples are spotted onto a PEI 
cellulose sheet (D1 development).  D1 sheets are run in 80 mL of 2.3 M NaH2PO4, pH 
5.75, for 16 hr (Figure 2.5).  D1 development removes traces of normal nucleotides after 
the nuclease P1 treatment, as well as residual orthophosphate by pushing them to the 
wick at the top of the sheet, leaving the [32P] adducted nucleotides behind.  D1 sheets are 
developed on autoradiographic film, and locations of the spots are then drawn on the 
back of the PEI-cellulose sheets.  Spots are then cutout from the D1 PEI-cellulose sheet 
and transferred to single PEI-cellulose sheets (2D maps) using a strong magnet (Figure 
2.6).  2D maps are run vertically in 65 mL of 95% LFU, pH 3.35 + 5% dH2O (D3 
development) to top marked line after being pre-developed in 25 mL of dH2O to the 
origin.  2D maps are then checked for transfer, cut at the second line from the top, 
washed twice in 250 mL of dH2O for 7 min, dried, and a wick attached to the right side 
in preparation for the final development (D4 development) (Figure 2.7).  For the D4 
development, the 2D maps are run horizontally in 65 mL of 90% PTU, pH 8.20 + 10% 
dH2O to the top of the wick after being pre-developed in 25 mL of 50% 0.8 M NaH2PO4, 
pH 8.2 + 50% dH2O to the second line marked from the left side.  2D maps are then 
checked for separation, cut just below the wick, washed twice in 250 mL of dH2O for 5 
min, dried, and cut for autoradiographic development and imager reading (Figure 2.7).  
An instant imager is used to calculate CPM per spot. 
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3.3 Results 
A small subset experiment was done using dermal application.  The goal of this 
was to compare back to i.p. application and determine differences.  3x3 (three chemicals, 
three doses) ANOVAs were preformed on this data, p-values listed in Table 3.2.  
Relative adduct labeling values (RAL per 109 nucleotides) are listed in Table 3.3, with 
all statistical significance data presented in Tables 3.4 and 3.5.  For dermal application in 
the liver tissue, spot 4, chosen because it has been associated with the BAP-diolepoxide 
(BPDE) adduct in previous studies, elicited the only significant differences observed 
(Figure 3.2 and Table 3.4).  BAP at the 0.429 mg/g bw and 0.171 mg/g bw doses were 
significantly higher than NF+BAP at the same doses (RAL of 34.15 ± 3.73 and 34.42 ± 
0.64 compared to 33.60 ± 2.36 and 33.24 ± 1.83 per 109 nucleotides, Table 3.3).  BAP 
was also significantly larger than the RM at the 0.171 mg/g bw and 0.069 mg/g bw 
doses.  RM was significantly higher than NF+BAP at the 0.429 mg/g bw dose, while 
NF+BAP was significantly higher than RM at the 0.069 mg/g bw dose.  All treatments at 
the 0.069 mg/g bw dose showed a significant increase from the control in this tissue for 
both spot 4 and total adducts (Table 3.4).  All treatments had the same amount of BAP 
present at each dose, so it is interesting that the BAP would elicit a larger response 
alone.  Interactions within the mixtures are having some effect on the overall 
genotoxicity. 
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Figure 3.2.  Autoradiograms from dermal and intraperitoneal injection (i.p.) exposure of liver 
tissues, exposure time 1 day.
NF+BAP (IP) Control (IP) BAP (IP) 
BAP (Dermal) Control (Dermal) NF+BAP (Dermal) 
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Table 3.3.  Table of DNA adduct levels detected in liver, lung, forestomach and skin of 
B6CDF1 male mice treated dermally.  Data are presented as RAL per 10
9
 nucleotides ± SEM. 
Control
Tissue 0.069 0.171 0.429
Liver 13.24 ± 1.66 24.99 ± 3.04 34.42 ± 0.64 34.15 ± 3.73
Lung 10.13 ± 1.37 21.37 ± 1.87 30.84 ± 3.86 35.06 ± 2.14
Forestomach 7.87 ± 2.52 38.42 ± 5.72 47.80 ± 4.26 37.78 ± 3.32
Skin 7.57 ± 1.03 616.81 ± 99.85 441.92 ± 74.79 640.47 ± 112.09
Liver 1.84 ± 0.20 14.68 ± 1.99 13.53 ± 0.42 7.43 ± 0.45
Lung 2.34 ± 0.31 21.00 ± 1.48 17.89 ± 2.20 11.68 ± 0.60
Forestomach 1.10 ± 0.32 17.49 ± 2.03 19.89 ± 1.20 15.10 ± 2.28
Skin 1.55 ± 0.47 426.86 ± 74.26 303.65 ± 52.27 417.36 ± 61.63
Mean Total RAL / 10
9
 Nucleotides for Skin Application
Mean Spot 4 RAL / 10
9
 Nucleotides for Skin Application
BAP (mg/g bw)
 
 
 
 
 
Control
Tissue 0.069 0.171 0.429
Liver 13.24 ± 1.66 23.68 ± 3.37 29.40 ± 2.09 38.80 ± 4.05
Lung 10.13 ± 1.37 9.53 ± 0.67 11.41 ± 3.07 38.94 ± 4.58
Forestomach 7.87 ± 2.52 18.95 ± 2.35 30.96 ± 3.99 60.10 ± 12.34
Skin 7.57 ± 1.03 148.66 ± 20.18 240.44 ± 58.17 492.04 ± 27.77
Liver 1.84 ± 0.20 18.14 ± 2.83 8.20 ± 0.98 3.33 ± 0.36
Lung 2.34 ± 0.31 24.31 ± 3.15 6.11 ± 1.54 4.07 ± 0.41
Forestomach 1.10 ± 0.32 26.74 ± 5.19 12.22 ± 1.62 4.74 ± 0.60
Skin 1.55 ± 0.47 322.83 ± 16.21 149.70 ± 38.70 89.39 ± 11.76
RM (mg/g bw)
Mean Total RAL / 10
9
 Nucleotides for Skin Application
Mean Spot 4 RAL / 10
9
 Nucleotides for Skin Application
 
 
 
 
Control
Tissue 0.069 0.171 0.429
Liver 13.24 ± 1.66 33.62 ± 2.73 33.24 ± 1.83 33.60 ± 2.36
Lung 10.13 ± 1.37 13.55 ± 1 16.81 ± 1.82 19.73 ± 1.12
Forestomach 7.87 ± 2.52 33.88 ± 3.63 53.44 ± 5.26 130.75 ± 18.77
Skin 7.57 ± 1.03 181.04 ± 27.38 224.37 ± 17.76 343.63 ± 70.80
Liver 1.84 ± 0.20 6.59 ± 0.39 7.22 ± 0.85 6.26 ± 0.68
Lung 2.34 ± 0.31 10.99 ± 0.68 9.02 ± 1.24 6.45 ± 0.45
Forestomach 1.10 ± 0.32 67.16 ± 10.00 23.69 ± 2.12 11.22 ± 0.86
Skin 1.55 ± 0.47 218.44 ± 47.41 143.56 ± 11.61 108.51 ± 16.86
Mean Spot 4 RAL / 10
9
 Nucleotides for Skin Application
NF+BAP (mg/g bw)
Mean Total RAL / 10
9
 Nucleotides for Skin Application
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The lung tissue had two significant interactions, one in the total DNA adduct 
analysis and the other in the spot 4 analysis (Table 3.4).  In both significant responses, 
the BAP was significantly higher than the RM at the 0.171 mg/g bw dose (RAL of 30.84 
± 3.86 and 11.41 ± 3.07 per 109 nucleotides for total adducts, Table 3.3).  No other 
response was considered significant in this tissue for dermal application.  All treatments 
were observed to have no significant difference from the control at the 0.069 mg/g bw 
dose for total adducts (Table 3.4).  However, for spot 4 adducts, BAP did elicit a 
significantly higher response than the control.   
In the forestomach, the NF+BAP was observed to be significantly larger than the 
BAP and RM at the 0.429 mg/g bw dose for total DNA adduct formation (RAL of 
130.75 ± 18.77 compared to 37.78 ± 3.32 and 60.10 ±12.34 per 109 nucleotides, Tables 
3.3 and 3.4).  In spot 4 DNA adduct formation, this same response was observed with 
one difference.  NF+BAP was also significantly larger than the RM at the 0.069 mg/g 
bw dose.  All treatments elicit a significantly larger response than the control in this 
tissue for both total and spot 4 DNA adduct formation at the 0.069 mg/g bw dose (Table 
3.5).  In this tissue, the NF+BAP elicits larger response than the BAP alone and RM, 
suggesting unknown interactions are occurring to heighten the response.   
Finally, BAP was observed to be significantly higher than NF+BAP at the 0.429 
mg/g bw and 0.069 mg/g bw doses in the skin for total DNA adducts formed (RAL of 
640.47 ± 112.09 and 616.81 ± 99.85 compared to 343.63 ± 70.80 and 181.04 ± 27.38 per 
109 nucleotides, Tables 3.3 and 3.4).  It was also observed that BAP was significantly 
higher than the RM at the 0.069 mg/g bw dose.  In spot 4, the same responses were 
observed, along with the BAP also being significantly higher than the RM 0.171 mg/g 
bw dose.  For the control, all treatments at the 0.069 mg/g bw dose were significantly 
higher than the control in both spot 4 and total DNA adduct formation (Table 3.5).  This 
tissue is the site of application, and is interesting that the BAP alone would elicit larger 
responses here. 
Dermal data was compared to the i.p. application data at time 24 hr.  A 3x3 
ANOVA was preformed, and all p-values are listed in Table 3.2.  A complex three-way 
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interaction (application-chemical-dose) was found to be significant for all tissues except 
the forestomach, in which a two-way interaction was significant (chemical-dose).  The 
three-way interaction indicated that none of the factors are significant on their own.  
Application along with chemical and dose are all connected in the significance.  In the 
two-way interaction, application alone is significant, but only the chemical and dose 
factors are connected.  Interaction plots showing application and chemical-dose 
interactions for liver are presented in Figure 3.3.  There is a significantly different 
pattern observed based on application and dose and chemical.  It is also observed that the 
i.p. application response is elevated as compared to the dermal response.  For BAP dose-
response, the dermal levels are observably smaller than those of the i.p. DNA adduct 
levels (Figure 3.4).  When observing each treatment at the 0.429 mg/g bw dose, the same 
patter for application is again observed, with the NF+BAP eliciting the highest response 
in the dermal application and the BAP and NF+BAP eliciting similar responses in the 
i.p. application (Figure 3.5). 
Lung total DNA adducts interaction plots for chemical-dose interactions by 
application are presented in Figure 3.6.  Again, a different pattern is observed through 
the interaction plots based on chemical-dose and application.  In the dermal application, 
BAP and NF+BAP are almost parallel in their response.  However, in the i.p. 
application, BAP begins lower than NF+BAP and then it crosses over at the 0.171 mg/g 
bw dose to again become parallel to NF+BAP.  It is also apparent that the i.p. application 
is elevated over the dermal application.  For the BAP dose-response, plotted in Figure 
3.7, it is observed that the dermal application is much lower than the i.p. application.  
Over all tissues for the 0.429 mg/g bw dose, again it is obvious that the i.p. application is 
elevated over the dermal application, with apparent differences in patterns (Figure 3.8).  
In the dermal application, the RM and BAP elicit a similar response, both higher than the 
NF+BAP.  However, in the i.p. application, the NF+BAP clearly elicits a higher 
response than the RM and BAP.   
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BAP Treatment in Liver (mg/g bw)
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Figure 3.4.  Difference between dermal and i.p. application mean total DNA adducts of BAP 
treatment in liver.  Data are presented as RAL per 10
9
 nucleotides.   
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Liver Treatment (0.429 mg/g bw)
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Figure 3.5.  Difference between dermal and i.p. application mean total DNA adducts over all 
treatments in liver.  Data are presented as RAL per 10
9
 nucleotides.  *=Elevated response 
observed.
R
A
L
 /
 1
0
9
 N
u
c
le
o
ti
d
e
s
 
* 
* 
* 
  
127 
 
 
 F
ig
u
re
 3
.6
. 
 I
n
te
ra
c
ti
o
n
 p
lo
ts
 o
f 
th
e
 a
p
p
lic
a
ti
o
n
-c
h
e
m
ic
a
l-
d
o
s
e
 i
n
te
ra
c
ti
o
n
s
 f
o
r 
lu
n
g
. 
 
  
128 
BAP Treatment in Lung (mg/g bw)
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Figure 3.7.  Difference between dermal and i.p. application mean total DNA adducts of BAP 
treatment in lung.  Data are presented as RAL per 10
9
 nucleotides.  *=Elevated response 
observed. 
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Lung Treatment (0.069mg/g bw)
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Figure 3.8.  Difference between dermal and i.p. application mean total DNA adducts over all 
treatments in lung.  Data are presented as RAL per 10
9
 nucleotides.  *=Elevated response 
observed. 
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Finally, interaction plots for the forestomach dermal and i.p. chemical-dose 
interactions are presented in Figure 3.9.  For the forestomach, only a significant two-way 
interaction was observed.  The same pattern is formed based on the dose-chemical 
interaction.  This pattern is elevated in the i.p. application as compared to the dermal 
application.  In the BAP dose-response for this tissue, this pattern is observed (Figure 
3.10).  The doses appear to follow the same pattern, just eleveated for the i.p. 
application.  Over all of the chemical treatments, again the same pattern emerges.  The 
BAP shows the lowest response, with RM next above it, and NF+BAP eliciting the 
highest response in the dermal applications (Figure 3.11).  This is the same pattern 
observed in the i.p. application, just at an elevated level. 
A larger experiment was preformed to collect data from the i.p. injection 
application in three tissues, liver, lung and forestomach over three different time points 
in the lung and forestomach (1 day, 7 days and 21 days) and four different time points in 
the liver (1 day, 7 days, 21 days and 280 days).  Budget constraints did not allow for all 
four chemical treatments to be collected at all the time points; therefore, it was decided 
that the NF would be collected only at two time points (1 day and 21 days).  Tissue 
aliquot constraints prevented the lung and forestomach tissues from being sampled at 
time 280 days.  The DNA adduct data (Table 3.6) shows that NF+BAP was the most 
genotoxic in all three tissues.  Although the NF did not induce a response comparable to 
the other treatments, it did induce a response that was anywhere from ½ to ¼ as toxic as 
BAP, eventhough it contains a level of BAP less than 1% the level found in all other 
treatments.  All of the data was compared for differences in DNA adduct frequencies 
over time among chemical treatment groups, as well as within chemical treatment 
groups.  The BAP treatment groups were contrasted to the NF+BAP and RM treatment 
groups.  These contrasts were done to compare the differences between pure BAP to a 
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BAP Treatment in Forestomach (mg/g bw)
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Figure 3.10.  Difference between dermal and i.p. application mean total DNA adducts of BAP 
treatment in forestomach.  Data are presented as RAL per 10
9
 nucleotides.  *=Elevated 
response observed. 
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Forestomach Treatment (0.069mg/g bw)
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Figure 3.11.  Difference between dermal and i.p. application mean total DNA adducts over all 
treatments in forestomach.  Data are presented as RAL per 10
9
 nucleotides.  *=Elevated 
response observed. 
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complex mixture as well as to a mixture of carcinogenic PAHs (all groups containing the 
same amount of BAP).  The RM treatment groups were also contrasted to the NF+BAP 
treatment groups to compare the differences between a mixture of carcinogenic PAHs to 
a complex mixture containing the same level of those PAHs.  Next, the NF+BAP 
treatment groups were contrasted to the NF treatment groups to compare the differences 
between complex mixtures containing high and low levels of BAP.  Finally, all chemical 
treatments were contrasted among themselves to compare the differences over time.  All 
contrasts were built up to the final analysis as described in the materials and methods 
section.  A 4x3x3 (four chemicals, three doses and three times) ANOVA was preformed 
on the lung and forestomach tissues, while a 4x3x4 (four chemicals, three doses and four 
times) was preformed on the liver tissue.  Both analyses used the log transformed RAL 
per 109 nucleotides.  All p-values are listed in Table 3.7. 
It is important to note that autoradiograms, presented in Figure 3.12, show a large 
quantity of background present, especially in the longer time points.  This is due to 
different factors present, including PEI cellulose sheets and I compounds present in older 
animals.  This is most likely one factor that accounts for the increase that is observed at 
time point 280 days.  Controls were contrasted against treatment chemicals to determine 
statistical relationships (Table 3.8).  In the liver tissue, only at days 21 and 280 was the 
BAP not significantly higher than the control in both total and spot 4 analyses.  RM was 
not significantly higher than the control at day 21 in total and spot 4 analyses, and 
NF+BAP was not significantly higher than the control at day 280 in total and spot 4 
analyses.  NF was not significantly higher than the control at days 21 and 280 in the total 
analyses only.  At day 280, RM and NF+BAP were significantly lower than the control 
in total DNA adducts, as well as RM and NF were significantly lower than the control in 
the spot 4 DNA adducts.  Again, this is most likely due to the large presence of 
background in the samples.  For the lung tissue, all chemicals were significantly higher 
than the control, except for the NF at 21 days in both the total and spot 4 adduct data.  
The forestomach tissue, as well, was only not significantly higher than the control in the 
NF at days 1 and 21 in total and spot 4 adduct analyses.
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Figure 3.12.  Autoradiograms of liver tissues, i.p. exposure time of 1 day. 
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All contrast data for total and spot 4 adducts evaluated in the liver tissue over time 
is summarized in Tables 3.9, and 3.10.  For this tissue, a significant interaction was 
observed between chemical and time (Table 3.9).  Due to this interaction, all contrasts 
were made using this two-way interaction (Figure 3.13).  Overall, all chemicals decrease 
significantly over time (Figure 3.14).  NF+BAP (RAL of 276.46 ± 18.97 per 109 
nucleotides in 0.429 mg/g bw dose) is significantly higher than RM (RAL of 94.58 ± 
14.94 per 109 nucleotides in 0.429 mg/g bw dose) and NF (RAL of 39.24 ± 3.46 per 109 
nucleotides in 0.429 mg/g bw dose) at 1 day, RM at 7 days and finally significantly 
higher than BAP at 21 days (Table 3.9 and 3.10).  A significant interaction between 
treatment, dose and time was observed for spot 4 (Table 3.11).  As there was a 
significant three-way interaction, all contrasts were made using this three-way 
interaction (Figure 3.15).  In the spot 4 data, NF+BAP is significantly higher than BAP, 
RM and NF at 1 day, and BAP and RM at 7 days in the 0.429 mg/g bw dose.  For the 
0.171 mg/g bw dose, NF+BAP is again significantly higher than NF, while BAP is 
higher than RM at 1 day.  At 7 days, NF+BAP is higher than RM.  The pattern of the 
chemical response changes depending upon dose (Figures 3.15 and 3.16).  For the high 
dose, NF+BAP generally elicit the maximum response, while for the medium and low 
doses BAP generally elicits the maximum response.  This could be due to toxicity 
factors influencing the high dose response. 
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Table 3.9.  Significant confidence intervals for differences in mean total DNA adducts in 
liver, lung and forestomach tissues across time.  For all contrasts computed, the confidence 
level was 95%.  In total adducts, each tissue had a significant chemical-time interaction; 
therefore, data contrasts were computed across time.  P-values listed in Table 3.2. 
BAP x NF+BAP RM x NF+BAP NF+BAP x NF BAP x RM
Liver (-0.973, -0.103) (-1.203, -0.333) (0.483, 1.353) NS
Lung NS (-1.342, -0.428) (1.094, 2.008) (0.370, 1.284)
Forestomach NS (-1.439, -0.269) (1.501, 2.671) NS
Liver NS (-1.063, -0.159) N/A NS
Lung NS (-1.359, -0.411) N/A (0.308, 1.222)
Forestomach NS (-1.376, -0.162) N/A (0.024, 1.194)
Liver (-0.941, -0.039) NS NS NS
Lung (-1.212, -0.266) (-1.253, -0.323) (1.017, 1.981) NS
Forestomach NS NS (0.331, 1.565) NS
Liver (0.261, 1.385) NS NS (0.059, 1.183)
Lung N/A N/A N/A N/A
Forestomach N/A N/A N/A N/A
BAP x BAP RM x RM NF+BAP x NF+BAP NF x NF
Liver NS NS NS N/A
Lung NS NS NS N/A
Forestomach NS NS NS N/A
Liver (0.428, 1.314) NS (0.476, 1.362) NS
Lung (0.312, 1.242) NS NS NS
Forestomach NS NS (0.249, 1.441) NS
Liver (0.052, 1.058) (0.443, 1.449) (1.413, 2.419) (0.040, 1.548)
Lung N/A N/A N/A N/A
Forestomach N/A N/A N/A N/A
Liver (0.126, 1.012) NS (0.032, 0.950) N/A
Lung (0.255, 1.185) NS NS N/A
Forestomach NS NS (0.013, 1.247) N/A
Liver NS (0.172, 1.178) (0.971, 2.005) NS
Lung N/A N/A N/A N/A
Forestomach N/A N/A N/A N/A
Liver NS (0.037, 1.043) (0.488, 1.506) NS
Lung N/A N/A N/A N/A
Forestomach N/A N/A N/A N/A
NS = Not Significant
Confidence Intervals for Differences in Mean Total Adducts in B6C3F1 Male Mouse Tissues: Contrasts for 
Chemicals Across Time
N/A = Data Not Available
1 Day
7 Days
21 Days
280 Days
7 Days to 21 Days
7 Days to 280 Days
21 Days to 280 Days
1 Day to 7 Days
1 Day to 21 Days
1 Days to 280 Days
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Table 3.11.  Significant confidence intervals for difference in mean spot 4 DNA adducts in 
liver tissue across dose and time.  For all contrasts computed, the confidence level was 95%.  
In spot 4 adducts, each tissue had a significant chemical-dose-time interaction; therefore, data 
contrasts were computed across dose and time.  Spot 4 was chosen because in previous 
studies it has been shown to correspond with benzo(a)pyrene.  P-values listed in Table 3.2. 
BAP x RM BAP x NF+BAP RM x NF+BAP NF+BAP x NF
1 Day NS (-2.532, -0.590) (-2.165, -0.223) (1.943, 3.885)
7 Days NS (-2.077, -0.135) (-2.450, -0.508) NS
21 Days NS NS NS NS
280 Days NS NS NS NS
1 Day (0.267, 2.209) NS NS (0.467, 2.409)
7 Days NS NS (-2.612, -0.370) NS
21 Days NS NS NS NS
280 Days NS NS NS NS
1 Day NS NS NS NS
7 Days NS NS NS NS
21 Days NS NS NS NS
280 Days NS NS NS NS
NS = Not Significant
Confidence Intervals for Differences in Mean Spot 4 Adducts in Liver of B6C3F1 Male Mouse Tissues: Contrasts for 
Chemicals Across Dose & Time
High Dose              
(0.429mg/g bw)
Medium Dose 
(0.171mg/g bw)
Low Dose           
(0.069mg/g bw)
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Figure 3.13.  4x3x4 interaction plot for differences in mean total DNA adducts in liver tissue over 
time.  *Represents individual points for NF, a line could not be drawn as points are missing.
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Figure 3.14.  Mean total DNA adducts detected in liver tissue for treatments contrasted against 
time.  Data are presented as RAL per 10
9
 nucleotides ± SEM.  *Significantly lower than day 1.
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Figure 3.15.  4x3x4 interaction plots for differences in mean spot 4 DNA adducts in liver tissue 
over dose and time.  *Represents individual points for NF, a line could not be drawn as points 
are missing. 
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Total and spot 4 adducts data for the lung tissue are presented in Table 3.12.  A 
significant interaction between treatment and time was observed in this tissue (Tables 
3.7, 3.9 and 3.13).  Therefore, all contrasts were made using this two-way interaction, 
data graphed in Figures 3.17 and 3.18.  Both total and spot 4 analyses seem to show 
similar patterns (Figures 3.19 and 3.20).  A more dramatic decrease occurs after day 7 in 
the RM and NF+BAP fractions, but overall all fractions decrease with time.  The 
NF+BAP and BAP treatments both elicit the highest responses in this tissue (Figures 
3.19 and 3.20).  It isn’t until day 21 that the NF+BAP (RAL of 147.01 ± 69.34 per 109 
nucleotides) becomes significantly higher than the BAP (RAL of 39.26 ± 5.03 per 109 
nucleotides) (Table 3.9 and 3.10).  Both NF+BAP and BAP are significantly higher than 
RM, while NF+BAP is higher than NF at 1 day.  At day 7 NF+BAP and BAP are 
significantly higher than RM, and then at day 21 NF+BAP is significantly higher than 
RM and NF again.   
Statistical contrast data for total and spot 4 adducts in the forestomach is presented 
in Tables 3.9 and 3.12.  Once tested, a significant interaction was observed between 
treatment and time (Table 3.7).  Thus, all contrasts were made using this two-way 
interaction (Figures 3.21 and 3.22).  The same interaction pattern is observed in both the 
total and spot 4 adduct analyses, with the spot 4 being a slightly smaller response 
(Figures 3.23 and 3.24).  After time 7 days, the NF+BAP and BAP both significantly 
decrease.  The NF+BAP and BAP once again are the two chemicals that produce the 
maximum DNA adduct frequencies (RAL of 305.17 ± 115.88 and 162.40 ± 35.89 per 
109 nucleotides at time 7 days in the 0.429 mg/g bw dose, Table 3.13).  The RM seems 
to stay at the same level, with no significant change over time.  NF+BAP is consistently 
yields a significantly higher response than RM and NF, while BAP is consistently higher 
than RM until day 21.  At day 21, NF+BAP is significantly higher than RM, NF and 
BAP.  The spot 4 results follow the same pattern as the total results in the forestomach.  
There is also a fairly consistent pattern observed throughout all tissues.
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Table 3.13.  Significant confidence intervals for difference in mean spot 4 DNA adducts in 
lung and forestomach tissues across time.  For all contrasts computed, the confidence level 
was 95%.  In spot 4 adducts, each tissue had a significant chemical-time interaction; therefore, 
data contrasts were computed across time.  Spot 4 was chosen because in previous studies it 
has been shown to correspond with BAP.  P-values listed in Table 3.2.  
BAP x NF+BAP RM x NF+BAP NF+BAP x NF BAP x RM
Lung NS (-1.522, -0.480) (1.841, 2.883) (0.666, 1.708)
Forestomach NS (-2.022, -0.484) (2.552, 4.090) (0.215, 1.753)
Lung NS (-1.482, -0.400) N/A (0.371, 1.413)
Forestomach NS (-1.723, -0.127) N/A (0.167, 1.705)
Lung (-1.178, -0.098) (-1.338, -0.276) (1.560, 2.660) NS
Forestomach NS NS (1.311, 2.933) NS
BAP x BAP RM x RM NF+BAP x NF+BAP NF x NF
Lung NS NS NS N/A
Forestomach NS NS NS N/A
Lung (0.531, 1.593) NS NS NS
Forestomach NS NS (0.104, 1.668) NS
Lung (0.289, 1.351) NS NS N/A
Forestomach NS NS NS N/A
NS = Not Significant
Confidence Intervals for Differences in Mean Spot 4 Adducts in Lung & Forestomach of B6C3F1 Male Mouse 
Tissues: Contrasts for Chemicals Across Time
N/A = Data Not Available
7 Days to 21 Days
1 Day to 21 Days
1 Day
7 Days
21 Days
1 Day to 7 Days
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Figure 3.17.  4x3x3 interaction plot for differences in mean total DNA adducts in lung tissue over 
time.  *Represents individual points for NF, a line could not be drawn as points are missing. 
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Figure 3.18.  4x3x3 interaction plot for differences in mean spot 4 DNA adducts in lung tissue 
over time.  *Represents individual points for NF, a line could not be drawn as points are missing. 
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Figure 3.19.  Mean total DNA adducts detected in lung tissue for treatments contrasted against 
time.  Data are presented as RAL per 10
9
 nucleotides ± SEM.  *Significantly lower than day 1. 
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Figure 3.20.  Mean spot 4 DNA adducts detected in lung tissue for treatments contrasted 
against time.  Data are presented as RAL per 10
9
 nucleotides ± SEM.  *Significantly lower than 
day 1.
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Figure 3.21.  4x3x3 interaction plot for differences in mean total DNA adducts in forestomach 
tissue over time.  * Represents individual points for NF, a line could not be drawn as points are 
missing. 
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Figure 3.22.  4x3x3 interaction plot for differences in mean spot 4 DNA adducts in forestomach 
tissue over time.  *Represents individual points for NF, a line could not be drawn as points are 
missing. 
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Figure 3.23.  Mean total DNA adducts detected in forestomach tissue for treatments contrasted 
against time.  Data are presented as RAL per 10
9
 nucleotides ± SEM.   
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Figure 3.24.  Mean spot 4 DNA adducts detected in forestomach tissue for treatments 
contrasted against time.  Data are presented as RAL per 10
9
 nucleotides ± SEM.  *Significantly 
lower than day 1. 
 
 
After the data was analyzed over time, it was then compared among chemical 
treatments over dose to observe differences between chemical treatment groups, as well 
as within chemical treatment groups.  As before, budget constraints did not allow for all 
four chemical treatments to be collected at all the time points; therefore, it was decided 
that the NF would be collected at two time points (1 day and 21 days) instead of all three 
time points.  Tissue aliquot constraints prevented the lung and forestomach tissues from 
being sampled at time 280 days.  The BAP treatment groups were contrasted to the 
NF+BAP and RM treatment groups.  These contrasts were done to compare the 
differences between pure BAP to a complex mixture as well as to a mixture of 
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carcinogenic PAHs (all containing the same amount of BAP).  The RM treatment groups 
were also contrasted to the NF+BAP treatment groups to compare the differences 
between a mixture of carcinogenic PAHs to a complex mixture with the same level of 
those PAHs.  Next the NF+BAP treatment groups were contrasted to the NF treatment 
groups to compare the differences between complex mixtures containing high and low 
levels of BAP.  Finally, all chemical treatments were contrasted among themselves to 
compare the differences over dose.  All contrasts were built up to the final analysis as 
described in the materials and methods section.  A 4x3x3 (four chemicals, three doses 
and three times) ANOVA was preformed on the lung and forestomach tissues while a 
4x3x4 (four chemicals, three doses and four times) ANOVA was preformed on the liver 
tissue.  Both analyses used the log transformed RAL per 109 nucleotides.  P-values are 
reported in Table 3.7.   
Contrasts across dose for total adduct analysis in liver are presented in Table 3.14.  
A significant interaction between treatment and dose was observed in this tissue (Table 
3.7).  Consequently, all contrasts were made using this two-way interaction, data 
graphed in Figures 3.25 and 3.26.  The interaction plot shows a clear pattern in which all 
chemicals decrease with dose, except the NF.  NF+BAP decreases significantly with 
dose, and it elicited the highest response of the chemicals (Figure 3.26).  NF+BAP is 
significantly higher than NF, BAP and RM at the 0.429 mg/g bw dose, while it is only 
significantly higher than NF at the 0.171 mg/g bw dose.  BAP is also significantly higher 
than RM at the 0.171 mg/g bw dose (Table 3.14).  A significant dose response is also 
observed between NF+BAP and BAP.     
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Table 3.14.  Significant confidence intervals for difference in mean total DNA adducts in 
liver, lung and forestomach tissues across dose.  For all contrasts computed, the confidence 
level was 95%.  In total adducts, each tissue had a significant chemical-dose interaction; 
therefore, data contrasts were computed across dose.  P-values listed in Table 3.2. 
NF+BAP x NF BAP x NF+BAP RM x NF+BAP BAP x RM
Liver (0.716, 1.606) (-1.006, -0.228) (-1.032, -0.254) NS
Lung (1.85, 2.970) (-1.630, -0.680) (-1.700, -0.760) NS
Forestomach (1.422, 2.864) NS (-1.298, -0.088) NS
Liver (0.097, 1.023) NS NS (0.023, 0.789)
Lung (0.908, 1.980) NS (-1.310, -0.350) (0.442, 1.370)
Forestomach (0.989, 2.357) NS (-1.287, -0.053) (0.125, 1.313)
Liver NS NS NS NS
Lung (0.258 ,1.290) NS (-0.964 ,-0.038) (0.187 ,1.130)
Forestomach (0.279, 1.607) NS NS NS
BAP x BAP RM x RM NF+BAP x NF+BAP NF x NF
Liver NS NS (0.207, 1.007) NS
Lung NS (0.434, 0.897) (0.812, 1.790) NS
Forestomach NS NS NS NS
Liver (0.020, 0.798) (0.179, 0.945) (0.777, 1.555) NS
Lung (0.282, 1.230) (0.874 ,1.800) (1.590 ,2.540) NS
Forestomach (0.011, 1.221) (0.233, 1.421) (0.635, 1.845) NS
Liver (0.045, 0.823) NS (0.164, 0.954) NS
Lung (0.214, 1.160) NS (0.284 ,1.250) NS
Forestomach NS NS (0.030, 1.264) NS
NS = Not Significant
High to Low Dose (0.429 
- 0.069mg/g bw)
Medium to Low Dose 
(0.171 - 0.069mg/g bw)
Confidence Intervals for Differences in Mean Total Adducts in B6C3F1 Male Mouse Tissues: Contrasts for Chemicals 
Across Dose
High Dose            
(0.429mg/g bw)
Medium Dose 
(0.171mg/g bw)
Low Dose            
(0.069mg/g bw)
High to Medium Dose 
(0.429 - 0.171mg/g bw)
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Figure 3.25.  4x3x4 interaction plot for differences in mean total DNA adducts in liver tissue over 
dose. 
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Figure 3.26.  Mean total DNA adducts detected in liver tissue for treatments contrasted against 
dose.  Data are presented as RAL per 10
9
 nucleotides ± SEM.  *Low dose significantly lower 
than high dose; **medium dose significantly lower than high dose. 
   
 
All contrasts for total and spot 4 adducts evaluated in lung tissue are summarized 
in Tables 3.14 and 3.15.  When these analyses were run, a significant interaction was 
observed between treatment and dose (Table 3.7).  Therefore, all contrasts were made 
using this two-way interaction, data graphed in Figurs 3.27 and 3.28.  The total and spot 
4 data follow the same pattern, with the total adducts being more elevated.  All 
chemicals decrease with dose, and we see the same cross effect here where the NF+BAP 
begins by eliciting the maximum response, and then the BAP ends up eliciting a slightly 
higher response than the NF+BAP (Figures 3.29 and 3.30).  The NF+BAP starts as being 
significantly higher than the BAP, RM and NF at the 0.429 mg/g bw dose.  After that, 
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the NF+BAP and BAP are not significantly different.  This tissue follows the same 
pattern as the liver, except that at the 0.069 mg/g bw dose, NF+BAP is significantly 
higher than RM and NF, while BAP is significantly higher than RM (Tables 3.14 and 
3.15).  A dose response is also observed within all chemicals.   
 
 
Table 3.15.  Significant confidence intervals for difference in mean spot 4 DNA adducts in 
lung and forestomach tissues across dose.  For all contrasts computed, the confidence level 
was 95%.  In spot 4 adducts, each tissue had a significant chemical-dose interaction; therefore, 
data contrasts were computed across dose.  Spot 4 was chosen because in previous studies it 
has been shown to correspond with BAP.  P-values listed in Table 3.2.  
NF+BAP x NF BAP x NF+BAP RM x NF+BAP BAP x RM
Lung (2.580, 3.864) (-1.668, -0.590) (-1.793, -0.715) NS
Forestomach (2.489, 4.383) NS (-1.591, -0.003) NS
Lung (1.602, 2.822) NS (-1.458, -0.360) (0.619, 1.677)
Forestomach (1.991, 3.789) NS (-1.834, -0.214) (0.444, 2.004)
Lung (0.794, 1.978) NS (-1.114, -0.056) (0.435, 1.513)
Forestomach (1.223, 2.967) NS NS (0.091, 1.679)
BAP x BAP RM x RM NF+BAP x NF+BAP NF x NF
Lung NS (0.534, 1.592) (0.850, 1.966) NS
Forestomach NS (0.142, 1.702) NS NS
Lung (0.302, 1.380) (1.161, 2.219) (1.820, 2.898) NS
Forestomach NS (0.562, 2.122) (0.678, 2.266) NS
Lung (0.262, 1.340) (0.098, 1.156) (0.402, 1.500) NS
Forestomach NS NS NS NS
NS = Not Significant
High Dose          
(0.429mg/g bw)
Medium Dose 
(0.171mg/g bw)
Medium to Low Dose 
(0.171 - 0.069mg/g bw)
Low Dose          
(0.069mg/g bw)
High to Medium Dose 
(0.429 - 0.171mg/g bw)
High to Low Dose (0.429 
- 0.069mg/g bw)
Confidence Intervals for Differences in Mean Spot 4 Adducts in Lung & Forestomach of B6C3F1 Male Mouse Tissues: 
Contrasts for Chemicals Across Dose
 
 
 
 
  
162 
 
Figure 3.27.  4x3x3 interaction plot for differences in mean total DNA adducts in lung tissue over 
dose. 
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Figure 3.28.  4x3x3 interaction plot for differences in mean spot 4 DNA adducts in lung tissue 
over dose. 
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Figure 3.29.  Mean total DNA adducts detected in lung tissue for treatments contrasted against 
dose.  Data are presented as RAL per 10
9
 nucleotides ± SEM.  *Low dose significantly lower 
than high dose; **medium dose significantly lower than high dose. 
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Figure 3.30.  Mean spot 4 DNA adducts detected in lung tissue for treatments contrasted 
against dose.  Data are presented as RAL per 10
9
 nucleotides ± SEM.  *Low dose significantly 
lower than high dose; **medium dose significantly lower than high dose. 
 
 
Data contrasts showing total and spot 4 adduct levels evaluated in forestomach 
tissue are reported in Tables 3.14 and 3.15.  After the data was run, a significant 
interaction was observed between treatment and dose (Table 3.7).  Thus, all contrasts 
were made using this two-way interaction (Figure 3.31 and 3.32).  Once again, a similar 
pattern is observed between total and spot 4 adduct analyses.  All chemicals decrease 
significantly with dose, except the NF, which decreases slightly.  The NF+BAP has 
elicited the maximum response at the 0.429 mg/g bw dose, whereas after that, the 
NF+BAP and BAP elicit a very similar level of adducts (Figures 3.33 and 3.34).  The 
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forestomach follows the same exact pattern as the lung for significance between 
chemicals.  A dose-response is observed for the RM, NF+BAP and BAP in the total 
analysis, with BAP not included in the spot 4 analysis (Table 3.14 and 3.15).   
 
 
Figure 3.31.  4x3x3 interaction plot for differences in mean total DNA adducts in forestomach 
tissue over dose. 
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Figure 3.32.  4x3x3 interaction plot for differences in mean spot 4 DNA adducts in forestomach 
tissue over dose. 
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Figure 3.33.  Mean total DNA adducts detected in forestomach tissue for treatments contrasted 
against dose.  Data are presented as RAL per 10
9
 nucleotides ± SEM.  *Low dose significantly 
lower than high dose; **medium dose significantly lower than high dose. 
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Figure 3.34.  Mean spot 4 DNA adducts detected in forestomach tissue for treatments 
contrasted against dose.  Data are presented as RAL per 10
9
 nucleotides ± SEM.  *Low dose 
significantly lower than high dose; **medium dose significantly lower than high dose. 
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3.4 Discussion 
The results of the current experiment are comparable to those observed in Chapter 
II.  The intraperitoneal (i.p.) injection application DNA adduct levels were observed to 
be greater than the dermal application DNA adduct levels.  The difference, for most of 
the tissues, reflects differences in application method, chemical treatment and dose.  
Pharmacokinetics plays an important role in determining the fate of a chemical once it 
has been introduced into a biological system.  There are multiple mechanisms which 
occur when an exogenous compound enters a cell.  One of the most important factors in 
how a compound will act is the route of exposure.  In most instances, dermal application 
will not elicit as large a response as a more direct route of administration due to 
absorption.  Chemicals cannot cross through the epidermis easily, which explains why 
DNA adduct levels are lower with the dermal application.  This would account for the 
NF+BAP treatment eliciting a larger response via i.p. injection.  When you have route of 
exposure in the intraperitoneal cavity, absorption of the chemical is made easier due to 
direct access to capillaries.  Once the chemicals have been adsorbed, distribution and 
metabolism become more important.  These factors can be influenced by chemical, as 
well as by route of exposure and dose.  Comparing the two routes of exposure for this 
research was important for determining differences that would be observed in the 
chemical responses based on administration.  The ultimate goal of the comparison was to 
determine if i.p. injection administration would be a comparable route of exposure to 
dermal application.   
The first step was to compare all low dose samples were to the controls.  This 
ensures that responses of treatments were significant over the control samples, while also 
ensuring the controls are not having an effect on the responses observed.  It was 
observed that all chemicals were either significantly larger than the control, or not 
significantly different from the control.  It was also observed that after 21 days controls 
did increase.  This is due to the detection of I-compounds.  As animals age, a linear 
correlation can be seen with respect to an increase in I-compound.  I-compounds are 
indigenous compounds in the organism which will bind with DNA and form DNA 
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adducts.  Results from the 280 day time point are difficult to interpret due to the high 
presence of I-compounds.   
Comparison between routes of exposure was the next big step.  It was observed 
that there were slight differences between route of administration and response of the 
treatment.  BAP responses via dermal application are smaller than responses via i.p. 
injection.  It was also observed that there was a difference in dose-response based on 
route of exposure.  Dermal doses showed smaller responses than those from i.p. 
injection.  This chemical-dose-application interaction suggests that it is very important to 
determine optimal dose and application methods for the chemicals to be tested.  
However, for testing complex mixtures this becomes a difficult task, as these 
interactions can be very different for each chemical within the mixture.  Overall, it was 
observed that i.p. injection as a route of exposure elicited larger responses than dermal 
application.  This route of exposure, which allows for a more direct absorption of the 
chemicals, is more efficient for the type of testing this research is conducting. 
All samples administered via i.p. injection were compared, and similar responses 
were observed over all three tissues collected (liver, lung, forestomach).  A similar 
response among tissues is an important observation.  When all tissues tested have similar 
responses, a presidence is set for that chemical-dose-application.  Future studies will be 
able to focus more attention on the target organ based on this observation.  The NF+BAP 
treatment elicited the maximum response at the high dose (0.429 mg/g bw) for all 
tissues.  BAP and NF+BAP appear to be closely parallel in their responses.  A dose 
response was observed with the NF+BAP treatment, while the BAP treatment showed a 
dose response between the intermediate dose and the low dose.  It was shown that 
absorption is more efficient via this route of exposure; therefore, results at the high dose 
for BAP could be attributed to a cytotoxic response from distribution in the cells, which 
would explain why the intermediate dose elicited a stronger response than the high dose. 
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DNA adducts in general do not persist for long periods of time.  After 
approximately a week, a decrease in DNA adducts present should be observed.  
However, there are instances were chemicals to persist in the form of DNA adducts.  
Therefore, it is important to characterize this persistence with these treatments.  All i.p. 
injection samples were compared over time for persistence.  Over time, it was observed 
that adduct levels decreased.  However, DNA adducts did persist shortly.  The BAP and 
NF+BAP responses persisted from 1 day to 7 days, and then began to decrease.  The RM 
and NF responses however persisted relatively at the same level from 1 day to 21 days.  
The responses to these chemicals were lower than those of the NF+BAP and BAP 
responses, which could account for the apparent persistence of their DNA adduct levels.   
The next stage of this research is the long-term tumorigenicity study, modeled after 
Rodriguez et al. 1997.  Rodriguez et al. (1997) exposed infant male mice to BAP or 
manufactured gas plant residues via i.p. injection.  This research has demonstrated that 
the most efficient method of treatment application is via i.p. injection.  This route of 
administration allows for more rapid absorption of PAHs, and therefore a more complete 
genotoxic response.  Based on the present results it is expected that the highest tumor 
incidence would be seen in the NF+BAP treatment.   
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CHAPTER IV 
RELATIONSHIP BETWEEN DNA ADDUCT AND TUMOR FORMATION IN 
INFANT MALE MICE 
 
4.1 Introduction 
In the United States, cancer is the cause of 1 in four deaths (Jemal et al. 2004).  In 
the years from 1999 to 2000, approximately 13 million adults had been diagnosed with 
cancer (CDC 2003a).  In 2003 nearly 1.3 million new cancer cases were diagnosed 
(CDC 2003b).  Cancer can be caused by various agents including environmental and 
occupational exposures, household use of chemicals and genetic predispositions.  
Smoking and exposure to environmental tobacco smoke has been associated with cancer 
in the lung, bronchus, larynx, bladder, cervix and oral mucosa (Lee et al. 2006; Phillips 
1997; Yach and Wipfli 2006) .  A study by Boffetta (2006) on human cancer due to 
environmental pollutants concludes that in Europe 10.7% of lung cancers are due to 
urban air pollution.  A connection between second-hand smoking and lung cancer has 
also been suggested, with an incidence of approximately 1.6%.  Excess rates of cancer 
have also been associated with exposure to asbestos, arsenic, nickel and chromium (Case 
2006; Kuo et al. 2006; Smith et al. 2006).  Occupational exposure to chemicals such as 
PAHs has been associated with cancer in liver, lung, and stomach (Binkova and Sram 
2004; Karlehagen et al. 1992; Vyskocil et al. 2004).   
Occupational exposure to PAHs has been a concern since 1775, when Sir Percival 
Pott discovered a link between chimney sweeps and scrotal cancer.  Numerous 
epidemiological studies have been conducted with regards to PAH exposure (Lloyd 
1971; Maclure and MacMahon 1980; Mazumdar et al. 1975; Redmond et al. 1976; 
Wynder and Hoffmann 1967).  32P-postlabeling can be a useful tool in the biomonitoring 
of exposure to genotoxic and carcinogenic compounds (Phillips 1997; Randerath et al. 
1992).  Pauisieux et al. (1991) did a study on selectivity of p53 genes.  They found that 
p53 nucleotide “hot spots” in the lung and liver are preferred targets for BAP in the 
environment.  Epidemiological studies are the best way to observe effects from exposure 
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to chemical mixtures in humans (Krewski and Thomas 1992).  Vyskocil et al. (2004) did 
a risk assessment on lung cancer and environmental exposure to PAHs.  They found that 
toxicity gradients based on animals studies for BAP were a magnitude higher than those 
that were based on BAP levels measured in the years studied.  Their approach is that risk 
assessment and epidemiology should be used jointly, in order to reduce uncertainty 
factors associated with risk assessments.  Wong and Harris (2005) did a retrospective 
occupational cohort study of workers at 11 wood-treating facilities.  They looked at 
mortality due to malignant and non-malignant effects.  Even though significant numbers 
of liver and lung cancers were observed, along with a multitude of other cancers, they 
found that mortality could not be linked to exposure at the facilities.  Kerr et al. (2000) 
conducted a study of parental occupational exposures and neuroblastoma probability in 
their children.  They found that maternal and paternal parents occupationally exposed to 
creosote (OR of 1.3 and 2.4 respectively) and coal tar (OR of none and 4.1 respectively) 
would have and increased probability for neuroblastoma to present in their children 
under the age of 15.  Jean Brender et al. (2003) did a study on health risks associated 
with a residential population living in community near an old wood preserving site.  In 
this study, she observed that there was a definite effect on health for residents in close 
proximity to a site that was contaminated with PAHs.  There was an increased incidence 
of skin rashes, chronic bronchitis, premature births and low birth weights.  However, 
higher rates of cancer had not been observed at this time.  All of these epidemiological 
studies give insight into effects complex PAH mixtures have on humans.  However, 
without toxicity testing, there is no absolute data on how chemicals react inside a 
biological system, and the amount of damage they may cause.   
PAHs, especially BAP, have been extensively studied using animals as models to 
determine carcinogenic potential.  One of the many models used is the 32P-postlabeling 
assay.  This assay has shown that complex PAH mixtures cause DNA aberrations, and as 
a result are potentially carcinogenic (Gupta et al. 1982; Hemminki et al. 2000; Lu et al. 
1986; Randerath et al. 1981; Randerath et al. 1985; Randerath et al. 1996).  However, it 
is not known if DNA adducts will definitely produce tumors in vivo.  The best way to 
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determine tumorigenicity, is to use an animal model.  Vesselinovitch et al. (1975a) 
carried out an extensive tumor study with B6C3F1 and C3AF strains of mice exposed to 
BAP.  Mice were exposed at different ages in order to determine the effect that BAP had 
at different ages.  The B6C3F1 mouse was the hardier of the two strains, as well as more 
susceptible to liver tumors.  Mice dosed in infancy tended to be smaller in weight and 
not live as long as those dosed in adulthood.  This is an important study, from it came a 
good liver model to determine tumor formation from PAH exposure.  Rodriguez et al. 
(1997) modified this study for manufactured gas plant residues.  They found that 
consistent dose-response relationships could not be obtained with the chemicals he used.  
However, tumor incidence was collected, and suggested that this is a good model to use 
for relatively quick carcinogenicity analysis of chemicals exposure.  Culp et al. (2000) 
did a similar study on DNA adduct measurements and tumor mutation with B6C3F1 
female mice.  This study used a complex mixture of coal tar that was fed to the animals.  
This study found that the forestomach had high levels of tumor incidence.  Suggesting 
that BAP (or similar PAHs) in coal tar mixtures are mostly responsible for the 
forestomach tumor induction.  Von Tungeln et al. (1999) carried out a tumorigenicity 
study of nitropolycyclic aromatic hydrocarbons in neonatal B6C3F1 male mice.  It was 
observed in this study that in vitro assays, while providing vital information on 
chemicals, are actually poor predictors of the tumorigenic potential of those chemicals.  
It was their assumption that liver tumors were induced by the nitro-PAHs from PAH-like 
metabolism.  The in vivo infant male mouse model is highly versatile.  Reynolds et al. 
(2004) conducted a study using this model to detect DNA damage-induced changes in 
the liver.  They concluded that this model not only can detect tumor formation, but can 
be used for studying hepatocyte proliferation, p53 observations, and gene expression 
changes.  The use of the model to look at these and other parameters is important, as it is 
more reliable than in vitro data.  Tumor studies are expensive, and alternative in vivo 
studies such as the 32P-postlabeling assay are ideal.   
32P-postlabeling is a sensitive method for determining DNA adduct formation in 
tissues from animals that have been treated with chemicals or chemical mixtures 
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(Phillips 1997; Randerath et al. 1984; Reddy 2000; Williams et al. 1996).  This assay has 
shown that DNA damage does in fact occur with certain chemicals.  In fact, this assay 
has been essential in showing that previously thought non-genotoxic chemicals did 
actually bind to and alter DNA (Phillips 1997).  It has been shown in previous studies 
that DNA binding activity of certain mixtures does in fact correlate with 
mutagenic/carcinogenic activity (Phillips 1997).   
The USEPA published “Guidelines for the Health Risk Assessment of Chemical 
Mixtures” in 1986.  These guidelines should be used when trying to assess the risk a 
mixture (more than one chemical) posses.  There are three approaches that can be used, 
based on mixture composition, the chronic or subchronic exposure approach, the 
sufficiently similar approach and the toxic or carcinogenic properties approach.  The 
chronic or subchronic exposure approach is the most accurate and preferred approach for 
assessing mixtures.  This approach is used when data is available for the mixture of 
concern.  When using this approach, the procedures for single compounds can be 
adopted for both systemic toxicants and carcinogens.  However, the dose-response is not 
the same for single compounds as compared to mixtures, and this should be taken into 
consideration.  The sufficiently similar approach is used when there is no data available 
on the mixture of concern, but a similar mixture does have data available.  It is important 
when using this approach that dissimilarity of the mixtures be taken into consideration.  
Finally, toxic or carcinogenic properties can be used when data is not available on the 
mixture of concern as well as any reasonably similar mixtures.  The toxic or 
carcinogenic properties of the individual components of the mixture may then be 
evaluated for the risk assessment.  Dose additivity is often assumed for systemic 
toxicants, but is not the most biologically plausible approach.  However, this approach 
predicts reasonably well the risk assessment of mixtures.  Risk assessment should be 
tailored to the mixture of concern, taking into account the many levels of complexity a 
mixture poses.  It is important to study mixtues as a whole, and as fractions of the whole, 
in order to obtain a better understanding of the risks posed by exposure to mixtures.   
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This study was conducted to test two hypotheses related to complex PAH mixtures.  
The first hypothesis is that the frequency of DNA adducts in tissues of mice treated with 
BAP or complex mixtures containing the same amount of BAP will correlate with the 
incidence of tumors in animals receiving comparable treatments.  The second hypothesis 
is that the incidence of tumors in animals treated with BAP, or complex mixtures 
containing equal amounts of BAP, will not be significantly different.  The data from 
these experiments provides useful information for understanding the impact of mixture 
interactions on BAP carcinogenicity.   
 
4.2 Materials and Methods 
4.2.1 Sample Collection and Extraction   
Methods on sample collection and extraction were previously described in Chapter 
II. 
 
4.2.2 Chemicals and Materials   
The following chemicals were purchased from EM Science (Gibbstown, NJ):  
methylene chloride (ACS reagent grade, 99.5% pure), isopropyl alcohol (HPLC grade) 
and acetone (ACS reagent grade, 99.5% pure).  Pentachlorophenol (98% pure), 
benz(a)anthracene (99% pure), chrysene (98% pure), benzo(b)fluoranthene 98% pure), 
benzo(k)fluoranthene (98% pure), benzo(a)pyrene (97% pure), dibenz(a,h)anthracene 
(200µg/mL in CH2Cl2), guanidine HCl (99+% pure), and trizma base (99%) were 
purchased from the Sigma-Aldrich Group (St. Louis, MO).  Indeno(1,2,3-c,d)pyrene 
(1000µg/mL in CH2Cl2) was purchased from Absolute Standards (Hamden, CT).  The 
following were purchased from QIAGEN Sciences, Inc (Germantaown, MD):  QIAGEN 
Genomic-tip 100/G and RNase A (17500 U).  Proteinase K (recombinant, PCR grade, 
lyphilizate) was purchased from Roche Diagnostics (Indianapolis, IN).  Tween-20 
(enzyme grade) was purchased from Fisher Scientific (Pittsburgh, PA).  Acide MOPS 3- 
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(N-morpholino) propane sulfonique (Molecular Biology Grade) was purchased 
from VWR International (Batavia, IL).  The following chemicals were purchased from 
EMD Biosciences, Inc. (San Diego, CA):  Na2EDTA•2H2O, triton X-100, and NaCl 
(ACS grade).   
 
4.2.3 Animals   
All animals were obtained from Harlan (Houston, TX).  Strains used were 
B6C3F1/Hsd male mice, 21 days old, 7 to 11 g.   These mice are inbred hybrid agouti 
offspring of a cross between a C57BL/6Nhsd inbred female mouse and a C3H/HeNHsd 
inbred male mouse.  Mice were shipped via Harlan truck in filtered shipping containers.  
Mice are housed in a barrier facility, 3 mice per filtered cage.  Mice were fed ad libitum 
using sterilized food provided by the facility.  Water was also ad libitum, using filtered 
and sterilized water provided by the facility. 
 
4.2.4 Statistics   
Statistics were carried out by a Graduate Student in the Department of Statistics at 
Texas A&M University using SAS software.  Mortality was computed using a logistic 
regression, with odd ratios computed for chemical and dose combinations.  Among each 
tissue, all tissues combined as well as liver tissue alone were the only groups with 
enough tumors to warrant analysis using logistic regression.  The first analysis run only 
included treatments that had a low, medium and high dose range (this excluded the NF 
and control).  Odds ratios were computed for all chemical-dose combinations.  Next, a 
logistic regression was run on only high dose treatments (this excluded all medium and 
low doses, and the control).  Odds ratios were computed for all chemical-chemical 
combinations.  The final analysis included all treatments, all doses and the control in a 
logistic regression.  Odds ratios were run for chemical-control as well as chemical-
chemical combinations.    
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4.2.5 Extraction and Fractionation of a Complex Chemical Mixture 
4.2.5.1 Extraction   
As previously described in Chapters II and III, the WPW was a pure oil, and 
therefore no extraction was necessary.   
 
4.2.5.2 Fraction Selection   
As stated in Chapter III, the neutral fraction isolated for Specific Aim I was chosen 
to be evaluated for Specific Aim II in Chapter III.  The neutral fraction will also be 
evaluated in this chapter for Specific Aim III.  The neutral fraction is the elutant which 
isolated mostly PAHs from the parent complex mixture.  The fractionation procedure 
was previously described in Chapter II.  This fraction was tested against BAP and a 
reconstituted mixture in Specific Aims II and III.   
 
4.2.5.3 Preparation of a Reconstituted Mixture   
Methods for preparation of a reconstituted mixture (RM) were previously 
described in Chapter II.  Table 4.1 lists the amount of PAHs present per treatment for the 
high dose (0.429 mg/g bw). 
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4.2.6 In Vivo Bioassays 
4.2.6.1 DNA Adducts in Mice, Topical Application 
DNA adducts were quantified in B6C3F1 21 day-old male mice exposed topically to 
150µl of sample (in CH2Cl2) at does of 3, 1.2, and 0.48mg/mouse for 24 hr.  Dosing 
procedures were followed as previously described by Reddy and Randerath (1986).  A 
brief description follows.  Mice were weighed and sorted into groups, 5 mice per group, 
so that average group weights were approximately equal.  The backs of the mice were 
then shaved, and left for 24 hr.  After 24 hr, the mice were shaved again, allowing the 
chemicals to be applied directly to the skin.  Mice were then reweighed, groups adjusted 
accordingly, and any nicked mice were removed.  A total of 10 groups were treated, 
including a control group.  Topical application was applied to the shaved skin via 
capillary tubes, and mice were left for 24 hr.  Three groups were tested, BAP, RM and 
NF+BAP.  Each group was tested for dose-response with 3, 1.2, and 0.48 mg/mouse 
doses.  Mice were sacrificed after 24 hr, and the exposed skin, lung, and liver were 
collected and stored at -80°C.   
 
4.2.6.2 Infant Male Mouse Model 
Tumor incidence in infant B6C3F1 male mice was first described by 
Vesselinovitch et al. (1975a) and Vesselinovitch et al. (1975b), and later modified for 
complex mixtures by Rodriguez et al. (1997).  For this study, tumor incidence and DNA 
adducts were evaluated in infant male B6C3F1 mice by using the protocol described by 
Rodriguez et al. (1997).  Briefly, 21 day old male B6C3F1 mice were injected 
intraperitoneally one time with sample or control.  The sample was dissolved in 50:50 
DMSO:Corn oil.  A total of 24 groups of mice were treated.  For ice with a 280 day 
endpoint (tumor mice), there were 10 treated groups with 20 mice per group (Control, 
BAP, reconstituted mixture, and neutral fraction + BAP) and one treated group having 
10 mice per group (neural fraction).  BAP, reconstituted mixture and neutral fraction + 
BAP had three groups each, one for each dose concentration.  Neutral fraction was dosed 
at the highest concentration only.  Mice with a 1 day, 7 day and 21 day endpoint (DNA 
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adduct mice), there were 13 treated groups with 15 mice per group (5 mice per sample 
endpoint).  Groups included control, BAP, reconstituted mixture, neutral fraction + BAP, 
and neutral fraction.  All treatments had three groups dosed with the dose-response 
concentrations.  Dose concentrations administered to the mice included 0.429, 0.171, 
and 0.069 mg/g body weight in a volume of 7.14 µL vehicle/g body weight.  Control 
was administered as a volume of 7.14 µL vehicle/g body weight.  Before treatment 
administration, mice were taken from their mothers and weighed.  After weight was 
determined, mice were injected according to dosing chart (Table 4.2).  After 
intraperitoneal injection, tumor mice were watched daily for 3 months, and then bi-
weekly until the 280 day endpoint.  DNA adduct mice were watched daily until the 
endpoints of 1 day, 7 days and 21 days were reached.  For DNA adduct mice, lung, liver 
and forestomach were collected and stored at -80°C.  For tumor mice, lung, liver and 
forestomach were collected and immediately put into 10% formalin.  A small piece of 
liver was collected from the first three mice of each group and stored at -80°C for DNA 
adduct testing.   
 
 
Table 4.2.  Intraperitoneal injection dose chart listing the volume of sample (mL) given 
based on the weight of the mouse (g).  Volume dose was based on mouse receiving 
approximately 0.429, 0.171, and 0.069 mg of sample per g body weight in a 7.14 µL vehicle per 
g of body weight dose.  Dose-response concentrations were calculated and mixed prior to 
dosing. 
Weight    
(g)
Dose Volume 
(mL)
5.0 - 6.5 40
6.6 - 7.7 50
7.8 - 9.1 60
9.2 - 10.5 70
10.6 - 11.9 80
12.0 - 13.3 90  
 
 
 
  
183 
4.2.6.3 
32
P-Postlabeling   
Methods previously described in chapters II and III. 
 
4.2.6.4 Histology   
Tissues were collected according to the Veterinary Integrated Biosciences 
departmental Histology Lab requirements.  Samples were taken from the animal 
immediately after sacrifice.  Tissues were then cut to be approximately the same size, 
taking the piece that is most abnormal in appearance.  Samples collected include liver, 
lung, forestomach and tumors (if large ones present).  Tissues were placed in a histology 
cassette, and then put in a container of 10% neutral buffered formalin for 7 days at 2◦C.  
Ten % neutral buffered formalin (100 mL formaldehyde (37-40%), 900 mL distilled 
water, 4 g monobasic sodium phosphate, and 6.5 g dibasic sodium phosphate) is the 
recommended solution for fixation, as the pH 6.8 and relatively sTable.  After fixation, 
tissues were transferred to 70% ethanol, and kept at 2◦C until sent for processing at the 
Texas A&M Univeristy Veterinary Integrative Biosciences (VIBS) Histology Lab.   
A description of methods used at the VIBS Histology Lab follows.  Tissues were 
processed in a tissue processor based on size of tissues.  The main purpose of the 
embedding is to exchange the unbound water within the tissue to paraffin—dehydrate 
the tissues.  The cycle for this process is: 70% ETOH, 80% ETOH two times, 89% 
ETOH two times, absolute alcohol two times, Pro-Par (clearing reagent) three times, and 
paraffin four times.  Pro-par is a clearing reagent that is used because it is miscible with 
alcohol and paraffin, whereas the alcohol alone is not miscible with paraffin.  The 
paraffin is run four times because the first run is always contaminated with Pro-Par.  
Once the tissue is done with the processing step, it is filled with paraffin.  The tissue is 
then embedded on the cassette.  The tissue is covered with paraffin to form a block wich 
will hold it steady while it is being sliced.  Tissues are then sliced at 4-5 µm.  After 
tissues were sliced, they underwent H&E staining.  The paraffin is then removed from 
the slices via the following cycle: Pro-Par three times, absolute alcohol two times, 95% 
ETOH two times, 70% ETOH one time, tap water one time, and deionized water one 
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time.  Haematoxylin is then added to the slide for 5 min, to stain the nuclei.  The slice is 
then rinsed with tap water, and then with acid alcohol (0.5% HCl in 70% ETOH).  The 
acid alcohol removes any extra haematoxylin from the slice.  Lithium carbonate (0.5% 
lithium carbonate in deionized water) is added to the slice.  This step changes the pH of 
the nuclei, which in turn makes the stain a blue color.  The slice is then rinsed with tap 
water, and then 80% ETOH, followed by the addition of Eosin Y + Phloxine stain.  This 
will stain the cytoplasm (a light pink), muscle and connective tissue (a darker pink), and 
blood cells (magenta).  The slice is then rinsed with 95% ETOH two times, absolute 
alcohol two times, and Pro-Par four times.  These final rinses are done because Pro-Par 
is miscible with the mounting media.  The cover slip is mounted via mounting media, 
and the slides are ready.   
All tissue slides were packaged and hand delivered to a trained pathologist at the 
Baylor College of Dentistry in Dallas, TX.  She viewed each slide and made a diagnosis 
based on her knowledge in pathology.  She determined tumor presence, and type 
(malignant or benign) within each tissue (three slides per tissue). 
 
4.3 Results  
4.3.1 Mortality 
Mortality information was collected during the duration of the study.  Incidence of 
mortality by chemical and dose is presented in Table 4.3.  Information was not obtained 
for all animals to distinguish mortality due to acute toxicity or organ failure from 
mortalities caused by tumor formation.  NF+BAP had the largest incidence of mortality 
at the high dose (75%), with the NF having the second largest incidence of mortality at 
the high dose (46%).  BAP and RM follow with mortalitly incidences of 27% and 14%.  
Most mice that did not survive to the end point came from the high doses of each 
chemical (Figure 4.1).  Odds ratios for mortality, Table 4.4, confirm that the high dose 
(0.429 mg/g bw) has a probability of causing premature death 11.2 times that of the low 
dose (0.069 mg/g bw), and 3.7 times that of the medium dose (0.171 mg/g bw) (Table 
4.4).   
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Table 4.3.  Mortality and survival of B6C3F1 male mice treated with BAP and complex 
chemical mixtures containing BAP.  Mortality is a measure of animals found dead or 
euthanized due to poor health status prior to the 280 day end point.  RM = reconstituted mixture; 
NF+BAP = neutral fraction plus BAP, NF = neutral fraction. 
Chemical Dose Totals
Control -- 1 (5%) 19 (95%) 20
0.429 6 (27%) 16 (73%) 22
0.171 3 (14%) 19 (86%) 22
0.069 0 (0%) 20 (100%) 20
0.429 4 (14%) 24 (86%) 28
0.171 2 (8%) 24 (92%) 26
0.069 0 (0%) 26 (100%) 26
0.429 15 (75%) 5 (25%) 20
0.171 5 (25%) 15 (75%) 20
0.069 3 (15%) 17 (85%) 20
NF (mg/g bw)
0.429 6 (46%) 7 (46%) 13
Totals 45 (19%) 192 (81%) 237
NF+BAP 
(mg/g bw)
Fatalities Survivals
BAP                
(mg/g bw)
RM                     
(mg/g bw)
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Figure 4.1.  Percent mortality in each treatment group prior to 280 days.   
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Table 4.4.  Odds ratios for mortality from chemical and dose treatments in B6C3F1 male 
mice treated with BAP and complex chemical mixtures containing BAP.  Odds ratios 
represent the probability of one factor causing mortality over the other factor. 
Factor 1 vs Factor 2 OR (95% CI)
0.429 x 0.069 11.2 (3.6, 35.3)
0.429 x 0.171 3.7 (1.5, 8.8)
0.171 x 0.069 3.1 (0.9, 10.1)
NF+BAP x BAP 4.4 (1.8, 11.0)
BAP x RM 2.0 (0.7, 5.6)
NF+BAP x RM 8.7 (3.3, 23.6)
Odds Ratios
Mortality
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4.3.2 Tumor Incidence 
Upon dissection of the mice that survived to the 280 day end point, gross tumor 
formation was observed.  All observable gross tumors are reported in Table 4.5.  The 
liver tissue is the one tissue that had the most gross tumors.  The RM low dose (0.069 
mg/g bw) showed the largest incidence of gross tumor formation (38% overall).  The 
second highest frequency of gross tumors was seen in the BAP medium dose treatment 
group (0.171 mg/g bw), at 32%.  Overall, NF+BAP showed a dose-response when 
graphed (Figure 4.2).  BAP increases at the medium dose (0.171 mg/g bw), while RM 
decreases at the same dose.  BAP and RM appear to show opposite gross tumor 
incidence.  Each treatment (BAP, reconstituted mixture, neutral fraction plus BAP and 
neutral fraction), except the control, had some level of gross tumor formation observed.   
 
 
Table 4.5.  Incidence of visible tumors in B6C3F1 male mice treated with BAP or complex 
chemical mixtures containing BAP.  Values represent number of animals in each treatment 
group with tumors visible upon dissection at day 280 and total number of animals (values in 
parentheses are percentages). 
Chemical Dose
Control -- 0/19 (0%) 0/19 (0%)
0.429 1/16 (6%) 1/16 (6%)
0.171 6/19 (32%) 4/19 (21%)
0.069 4/20 (20%) 4/20 (20%)
0.429 4/26 (15%) 4/26 (15%)
0.171 1/24 (4%) 1/24 (4%)
0.069 10/26 (38%) 9/26 (35%)
0.429 1/8 (13%) 1/8 (13%)
0.171 4/17 (24%) 4/17 (24%)
0.069 2/18 (11%) 2/18 (25%)
NF (mg/g bw) 0.429 1/8 (13%) 1/8 (13%)
NF+BAP 
(mg/g bw)
BAP        
(mg/g bw)
RM          
(mg/g bw)
Incidence Incidence
LiverTotal 
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Figure 4.2.  Percent of animals in each treatment group exhibiting tumors that were visible 
(without magnification) upon dissection.  Percentages are calculated as number of total tumors 
divided by total number of animals in each dose and group. 
 
 
Histopathologic observation of the tissue slices, along with the gross tumor 
incidence are added together to give the tumor incidence.  Overall tumor incidence, as 
well as liver tumor incidence was determined.  For overall tumor incidence, data 
reported in Table 4.6, NF+BAP at the high dose (0.429 mg/g bw) had the largest 
incidence (75%).  BAP at the medium dose (0.171 mg/g bw) had the second largest 
incidence (63%), with RM low dose (0.096 mg/g bw) next with 46%.  The trend seen in 
gross tumor incidence is also apparent in the overall tumor incidence (Figure 4.3).  
Tumors were classified as either benign or malignant in Table 4.7.  Most tumors 
observed were benign, with the RM and NF+BAP high dose (0.429 mg/g bw) treatments 
showing 4% and 13% respectively.   
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Table 4.6.  Overall tumor incidence (gross and microscopic) in B6C3F1 male mice treated 
with BAP and complex chemical mixtures containing BAP.  Data represent total number of 
animals with tumors (gross and microscopic) in each treatment group and percentage of animals 
with tumors. 
Treatment Dose
Control -- 1 (5%)
0.429 7 (44%)
0.171 12 (63%)
0.069 6 (30%)
0.429 11 (42%)
0.171 3 (13%)
0.069 12 (46%)
0.429 6 (75%)
0.171 8 (47%)
0.069 6 (33%)
NF (mg/g bw) 0.429 1 (13%)
BAP        
(mg/g bw)
RM          
(mg/g bw)
NF+BAP 
(mg/g bw)
Tumor Incidence
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Figure 4.3.  Overall tumor incidence (gross and microscopic) in infant mice treated with BAP or 
complex mixtures.  Percentage represents total animals in each treatment group with at least 
one tumor divided by total animals in that group.  *Highest probability in this group at this dose of 
developing a tumor. 
 
 
* 
* 
* 
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Table 4.7.  Histologic classification of tumors observed in B6C3F1 infant mice treated with 
BAP or complex PAH mixtures.  Data are presented as total number of animals with benign or 
malignant tumors within each treatment group and total animals in group; values in parenthesis 
are percentage of animals in group with benign or malignant tumors. 
Treatment Dose
Control -- 1/19 5% 0/19 0%
0.429 7/16 44% 0/16 0%
0.171 13/19 68% 0/19 0%
0.069 6/20 30% 0/20 0%
0.429 10/26 38% 1/26 4%
0.171 3/24 13% 0/24 0%
0.069 13/26 50% 0/26 0%
0.429 5/8 63% 1/8 13%
0.171 6/17 35% 0/17 0%
0.069 5/18 28% 0/18 0%
NF (mg/g bw) 0.429 1/8 13% 0/8 0%
NF+BAP 
(mg/g bw)
BAP        
(mg/g bw)
RM          
(mg/g bw)
Benign Malignant
 
 
   
 
 
 
  
193 
Overall tumor incidence is reported with bulky DNA adduct relative adduct 
labeling (RAL) per 109 nucleotides values in Table 4.8.  NF+BAP has the largest 
incidence of tumors overall in the high dose (0.249 mg/g bw) (Table 4.9a), while the 
DNA adduct frequencies are highest in the high dose (0.249 mg/g bw) for each tissue.  
The largest incidence of overall tumor in BAP was in the middle dose (0.171 mg/g bw) 
(Table 4.9b), while the DNA adduct frequencies were highest in the high and middle 
doses (0.429 and 0.171 mg/g bw).  For RM, the largest tumor incidence was in the low 
dose (0.069 mg/g bw) (Table 4.9c), while the highest frequency of DNA adducts was in 
the high dose (0.429 mg/g bw) of all tissues.  It would appear that the 32P-postlabeing 
assay is a good predictor of potential tumor incidence for NF+BAP and BAP, but not as 
good of a predictor for RM.  When comparing the 32P-postlbeling assay to tumor 
incidence (Figures 4.4, 4.5 and 4.6), it is apparent that a clear relationship cannot be 
deciphered.  With the high dose, the larger the RAL value, the higher percentage of 
tumors formed (Figure 4.4).  the same trend can be seen in the intermediate dose, with 
the exception of BAP (Figure 4.5).  For the low dose, it appears that the larger the RAL 
value, the smaller the percent tumor formation (Figure 4.6).  Therefore, while 32P-
postlabeling is a good indication of the tumor forming potential of a chemical, a 
correlation cannot be made with respect to actual percentage tumor formation.
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Table 4.9a.  Tumor incidence and DNA adduct formation in various tissues isolated from 
infant male B6C3F1 mice administered high dose BAP or complex mixture (RM, NF+BAP, 
NF). 
Treatment Liver Lung Forestomach Liver Lung Forestomach
BAP 31 13 0 81.57 ± 23.38 88.02 ± 27.13 126.44 ± 34.86
RM 31 8 4 94.58 ± 14.94 77.57 ± 15.92 132.16 ± 20.77
NF+BAP 50 13 13 276.46 ± 18.97 237.93 ± 11.54 378.93 ± 31.93
NF 13 0 0 44.90 ± 5.47 12.23 ± 0.59 18.11 ± 1.07
RAL / 10
9
 nucleotides ± SEM% Animals with Tumors
 
 
 
 
Table 4.9b.  Tumor incidence and DNA adduct formation in various tissues isolated from 
infant male B6C3F1 mice administered medium dose BAP or complex mixture (RM, 
NF+BAP). 
Treatment Liver Lung Forestomach Liver Lung Forestomach
BAP 58 11 0 74.88 ± 10.76 86.81 ± 13.59 150.78 ± 13.79
RM 13 0 0 42.14 ± 11.17 21.07 ± 6.42 68.32 ± 21.46
NF+BAP 35 0 0 85.07 ± 14.46 48.60 ± 10.60 140.33 ± 22.42
% Animals with Tumors RAL / 10
9
 nucleotides ± SEM
 
 
 
 
Table 4.9c.  Tumor incidence and DNA adduct formation in various tissues isolated from 
infant male B6C3F1 mice administered low dose BAP or complex mixture (RM, NF+BAP). 
Treatment Liver Lung Forestomach Liver Lung Forestomach
BAP 25 5 0 64.62 ± 6.53 40.89 ± 6.03 81.36 ± 23.64
RM 42 4 4 31.33 ± 3.70 14.19 ± 1.41 44.18 ± 8.80
NF+BAP 28 0 0 45.44 ± 2.30 23.64 ± 1.64 82.38 ± 4.41
% Animals with Tumors RAL / 10
9
 nucleotides ± SEM
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Figure 4.4.  Relationship between the formation of DNA adducts (24 hr after exposure) and 
tumor formation (after 280 days) in liver from male B6C3F1 infant mice administered high dose 
of BAP (0.429 mg/g bw), RM, NF+BAP and NF. 
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Figure 4.5.  Relationship between the formation of DNA adducts (24 hr after exposure) and 
tumor formation (after 280 days) in liver from male B6C3F1 infant mice administered optimal 
dose of BAP (0.171 mg/g bw), RM and NF+BAP. 
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Figure 4.6.  Relationship between the formation of DNA adducts (24 hr after exposure) and 
tumor formation (after 280 days) in liver from male B6C3F1 infant mice administered low dose of 
BAP (0.069 mg/g bw), RM, NF+BAP and NF. 
 
 
Odds ratios for overall tumor incidence can confirm that BAP medium dose (0.171 
mg/g bw) is 4.0 times more probable to produce tumors than in the low dose (0.069 
mg/g bw) (Table 4.10).  The high dose (0.429 mg/g bw) is 5.1 times more probable to 
produce tumor formation than the medium dose (0.171 mg/g bw) for the RM.  Liver 
tumor incidence odds ratios follow the same trend as overall tumor incidence (Table 
4.10).  The overall trend of these odd ratios can be seen in Figures 4.7 and 4.8.  NF+BAP 
tumor incidence decreases with dose.  BAP increases from the high (0.429 mg/g bw) to 
the medium (0.171 mg/g bw) dose, while the RM decreases from the high (0.429 mg/g 
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bw) to the medium (0.171 mg/g bw) and visa versa from the medium (0.171 mg/g bw) to 
the low (0.069 mg/g bw) doses.  Both the overall and the liver tumor incidence 
probability trends are similar.  The liver is the target organ for tumor formation in this 
study, which would account for the similarities between overall and liver tumor trends.  
Odds ratios for the effect of the treatment for overall and liver are listed in Table 4.11.  
This data confirms that the chemical treatments have a higher probability of causing 
tumors than the control.  This is an expected observation. 
 
 
Table 4.10.  Total risk of developing a tumor, as measured by odds ratios, in B6C3F1 
infant male mice treated with BAP or complex mixtures.  Odds ratios were calculated as the 
probability of one chemical causing tumor presence over the other chemical. 
Chemical 1 vs Chemical 2 OR (95% CI) OR (95% CI)
BAP 0.429 x BAP 0.069 1.8 (0.5, 7.2) 1.4 (0.3, 5.9)
BAP 0.429 x BAP 0.171 0.5 (0.1, 1.8) 0.3 (0.1, 1.3)
BAP 0.171 x BAP 0.069 4.0 (1.1, 15.2) 4.1 (1.1, 16.1)
RM 0.429 x RM 0.069 0.9 (0.3, 2.6) 0.6 (0.2, 1.9)
RM 0.429 x RM 0.171 5.1 (1.2, 21.6) 3.1 (0.7, 13.5)
RM 0.171 x RM 0.069 0.2 (0.0, 0.7) 0.2 (0.0, 0.8)
NF+BAP 0.429 x NF+BAP 0.069 6.0 (0.9, 39.2) 2.6 (0.5, 14.6)
NF+BAP 0.429 x NF+BAP 0.171 3.4 (0.5, 21.7) 1.8 (0.3, 10.1)
NF+BAP 0.171 x NF+BAP 0.069 1.8 (0.5, 7.0) 1.4 (0.3, 5.9)
NF+BAP 0.429 x BAP 0.429 3.9 (0.6, 25.3) 2.2 (0.4, 12.6)
BAP 0.429 x RM 0.429 1.1 (0.3, 3.7) 1.0 (0.3, 3.9)
NF+BAP 0.429 x RM 0.429 4.1 (0.7, 24.2) 2.3 (0.4, 11.3)
BAP 0.171 x NF+BAP 0.171 1.9 (0.5, 7.3) 2.5 (0.7, 9.7)
BAP 0.171 x RM 0.171 12.0 (2.6, 55.3) 9.6 (2.1, 43.7)
NF+BAP 0.171 x RM 0.171 6.2 (1.3, 29.0) 3.8 (0.8, 18.3)
NF+BAP 0.069 x BAP 0.069 1.2 (0.3, 4.6) 1.2 (0.3, 4.9)
RM 0.069 x BAP 0.069 2.0 (0.6, 6.8) 2.2 (0.6, 7.9)
RM 0.069 x NF+BAP 0.069 1.7 (0.5, 6.0) 1.9 (0.5, 6.9)
Overall Tumor 
Presence
Liver Tumor 
Presence
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Figure 4.7.  Overall probability of developing a tumor in B6C3F1 male mice treated with BAP or 
complex mixtures containing the same level of BAP.  Probability is a statistically estimated value 
for all tissues.   
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Figure 4.8.  Probability of developing a liver tumor in B6C3F1 male mice treated with BAP or 
complex mixtures containing the same level of BAP.  Probability is shown for each chemical and 
dose treatment.  Probability is a statistically estimated value for all tissues.   
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Table 4.11.  Risk of tumor formation, total and liver, in B6C3F1 infant male mice treated 
with BAP or a complex mixture.  Risk is presented as an odds ratio calculated as the 
probability of one chemical causing tumor formation compared to the control. 
Chemical 1 vs Chemical 2 OR (95% CI) OR (95% CI)
BAP 0.429 x Control 14.0 (1.5, 131.7) 18.7 (0.9, 369.1)
BAP 0.171 x Control 30.8 (3.4, 283.5) 52.8 (2.8, >999.9)
BAP 0.069 x Control 7.7 (0.8, 71.6) 13.8 (0.7, 269.9)
RM 0.429 x Control 13.2 (1.5, 114.2) 17.9 (1.0, 332.9)
RM 0.171 x Control 2.6 (0.2, 26.9) 6.3 (0.3, 130.8)
RM 0.069 x Control 15.4 (1.8, 133.1) 28.9 (1.6, 530.5)
NF+BAP 0.429 x Control 54.0 (4.1, 706.3) 39.0 (1.8, 862.4)
NF+BAP 0.171 x Control 16.0 (1.7, 148.3) 22.0 (1.1, 428.4)
NF+BAP 0.069 x Control 9.0 (1.0, 84.4) 15.9 (0.8, 311.8)
NF 0.429 x Control 2.6 (0.1, 47.0) 7.8 (0.3, 213.5)
Total Tumors Liver Tumors
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Tumor incidence was also calculated for the liver, as that was the tissue that had 
the highest amount of tumor formation.  Liver tumor incidence is reported in Table 4.12.  
The same trend that was seen in the overall tissues are seen in the liver tissue as well.  
Liver tumor classification is listed in Table 4.13.  No malignant tumors were observed in 
the liver tissue, as mentioned above.  Liver tumor incidence is reported with liver DNA 
adduct frequency in Table 4.14.  As with the overall tumor incidence and DNA adduct 
formation, a similar trend is observed in the liver.  The over all trend from liver tumor 
incidence can be seen in Figure 4.9.  Again, the same trend that has been seen in the 
gross tumors and overall tumor incidences is observed here as well.  In Figure 4.10, all 
chemical treatments that contain the same level of BAP are graphed together.  The RM 
and BAP treatments show opposite tumor incidence, while the NF+BAP show a slight 
dose-response.  Even though these chemicals have the same levels of BAP, there are 
unknown interactions occurring which account for the different patterns, interactions that 
could be inhibitory, synergistic, etc.  NF+BAP and NF, chemical treatments that have 
the same composition, except for BAP, are graphed in Figure 4.11.  NF+BAP is clearly 
eliciting a higher tumor incidence in liver than NF.  The difference between these two 
mixtures is the concentration of BAP.  A larger concentration of BAP is apparently 
enhancing the potency of the neutral fraction, possibly through synergism, potentiation, 
etc. 
 
  
204 
Table 4.12.  Frequency of liver tumors (gross and microscopic) detected in B6C3F1 infant 
male mice treated with BAP or complex mixtures.  Data are presented as total number of 
animals within each treatment group with liver tumors over total animals in group.  Values in 
parenthesis are percentage of animals with tumors at day 280.   
Chemical Dose
Control -- 0 (0%)
0.429 5 (31%)
0.171 11 (58%)
0.069 5 (25%)
0.429 8 (31%)
0.171 3 (13%)
0.069 11 (42%)
0.429 4 (50%)
0.171 6 (35%)
0.069 5 (28%)
NF (mg/g bw) 0.429 1 (13%)
RM          
(mg/g bw)
NF+BAP 
(mg/g bw)
BAP        
(mg/g bw)
Tumor Present
 
 
     
Table 4.13.  Histologic classification of liver tumors in B6C3F1 male mice treated with 
BAP or complex mixtures containing BAP.  Data are presented as total number of tumors per 
group divided by total number animals that survived to 280 day end point (percentage).  
Chemical Dose
Control -- 0/19 0% 0/19 0%
0.429 5/16 31% 0/16 0%
0.171 11/19 58% 0/19 0%
0.069 5/20 25% 0/20 0%
0.429 8/26 31% 0/26 0%
0.171 3/24 13% 0/24 0%
0.069 11/26 42% 0/26 0%
0.429 4/8 50% 0/8 0%
0.171 6/17 35% 0/17 0%
0.069 5/18 63% 0/18 0%
NF (mg/g bw) 0.429 1/8 13% 0/8 0%
NF+BAP 
(mg/g bw)
Typing at 280 Days Post Exposure
Benign Malignant
BAP        
(mg/g bw)
RM          
(mg/g bw)
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Figure 4.9.  Percent tumor formation in the liver for each treatment and dose.  Percentages are 
calculated as number of total tumors divided by total number of animals in each dose and group.  
*Highest probability in this group at this dose of developing a tumor. 
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Figure 4.10.  Percent tumor formation in the liver for treatments which contain the same level of 
BAP.  Percentages are calculated as number of total tumors divided by total number of animals 
in each dose and group.  *Highest probability in this group at this dose of developing a tumor. 
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Figure 4.11.  Percent tumor formation in the liver for treatments which contain different levels of 
BAP.  Percentages are calculated as number of total tumors divided by total number of animals 
in each dose and group. 
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4.4  Discussion 
This research was modeled after a long-term tumor study for animals receiving one 
of four treatments.  For the current experiment, the four treatments consisted of BAP, 
RM, NF+BAP and NF.  All treatments were administered via i.p. injection.  DNA 
adducts were measure after 24 hr in mice.  In a separate group of animals tumor 
formation was monitored for 280 days.  As is standard practice for cancer studies, 
threatments were administered at a maximum tolerable dose.   
Primary toxicity was observed in the NF+BAP and NF treatments.  Although some 
toxicity was observed in animals administered RM and BAP treatments, fatalites were 
less than those observed in the other treatments.  Among the animals that did not survive 
to 280 days, the majority of them had aggressive tumor formation.  Gross tumors were 
observed in all treatment goups.  The highest gross tumor frequency was observed in the 
RM treatment receiving the lowest dose, whereas total tumors were highest in the high 
dose NF+BAP treatment.  It is possible that more visible tumors were present on the 
outside of the organs with regard to the RM treatment.  Another explanation would be 
that we did not take enough slices to discover all tumors present.  Only three slices were 
taken per tissue for this research due to time and monetary constraints.  Animals 
receiving treatment with BAP, RM or NF+BAP received equivalent amounts of BAP.  
However, tumor incidence observed in these treatment goups was different.  A 
consistent dose response relationship from low to high dose for tumor incidence was 
observed in the NF+BAP treatment.  The high dose NF+BAP treatment also produced 
the highest overall tumor indcidence.  For animals administered only BAP, the optimal 
dose for tumor incidence was the intermediate dose.  Whereas for animals administered 
the RM treatment, the low and the high dose induced the highest tumor incidence, while 
the intermediate dose induce approximately a three fold decrease in tumor incidence.  
These differences appear to reflect ineractions of the seven components of the RM and 
the unknown number of components of the NF+BAP treatment.  The increase in 
response from the high dose to the intermediate dose for the BAP treatment could be due 
to a cytotoxic effect from the high dose.  At the same dose of BAP there were six tumors 
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in the BAP treatment group, whereas the group that received the RM treatment exhibited 
only one tumor.  There are several explanations surrounding this.  One would be that we 
don’t have the full picture with only interpreting three slices per tissue.  Another would 
be that there is some inhibitory interaction occurring between the eight chemicals 
present.  However, at the lowest dose animals receiving only BAP exhibited 20% tumor 
incidence, while those receiving the RM treatment exhibited a tumor incidence of 38%.  
Rodriguez et al. (1997) observed primarily liver tumors as well.  While Rodriguez et al. 
(1997) observed tumor incidence in BAP, they did not observe tumor incidence for the 
manufactured gas plant residue (MGPR).  In this research, we also primarily observed 
liver tumors, with smaller numbers of tumors seen in the forestomach and lung. This is a 
liver model, which would account for the smaller numbers seen in the other organs.  
However, even though we also observed tumor formation after exposureto BAP, we also 
observed tumor formation avter exposure to NF+BAP.  These two studes are similar, 
however the makeup of the mixtures tested has resulted in different outcomes.  
Metabolism and distribution have played a ey role in this part of this research.  Since 
liver is the target organ in this model, metabolism seems to be more important.  
Interactions by chemicals in the mixtures are influencing metabolism, which in turn is 
influencing genotoxicity.  For instance, PAH is possibly inhibiting phase I and phase II 
enzymes while NF+BAP is enhancing these enzymes at the high dose.  However, at the 
low dose, these two treatments are approximately equal.  There are multiple interactions 
occurring which need to be dissected further.  There are interactions with metabolic 
enzymes occurring, as well as dose specific interactions and chemical interactions within 
the mixtures.   
A relationship between DNA adducts and tumor formation was difficult to 
delineate.  For selected treatments, however, a relationship was seen between adduct 
levels and tumor formation.  BAP had an increased response at the intermediate dose, 
preceded and followed by a lower response.  This suggests that the high dose may have 
been cytotoxic, while the intermediate dose was optimal for a response.  At this optimal 
treatment dose for BAP (0.171 mg/g bw), the tumor incidence was 58% and the RAL 
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was approximately 75 per 109 nucleotides.  At the same treatment dose for the RM, 
tumor incidence was reduced to 13% and the RAL was reduced to approximately 42 per 
109 nucleotides.  Similarly, at the highest treatment dose the RM induced tumors in 31% 
of animlas and RAL was 95 per 109 nucleotides.  The NF+BAP induced approximately 
an approximate two fold increase in tumor incidence and six fold increase in DNA 
adduct formation. 
Overall, the data demonstrates that the NF+BAP treatment is the most genotoxic 
and carcinogenic mixture tested.  Even though all three treatments (BAP, RM and 
NF+BAP) have the same amount of BAP present, there were appreciable differences in 
the incidence of tumors formed due to interactions of the constituents within the 
mixtures.  Although a consistent relationship was not observed between DNA adducts 
and tumor incidence, there were possible relationships between certain treatments, which 
could not be confirmed statistically.  It is possible that a relationship between DNA 
adduct formation is more apparent with tumor formation when cytotoxicity does not play 
a role.  Based on the data from this research, DNA adducts are a good measure of the 
tumorigenic potential of complex mixtures, especially when cytotoxicity does not 
influence the response.  Both inhibitory and enhanced responses were ultimately 
observed in the RM and NF+BAP treatments, respectively.  At the same level of BAP, 
NF+BAP and BAP both elicited very different responses.  NF+BAP induced 
significantly more tumors than BAP, which has implications for risk assessment.  It is 
very important to understand these interactions, so that risk assessment of these types of 
chemicals may be improved in the future.  
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CHAPTER V 
SUMMARY 
 
The research in this dissertation was conducted to investigate the genotoxic and 
carcinogenic interactions of the components of fractions isolated from WPW oil.  The 
WPW was used in this study as a representative complex mixture of PAHs and PCAs.  
Chemical analysis of the WPW identified a variety of compounds including low and 
high molecular weight PAHs, pentachlorophenol and smaller concentrations of PCDDs.  
These compounds are ubiquitous in the environment, and pose a threat to humans and 
ecological receptors that may be exposed to contaminated media.  Current regulatory 
guidelines recommend that the risk of a complex mixture is estimated assuming additive 
interactions.  However, mixture interactions may enhance or inhibit component toxicity 
and genotoxicity.  These studies were conducted to investigate the interactions of several 
fractions isolated from a WPW.  Data were obtained to investigate the genotoxicity of 
the isolated fractions in microbial mutagenicity assays, as well as in an animal model 
using 32P-postlabeling.  The results obtained from short-term bioassays were compared 
with the results from a 40-week tumor study using a juvenile mouse model.   These 
studies were conducted to investigate the hypothesis that the isolation of high molecular 
weight PAHs from the complex WPW mixture will allow increased expression of 
genotoxicity in vitro and in vivo.   
This research included chemical separation and fractionation of a complex WPW 
mixture, analysis of chemical components and genotoxicity using microbial cell cultures 
and animal models, and for a limited number of samples evaluation of carcinogenic 
potential in an infant mouse model.  The complex oily WPW waste was initially 
fractionated into acid, base and neutral fractions using liquid-liquid separations.  An 
aliquot of the neutral fraction was further separated using column chromatography into 
two fractions enriching the high molecular weight PAHs and the PCDDs.  The acid 
fraction was found to contain the highest concentration of pentachlorophenol, the neutral 
fraction isolated the high and low molecular weight PAH compounds, and the base 
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fraction retained a smaller amount of pentachlorophenol with PAH concentrations below 
detection limits.   Two fractions were isolated from the neutral fraction.  The PAH 
fraction contained primarily high molecular weight carcinogenic PAHs (i.e., BAP, IP, 
and DA), while the PCDD fraction contained the maximum levels of carcinogenic 
PAHs.   
A series of short-term bioassays were then conducted to investigate potential 
interactions of the components of the various fractions isolated from the WPW.  In the 
Salmonella microsome assay, the base fraction induced the maximum genotoxic 
response.  It is unclear which components of this fraction were genotoxic.  PAH 
concentrations in the base fraction were generally below levels of detection.  Thus, it is 
assumed that nitrogen containing hydrocarbons may have produced the mutagenic 
response observed in this bioassay.  The PAH and crude extract also induced a positive 
mutagenic response in Salmonella, while the neutral fraction induced a weak positive 
response (i.e., a doubling of revertants at only one dose).  In the E. coli assay, the acid 
fraction induced more than a 20-fold increase in plaque formation.  The base fraction 
also induced a weak positive response, possibly due to residual pentachlorophenol in this 
fraction.    
These fractions were also applied to the skin of CD-1 mice to measure the 
induction of DNA adducts.  For comparative purposes, a reconstituted mixture was 
synthesized to match the levels of eight class B2 carcinogens found in the neutral 
fraction (benzo(a)pyrene, benz(a)anthracene, benzo(b)fluoranthene, 
benzo(k)fluoranthene, chrysene, dibenz(a,h)anthracene, indeno(1,2,3-cd)pyrene and 
pentachlorophenol).  All fraction constituents were confirmed via GC/MS (the levels of 
sixty PAHs were tested, as well as the levels of PCDDs and PCDFs in the PCDD 
fraction).  Following dermal application, most fractions induced the maximum level of 
genotoxic damage in lung tissue, with the lowest frequency of adduct observed in liver.  
The exception to this, was the PAH fraction which induced the highest level of DNA 
adducts in liver.  The PAH fraction induced a RAL level of 383 per 109 nucleotides in 
the liver, 306 per 109 nucleotides in the lung, and 109 per 109 nucleotides in skin.  It was 
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also observed that the overall pattern of bulky DNA adducts were similar for the RM and 
NF.  The autoradiogram for the RM showed multiple distinct spots, apparently reflecting 
the seven carcinogenic PAHs present in this mixture.  Whereas the NF, containing 
comparable levels of the seven carcinogenic PAHs exhibited less distinct spots from the 
bulky adducts suggesting that PAH interactions may have modified PAH metabolism.  
Based on results from the short-term bioassay, the NF and RM were selected for a long 
term tumor study.   
Prior to the long term study, an in vivo study was conducted to compare the 
persistence of DNA adducts from various fractions.  In addition, the level of adducts 
induced from dermal exposure was compared to adduct levels following intraperitoneal 
injection of various fractions.  It is assumed that the persistence of DNA adducts induced 
by genotoxic chemicals can have an influence on potential carcinogenic outcomes.  This 
study was modeled after a previously published infant male mouse model (Rodriguez et 
al. 1997).  Based on the previous study, three doses of BAP were selected (0.429, 0.171 
and 0.069 mg/g body weight (bw)).  The NF and RM were amended with BAP so that 
animals would receive the same BAP concentration as was administered in the BAP 
alone treatment groups.  All mice were injected intraperitoneally (i.p.) one time at 21 
days of age.  Mice were euthanized after 1, 7, 21, and 280 days (280 for liver only).  In 
addition, mice were treated topically once with a dose of 3, 1.2 and 0.48 mg/mouse (the 
dose used in the standard complex mixture protocol for 32P-postlabeling).  These mice 
were euthanized 1 day following treatment.  Mice administered complex mixture via 
dermal application mice showed a different pattern of DNA adduct frequencies than 
mice administered the mixtures via i.p. injection.  Overall, the BAP treatment elicited a 
higher DNA adduct frequency than the NF+BAP and the RM treatments for the dermal 
application.  The reason for this is adsorption and distribution.  The NF+ABP and RM 
treatments contain structurally larger compounds than BAP alone.  Larger compounds 
have a diffictult time passing through barriers.  For mice sacrificed one day following 
i.p. application, the NF+BAP fraction induced a relative adduct level of 276 per 109 
nucleotides, while BAP induced 82 PER 109 nucleotides.  The chemical-dose-
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application interactions were not significantly different in the forestomach for treatment 
groups administered the fractions by i.p. and dermal application.  However, for the liver 
and lung there were significant chemical-dose-application interactions observed from 
dermal and i.p. treatments.   
The persistence of DNA adducts were measured in animals treated with the three 
mixtures or BAP.  At the high treatment dose, the NF+BAP group exhibited higher 
adduct frequencies than was observed for the other treatments.  However, at the medium 
and low dose, the BAP treatment elicited the highest adduct frequencies.  This appears to 
indicate that the intermediate dose was optimal for BAP.  It was also observed that the 
DNA adduct pattern in tissues from animals receiving the NF treatment was similar to 
the pattern for animal receiving the RM treatment.  For BAP, RM and NF+BAP 
treatment, DNA adduct frequencies in liver exhibited a consistent decrease over time.  
After 21 days, adduct frequencies in liver from animals receiving each of these 
treatments was reduced by approximately 70%.  Whereas for animals receiving the NF 
treatment, DNA adduct frequencies after 21 days were reduced by less than 20%.  This 
indicates that this treatment was more persistent than the other treatments.  Perhaps the 
lower levels of BAP allowed for a slower response from the metabolizing enzymes, 
enableing the NF to persist longer than the other treatments.   
The ability of the four treatments, BAP and the three complex mixtures, to induce 
the formation of tumors was investigated using the infant mouse model following a 
protocol used by Rodriguez et al. (1997).  Measurement of the ability of the pure 
compound and complex mixtures to induce tumor formation is important in the overall 
understanding of the interactions that occur within these and similar mixtures.  In 
comparison to a 40-week tumor study, 32P-postlabeling is a less costly and more efficient 
method for screening the genotoxic potential of chemicals and chemical mixtures.  
However, the ability of this assay to predict potential tumor formation for chemical 
mixtures has not been studied in depth.  Therefore, comparing the frequency of DNA 
adduct formation to tumor induction will assist in understanding the utility of the short-
term protocol.   
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Prior to the 280 day end point, several mice were euthanized due to illness or 
tumor formations that affected the animals’ health.  Mortality incidence was highest 
(75%) in animals receiving the NF+BAP treatment, while the NF produced a mortality 
rate of 46%.  Upon dissection, gross tumors were observed on the organs of the animals.  
The highest gross tumor incidence, 38%, was observed in animals receiving the low dose 
RM treatment.  Tissues were classified as benign or malignant based on histopathologic 
observations.  Total incidence of tumor formation was calculated as gross plus 
microscopic for each tissue.  For all tissues combined, the highest incidence of tumors 
included 75% for the NF+BAP treatment high dose, 63% in the BAP treatment medium 
dose and 46% in the RM low dose.  Note that the concentration of BAP administered 
was the same across these three treatment groups, although the optimal dose for tumor 
formation was different.  This suggests that component interactions influenced the 
optimal treatment dose for induction of tumors.  As was observed in the Rodriguez et al. 
(1997) study, histologic classification confirmed that most of the tumors were benign.  
While most of the tumors observed were bening at the stage they were collected, there is 
a potential for a malignancy to form from the benign tumor.  Malignant tumors were 
observed in animals receiving high dose RM treatment (4%) and NF+BAP treatment 
(13%).  All tumors observed in liver tissue were benign.   
The relationship between DNA adduct frequencies and tumor incidence was 
inconsistent.  For select treatments and dosages, there did appear to be a relationship 
between DNA adduct and tumor formation.  The optimal (intermediate) treatment dose 
for BAP induced a tumor incidence of 58% and a relative adduct level of 75 per 109 
nucleotides.  The same dose for the RM treatment induced a tumor incidence of 13%, 
and a RAL of 42 per 109 nucleotides.  For the high dose of the RM in liver, the tumor 
incidence was 31% and the RAL 95 per 109 nucleotides; and, for the NF+BAP the tumor 
incidence was 50% and DNA adduct formation 276 per 109 nucleotides.  The NF+BAP 
treatment induced the highest tumor frequency at the high dose, and DNA adduct 
frequencies were also highest at this dose.  The data suggest that there is a relationship 
between the formation of DNA adducts and tumors, however this relationship is not a 
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very accurate one with an unknown mechanism.  While there may not be a direct 
correlation between adduct formation and tumors, measurement of elevated adduct 
frequencies does appear to reflect an increased risk of cancer.    
Complex chemical mixtures are ubiquitous in the human diet and the environment.  
These mixtures are also of concern at wood treating plants.  There are 26 wood treatment 
sites on the National Priorities List (NPL) in the United States.  There are 749 additional 
sites on the NPL which list PAH mixtures as contaminants of concern.  In order to 
develop improved methods to rank and remediate these sites, it is important to obtain 
information to understand how chemical mixtures interact.  The conclusions of this 
research include: 
1. Fractionation of complex mixture is capable of isolating genotoxic 
components and specific chemical classes, although compound separation 
frequently overlaps. 
2. Mixture isolates were genotoxic in short-term bioassays.  The Salmonella 
bioassay was capable of detecting genotoxic PAHs and the E. coli 
bioassay was sensitive to pentachlorophenol in the complex mixture. 
These results were not very predictive of the 32P-postlabeling results.   
3. DNA adduct formation was higher when mixtures were administered by 
intraperitoneal application than by dermal application. 
4. DNA adducts levels were generally reduced over time.  However, adduct 
levels for certain treatment groups did persist for longer periods of time.    
5. Tumor formation could not be predicted by the concentration of BAP 
alone.  Component interactions appear to have affected the carcinogenic 
potential of the complex mixtures. It is important to determine how dose 
influences these chemicals to cause cancer.   
Future studies are warranted on determining the mechanism of these interactions, 
and how this affects the carcinogenic outcomes.  The data indicate that the liver is the 
target organ for PAH carcinogenesis in the infant mouse model.  DNA adducts correlate 
most closely with tumor formation in this organ.  Future studies would benefit from a 
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larger number of animals per treatment group, and a smaller number of treatment doses.  
Based on the statistical evaluation of the data, it is recommended that two doses and a 
single tissue be the focus of additional investigations into the carcinogenic interactions 
of complex mixtures. 
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